CA2369605A1 - Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same - Google Patents
Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same Download PDFInfo
- Publication number
- CA2369605A1 CA2369605A1 CA002369605A CA2369605A CA2369605A1 CA 2369605 A1 CA2369605 A1 CA 2369605A1 CA 002369605 A CA002369605 A CA 002369605A CA 2369605 A CA2369605 A CA 2369605A CA 2369605 A1 CA2369605 A1 CA 2369605A1
- Authority
- CA
- Canada
- Prior art keywords
- chepo
- acid sequence
- amino acid
- polypeptide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 297
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 286
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 277
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 223
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 66
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 66
- 102000003951 Erythropoietin Human genes 0.000 title abstract description 16
- 108090000394 Erythropoietin Proteins 0.000 title abstract description 16
- 241000282577 Pan troglodytes Species 0.000 title abstract description 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title description 19
- 229940105423 erythropoietin Drugs 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 132
- 239000013598 vector Substances 0.000 claims abstract description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 165
- 210000004027 cell Anatomy 0.000 claims description 162
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 141
- 239000002773 nucleotide Substances 0.000 claims description 100
- 125000003729 nucleotide group Chemical group 0.000 claims description 100
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 125000000539 amino acid group Chemical group 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 40
- 108060003951 Immunoglobulin Proteins 0.000 claims description 37
- 102000018358 immunoglobulin Human genes 0.000 claims description 37
- 238000004113 cell culture Methods 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 143
- 108020004414 DNA Proteins 0.000 description 114
- 102000004169 proteins and genes Human genes 0.000 description 90
- 235000018102 proteins Nutrition 0.000 description 86
- 235000001014 amino acid Nutrition 0.000 description 69
- 239000012634 fragment Substances 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 59
- 230000027455 binding Effects 0.000 description 58
- 241000282414 Homo sapiens Species 0.000 description 53
- 241001465754 Metazoa Species 0.000 description 34
- 239000000523 sample Substances 0.000 description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 28
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 28
- 239000005557 antagonist Substances 0.000 description 28
- 108091034117 Oligonucleotide Proteins 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 25
- 238000009396 hybridization Methods 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 24
- 230000000295 complement effect Effects 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 239000011800 void material Substances 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 20
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 20
- 230000003068 static effect Effects 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000004743 Polypropylene Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 16
- 239000000556 agonist Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 210000004408 hybridoma Anatomy 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 102000053602 DNA Human genes 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000002502 liposome Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 210000004962 mammalian cell Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- 230000013595 glycosylation Effects 0.000 description 11
- 238000006206 glycosylation reaction Methods 0.000 description 11
- -1 his Chemical compound 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 229940127089 cytotoxic agent Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 108020005544 Antisense RNA Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 238000007423 screening assay Methods 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 229940124452 immunizing agent Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108020004491 Antisense DNA Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 6
- 102100031939 Erythropoietin Human genes 0.000 description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 238000004590 computer program Methods 0.000 description 6
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000003816 antisense DNA Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013522 chelant Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 108020001096 dihydrofolate reductase Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101100390711 Escherichia coli (strain K12) fhuA gene Proteins 0.000 description 4
- 102100039556 Galectin-4 Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229960000633 dextran sulfate Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 101150002621 EPO gene Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 3
- 101100407828 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-3 gene Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 101150018266 degP gene Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 239000006167 equilibration buffer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 102000044890 human EPO Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 101150009573 phoA gene Proteins 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 231100000607 toxicokinetics Toxicity 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- PQYGLZAKNWQTCV-HNNXBMFYSA-N 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA Chemical compound OCCNC(=S)NC1=CC=C(C[C@@H](CN(CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 PQYGLZAKNWQTCV-HNNXBMFYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100332563 Caenorhabditis elegans dhfr-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710202200 Endolysin A Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710092857 Integrator complex subunit 1 Proteins 0.000 description 1
- 102100024061 Integrator complex subunit 1 Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 1
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 101150074451 clpP gene Proteins 0.000 description 1
- 101150043719 clpP1 gene Proteins 0.000 description 1
- 101150102296 clpP2 gene Proteins 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- HVCNNTAUBZIYCG-UHFFFAOYSA-N ethyl 2-[4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenoxy]propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=NC2=CC=C(Cl)C=C2S1 HVCNNTAUBZIYCG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 101150020087 ilvG gene Proteins 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102220009232 rs111430410 Human genes 0.000 description 1
- 210000000468 rubriblast Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 208000014745 severe cutaneous adverse reaction Diseases 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention is directed to novel chimpanzee erythropoietin polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Description
NOVEL CHIMPANZEE ERYTHROPOIETIN ICHEP0) POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE
SAME
FIELD OF THE INVENTION
The present invention relates generally to the identification and isolation of novel chimpanzee erythropoietin polypeptides, nucleic acid molecules encoding those polypeptides and to the recombinant production of those polypeptides.
BACKGROUND OF THE INVENTION
Erythropoiesis, the production of red blood cells, occurs continuously throughout the human life span to offset cell destruction. Erythropoiesis is a very precisely controlled physiological mechanism enabling sufficient numbers of red blood cells to be available in the blood for proper tissue oxygenation, but not so many that the cells would impede circulation. The formation of red blood cells occurs in the bone marrow and is under control of the hormone, erythropoietin.
Erythropoietin, an acidic glycoprotein is approximately 34,000 dalton molecular weight, may occur in three forms:
alpha, beta and asialo. The alpha and beta forms different slightly in carbohydrate components have the same potency, biological activity and molecular weight. The asialo form is an alpha or beta form with the terminal carbohydrate (sialic acid) removed. Erythropoietin is present in a very low concentrations in plasma when the body is in a healthy state wherein tissues receive sufficient oxygenation from the existing number of erythrocytes. Tbis normal low concentration is enough to stimulate replacement of red blood cells which are lost normally through aging.
The amount of erythropoietin in the circulation is increased under conditions of hypoxia when oxygen transport 2 0 by blood cells in the circulation is reduced. Hypoxia may be caused by loss of large amounts of blood through hemorrhage, destruction of red blood cells by over-exposure to radiation, reduction in oxygen intake due to high altitudes or prolonged unconsciousness, or various forms of anemia. In response to tissues undergoing hypoxic stress, erythropoietin will increase red blood cell production by stimulating the conversion of primitive precursor cells in the bone marrow into proerythroblasts which subsequently mature, synthesize hemoglobin and are released into the circulation as red blood cells. When the 2 5 number of red blood cells in circulation is greater than needed for normal tissue oxygen requirements, erythropoietin in circulation is decreased.
Because erythropoietin is essential in the process of red blood cell formation, the hormone has potential useful application in both the diagnosis and treatment of blood disorders characterized by low or defective red blood cell production. See, generally, Pennathur-Das, et al., Blood 63(5):1168-71 (1984) and Haddy, Am. Jour. Ped. Hematol. Oncol..
ENCODING THE
SAME
FIELD OF THE INVENTION
The present invention relates generally to the identification and isolation of novel chimpanzee erythropoietin polypeptides, nucleic acid molecules encoding those polypeptides and to the recombinant production of those polypeptides.
BACKGROUND OF THE INVENTION
Erythropoiesis, the production of red blood cells, occurs continuously throughout the human life span to offset cell destruction. Erythropoiesis is a very precisely controlled physiological mechanism enabling sufficient numbers of red blood cells to be available in the blood for proper tissue oxygenation, but not so many that the cells would impede circulation. The formation of red blood cells occurs in the bone marrow and is under control of the hormone, erythropoietin.
Erythropoietin, an acidic glycoprotein is approximately 34,000 dalton molecular weight, may occur in three forms:
alpha, beta and asialo. The alpha and beta forms different slightly in carbohydrate components have the same potency, biological activity and molecular weight. The asialo form is an alpha or beta form with the terminal carbohydrate (sialic acid) removed. Erythropoietin is present in a very low concentrations in plasma when the body is in a healthy state wherein tissues receive sufficient oxygenation from the existing number of erythrocytes. Tbis normal low concentration is enough to stimulate replacement of red blood cells which are lost normally through aging.
The amount of erythropoietin in the circulation is increased under conditions of hypoxia when oxygen transport 2 0 by blood cells in the circulation is reduced. Hypoxia may be caused by loss of large amounts of blood through hemorrhage, destruction of red blood cells by over-exposure to radiation, reduction in oxygen intake due to high altitudes or prolonged unconsciousness, or various forms of anemia. In response to tissues undergoing hypoxic stress, erythropoietin will increase red blood cell production by stimulating the conversion of primitive precursor cells in the bone marrow into proerythroblasts which subsequently mature, synthesize hemoglobin and are released into the circulation as red blood cells. When the 2 5 number of red blood cells in circulation is greater than needed for normal tissue oxygen requirements, erythropoietin in circulation is decreased.
Because erythropoietin is essential in the process of red blood cell formation, the hormone has potential useful application in both the diagnosis and treatment of blood disorders characterized by low or defective red blood cell production. See, generally, Pennathur-Das, et al., Blood 63(5):1168-71 (1984) and Haddy, Am. Jour. Ped. Hematol. Oncol..
3 0 4:191-196 (1982) relating to erythropoietin in possible therapies for sickle cell disease, and Eschbach et al., J. Clin. Invest.
7412):434-441 (1984), describing a therapeutic regimen for uremic sheep based on in viva response to erythropoietin-rich plasma infusions and proposing a dosage of 10 U EOPIkg per day for 15-40 days as corrective of anemia of the type associated with chronic renal failure. See also, Krane, Henry Ford Hosp. Med.
J., 31(31:177-181 119831.
We describe herein the identification and characterization of a novel erythropoietin polypeptide derived from the 3 5 chimpanzee, designated herein as ~ CHEPO .
SUMMARY OF THE INDENTION
A cDNA clone has been identified that has homology to nucleic acid encoding human erythropoietin that encodes a novel chimpanzee erythropoietin polypeptide, designated in the present application as "CHEPO".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a CHEPO polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84°'o nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 909'o nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'°
nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 979'o nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99~ nucleic acid sequence identity to (a) a DNA molecule encoding a CHEPO polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (bl the complement of the DNA molecule of (a).
2 0 In another aspect, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding a CHEPO
polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO
ID NOS:2 and 51, or (b) the complement of the nucleotide sequence of (a1.
In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 2 5 829'o nucleic acid sequence identity, alternatively at least about 839'o nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 859'° nucleic acid sequence identity, alternatively at least about 869'o nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 889'° nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid 3 0 sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'0 nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 989'o nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule having the sequence of nucleotides from about 1 or 3 5 about 82 to about 579, inclusive, of Figure 2 (SEO ID N0:31, or (b) the complement of the DNA molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) the nucleotide sequence of from about 1 or about 82 to about 579, inclusive, of Figure 2 (SEO ID N0:3), or (b) the complement of the nucleotide sequence of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active CHEPO
polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of a nucleic acid sequence that encodes amino acids 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 51. Preferably, hybridization occurs under stringent hybridization and wash conditions.
In yet another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active CHEPO
polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of the nucleic acid sequence between about nucleotides 1 or about 82 and about 579, inclusive, of Figure 2 (SEO ID N0:31. Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule which is produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a CHEPO polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about an 809'o nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86~
nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 889~o nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least 2 0 about 909'o nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 989'o nucleic acid sequence identity and alternatively at least about 999'0 nucleic acid sequence identity to la) or (b), and isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) a nucleotide sequence encoding a polypeptide scoring at least about 809'o positives, alternatively at least about 81 % positives, alternatively at least about 829'° positives, alternatively at least about 839'o positives, alternatively at least about 84% positives, alternatively at least about 85% positives, alternatively at least about 86%
positives, alternatively at least about 87°~
3 0 positives, alternatively at least about 88% positives, alternatively at least about 89% positives, alternatively at least about 90% positives, alternatively at least about 91 % positives, alternatively at least about 92% positives, alternatively at least about 93% positives, alternatively at least about 94% positives, alternatively at least about 95% positives, alternatively at least about 96% positives, alternatively at least about 979'°
positives, alternatively at least about 98% positives and alternatively at least about 99% positives when compared with the amino acid sequence of residues about 1 or about 28 3 5 to 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (b) the complement of the nucleotide sequence of (al.
WO 00/68376 PCT/t1S00/12370 In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a CHEPO
polypeptide without the N-terminal signal sequence andlor the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 27 in the sequence of Figure 3 (SEO ID NOS:2 and 51. It is noted, however, that the C-terminal boundary of the signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot~En4. 10:1-6 (1997) and von Heinje et al., Nucl. Acids.
Res.14:4683-4690 (1986)1. Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding them, are contemplated by the present invention. As such, for purposes of the present application, the signal peptide of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5) extends from amino acids 1 to X of Figure 3 (SEO ID NOS:2 and 51, wherein X is any amino acid from 23 to 32 of Figure 3 (SED ID NOS:2 and 5). Therefore, mature forms of the CHEPO polypeptide which are encompassed by the present invention include those comprising amino acids X to 193 of Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid from 23 to 32 of Figure 3 (SEO ID NOS:2 and 51 and variants thereof as described below.
Isolated nucleic acid molecules encoding these polypeptides are also contemplated.
Another embodiment is directed to fragments of a CHEPO polypeptide coding sequence that may find use as, for example, hybridization probes or for encoding fragments of a CHEPO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-CHEPO antibody. Such nucleic acid fragments are usually at least about 20 2 0 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides 2 5 in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides 3 0 in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term about means the referenced nucleotide sequence length plus or minus 10% of that referenced length. In a preferred embodiment, the nucleotide sequence fragment is derived from 35 any coding region of the nucleotide sequence shown in Figure 1 (SEO ID
N0:1). It is noted that novel fragments of a CHEPO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the CHEPO
7412):434-441 (1984), describing a therapeutic regimen for uremic sheep based on in viva response to erythropoietin-rich plasma infusions and proposing a dosage of 10 U EOPIkg per day for 15-40 days as corrective of anemia of the type associated with chronic renal failure. See also, Krane, Henry Ford Hosp. Med.
J., 31(31:177-181 119831.
We describe herein the identification and characterization of a novel erythropoietin polypeptide derived from the 3 5 chimpanzee, designated herein as ~ CHEPO .
SUMMARY OF THE INDENTION
A cDNA clone has been identified that has homology to nucleic acid encoding human erythropoietin that encodes a novel chimpanzee erythropoietin polypeptide, designated in the present application as "CHEPO".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a CHEPO polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84°'o nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 909'o nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'°
nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 979'o nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99~ nucleic acid sequence identity to (a) a DNA molecule encoding a CHEPO polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (bl the complement of the DNA molecule of (a).
2 0 In another aspect, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding a CHEPO
polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO
ID NOS:2 and 51, or (b) the complement of the nucleotide sequence of (a1.
In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 2 5 829'o nucleic acid sequence identity, alternatively at least about 839'o nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 859'° nucleic acid sequence identity, alternatively at least about 869'o nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 889'° nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid 3 0 sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'0 nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 989'o nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule having the sequence of nucleotides from about 1 or 3 5 about 82 to about 579, inclusive, of Figure 2 (SEO ID N0:31, or (b) the complement of the DNA molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) the nucleotide sequence of from about 1 or about 82 to about 579, inclusive, of Figure 2 (SEO ID N0:3), or (b) the complement of the nucleotide sequence of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active CHEPO
polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of a nucleic acid sequence that encodes amino acids 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 51. Preferably, hybridization occurs under stringent hybridization and wash conditions.
In yet another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active CHEPO
polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of the nucleic acid sequence between about nucleotides 1 or about 82 and about 579, inclusive, of Figure 2 (SEO ID N0:31. Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule which is produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a CHEPO polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about an 809'o nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86~
nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 889~o nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least 2 0 about 909'o nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 989'o nucleic acid sequence identity and alternatively at least about 999'0 nucleic acid sequence identity to la) or (b), and isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) a nucleotide sequence encoding a polypeptide scoring at least about 809'o positives, alternatively at least about 81 % positives, alternatively at least about 829'° positives, alternatively at least about 839'o positives, alternatively at least about 84% positives, alternatively at least about 85% positives, alternatively at least about 86%
positives, alternatively at least about 87°~
3 0 positives, alternatively at least about 88% positives, alternatively at least about 89% positives, alternatively at least about 90% positives, alternatively at least about 91 % positives, alternatively at least about 92% positives, alternatively at least about 93% positives, alternatively at least about 94% positives, alternatively at least about 95% positives, alternatively at least about 96% positives, alternatively at least about 979'°
positives, alternatively at least about 98% positives and alternatively at least about 99% positives when compared with the amino acid sequence of residues about 1 or about 28 3 5 to 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5), or (b) the complement of the nucleotide sequence of (al.
WO 00/68376 PCT/t1S00/12370 In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a CHEPO
polypeptide without the N-terminal signal sequence andlor the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 27 in the sequence of Figure 3 (SEO ID NOS:2 and 51. It is noted, however, that the C-terminal boundary of the signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot~En4. 10:1-6 (1997) and von Heinje et al., Nucl. Acids.
Res.14:4683-4690 (1986)1. Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding them, are contemplated by the present invention. As such, for purposes of the present application, the signal peptide of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5) extends from amino acids 1 to X of Figure 3 (SEO ID NOS:2 and 51, wherein X is any amino acid from 23 to 32 of Figure 3 (SED ID NOS:2 and 5). Therefore, mature forms of the CHEPO polypeptide which are encompassed by the present invention include those comprising amino acids X to 193 of Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid from 23 to 32 of Figure 3 (SEO ID NOS:2 and 51 and variants thereof as described below.
Isolated nucleic acid molecules encoding these polypeptides are also contemplated.
Another embodiment is directed to fragments of a CHEPO polypeptide coding sequence that may find use as, for example, hybridization probes or for encoding fragments of a CHEPO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-CHEPO antibody. Such nucleic acid fragments are usually at least about 20 2 0 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides 2 5 in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides 3 0 in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term about means the referenced nucleotide sequence length plus or minus 10% of that referenced length. In a preferred embodiment, the nucleotide sequence fragment is derived from 35 any coding region of the nucleotide sequence shown in Figure 1 (SEO ID
N0:1). It is noted that novel fragments of a CHEPO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the CHEPO
polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which CHEPO polypeptide-encoding nucleotide sequence fragments) are novel. All of such CHEPO polypeptide-encoding nucleotide sequences are contemplated herein and can be determined without undue experimentation. Also contemplated are the CHEPO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those CHEPO polypeptide fragments that comprise a binding site for an anti-CHEPO
antibody.
In another embodiment, the invention provides a vector comprising a nucleotide sequence encoding CHEPO or its variants. The vector may comprise any of the isolated nucleic acid molecules hereinabove identified.
A host cell comprising such a vector is also provided. By way of example, the host cells may be CHO cells, E.
coli, or yeast. A process for producing CHEPO polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of CHEPO and recovering CHEPO from the cell culture.
In another embodiment, the invention provides isolated CHEPO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence CHEPO
polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues from about 1 or about 28 to about 193 of Figure 3 (SED ID NOS:2 and 5).
In another aspect, the invention concerns an isolated CHEPO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81 % amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence 2 0 identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89%
amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96%
amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5).
3 0 In a further aspect, the invention concerns an isolated CHEPO polypeptide comprising an amino acid sequence scoring at least about 80% positives, alternatively at least about 81 %
positives, alternatively at least about 82% positives, alternatively at least about 83% positives, alternatively at least about 84%
positives, alternatively at least about 859'0 positives, alternatively at least about 869'o positives, alternatively at least about 87% positives, alternatively at least about 88°io positives, alternatively at least about 89% positives, alternatively at least about 90% positives, alternatively at least 3 5 about 919'o positives, alternatively at least about 92°Yo positives, alternatively at least about 93% positives, alternatively at least about 94% positives, alternatively at least about 95% positives, alternatively at least about 96% positives, alternatively at least about 979'° positives, alternatively at least about 98% positives and alternatively at least about 99%
positives when compared with the amino acid sequence of residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 51.
In a specific aspect, the invention provides an isolated CHEPO polypeptide without the N-terminal signal sequence andlor the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the CHEPO polypeptide and recovering the CHEPO
polypeptide from the cell culture.
In yet another aspect, the invention concerns an isolated CHEPO polypeptide, comprising the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 ISEO ID NOS:2 and 51, or a fragment thereof which is biologically active or sufficient to provide a binding site for an anti-CHEPO antibody, wherein the identification of CHEPO polypeptide fragments that possess biological activity or provide a binding site for an anti-CHEPO antibody may be accomplished in a routine manner using techniques which are well known in the art. Preferably, the CHEPO fragment retains a qualitative biological activity of a native CHEPO polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a CHEPO
polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID
NOS:2 and 5), or (b) the complement of the DNA molecule of (al, and if the test DNA molecule has at least about an 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, 2 0 alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 859'° nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 879'° nucleic acid sequence identity, alternatively at least about 88°Y° nucleic acid sequence identity, alternatively at least about 899'° nucleic acid sequence identity, alternatively at least about 90%
nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 2 5 92% nucleic acid sequence identity, alternatively at least about 93%
nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95%
nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) or (bl, (ii) culturing a host cell comprising the test DNA
molecule under conditions suitable for expression of 3 0 the polypeptide, and (iii) recovering the polypeptide from the cell culture.
In another embodiment, the invention provides chimeric molecules comprising a CHEPO polypeptide fused to a heterologous polypeptide or amino acid sequence, wherein the CHEPO polypeptide may comprise any CHEPO polypeptide, variant or fragment thereof as hereinbefore described. An example of such a chimeric molecule comprises a CHEPO
polypeptide fused to an epitope tag sequence or a Fc region of an immunoglobulin.
In another embodiment, the invention provides an antibody as defined below which specifically binds to a CHEPO
polypeptide as hereinbefore described. Optionally, the antibody is a monoclonal antibody, an antibody fragment or a single chain antibody.
In yet another embodiment, the invention concerns agonists and antagonists of a native CHEPO polypeptide as defined below. In a particular embodiment, the agonist or antagonist is an anti-CHEPO antibody or a small molecule.
In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a CHEPO
polypeptide which comprise contacting the CHEPO polypeptide with a candidate molecule and monitoring a biological activity mediated by said CHEPO polypeptide. Preferably, the CHEPO polypeptide is a native CHEPO polypeptide.
In a still further embodiment, the invention concerns a composition of matter comprising a CHEPO polypeptide, or an agonist or antagonist of a CHEPO polypeptide as herein described, or an anti-CHEPO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.
Another embodiment of the present invention is directed to the use of a CHEPO
polypeptide, or an agonist or antagonist thereof as herein described, or an anti-CHEPO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the CHEPO polypeptide, an agonist or antagonist thereof or an anti-CHEPO
antibody.
Yet another embodiment of the present invention is directed to CHEPO
polypeptides having altered glycosylation patterns in one or more regions of the polypeptide as compared to the native sequence CHEPO polypeptide, preferably in the region surrounding andlor including amino acid position 84 in the CHEPO
amino acids sequence shown in Figure 3 (SEO
ID NOS:2 and 51. In various embodiments, CHEPO variant polypeptides are prepared using well known techniques so as 2 0 to create an N- or 0-linked glycosylation site at or near amino acid position 84 in the CHEPO polypeptide sequence. For example, CHEPO polypeptides contemplated by the present invention include those where la) amino acids 81-84 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Met-Glu-Ual-Arg; SEO ID N0:6) are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X ISEO ID
N0:81, where X is any amino acid except for Pro; (b) amino acids 82-85 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Glu-Val-Arg-Gln; SEO ID N0:9) are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID
N0:7) or AsmX-Thr-X (SEO ID N0:8), where X is any amino acid except for Pro; (c) amino acids 83-86 of the CHEPO
amino acid sequence shown in Figure 3 (SEO
ID NOS:2 and 5) (i.e., Ual-Arg-Gln-Gln; SEO ID N0:101 are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X ISEO ID N0:81, where X is any amino acid except for Pro; or (d) amino acids 84-87 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Arg-Gln-Gln-Ala;
SEO ID N0:11 ) are replaced by the amino acid 3 0 sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X (SEO ID N0:8), where X
is any amino acid except for Pro, thereby creating an N-glycosylation site at those positions. Nucleic acids encoding these variant polypeptides are also contemplated herein as are vectors and host cells comprising those nucleic acids.
BRIEF DESCRIPTION OF THE DRAWINGS
3 5 Figures 1 A-C show a nucleotide sequence (SEO ID N0:1 ) of an isolated genomic DNA molecule containing a nucleotide sequence (nucleotides 134-146, 667-812, 1071-1157, 1760-1939 and 2074-2226, exclusive of others) encoding native sequence CHEPO. Also presented in the genomic sequence are the locations of the start codon, exons and introns as well as the amino acid sequence (SEO ID N0:2) encoded by the coding sequence of SEO ID N0:1.
Figure 2 shows the cDNA sequence of the CHEPO molecule (SEtl ID N0:3) and the amino acid sequence encoded thereby (SEQ ID N0:21.
Figure 3 shows a comparison of the human erythropoietin amino acid sequence (human) (SEQ ID N0:4) and that of the chimp erythropoietin (chepo) described herein, wherein the amino acid designated X at amino acid position 142 of the CHEPO sequence is either glutamine (SEl1 ID N0:2) or lysine ISEO ID N0:5).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. Definitions The terms "CHEPO polypeptide", "CHEPO protein" and "CHEPO" when used herein encompass native sequence CHEPO and CHEPO polypeptide variants (which are further defined hereinl. The CHEPO polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant and/or synthetic methods.
A "native sequence CHEPO" comprises a polypeptide having the same amino acid sequence as a CHEPO derived from nature. Such native sequence CHEPO can be isolated from nature or can be produced by recombinant andlor synthetic means. The term "native sequence CHEPO" specifically encompasses naturally-occurring truncated or secreted forms (eg., an extracellular domain sequenceh naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the CHEPO. In one embodiment of the invention, the native sequence CHEPO is a mature or 2 0 full-length native sequence CHEPO comprising amino acids 1 to 193 of Figure 3 (SEQ ID NOS:2 and 51. Also, while the CHEPO polypeptides disclosed in Figure 3 (SEO ID NOS:2 and 5) is shown to begin with the methionine residue designated herein as amino acid position 1, it is conceivable and possible that another methionine residue located either upstream or downstream from amino acid position 1 in Figure 3 (SEQ ID NOS:2 and 5) may be employed as the starting amino acid residue for the CHEPO polypeptide.
"CHEPO variant polypeptide" means an active CHEPO polypeptide as defined below having at least about 80%
amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEQ ID NOS:2 and 51, (b) X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SEO ID NOS:2 and 51 or (c) another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 51.
Such CHEPO variant polypeptides include, 3 0 for instance, CHEPO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- andlor C-terminus, as well as within one or more internal domains, of the sequence of Figure 3 (SEO ID NOS:2 and 51. Ordinarily, a CHEPO variant polypeptide will have at least about 809'o amino acid sequence identity, alternatively at least about 81 amino acid sequence identity, alternatively at least about 82~o amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least 3 5 about 859'o amino acid sequence identity, alternatively at least about 86%
amino acid sequence identity, alternatively at least about 879'o amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 899'° amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 ~° amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 949'° amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 989'°
amino acid sequence identity and alternatively at least about 99% amino acid sequence identity with (a) residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 51, (b) X to 193 of the CHEPO polypeptide shown in Figure 3 (SED ID NOS:2 and 51, wherein X is any amino acid residue from 23 to 32 of Figure 3 (SEO ID NOS:2 and 5) or (c) another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5).
CHEPO variant polypeptides do not encompass the native CHEPO polypeptide sequence. Ordinarily, CHEPO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.
"Percent (%) amino acid sequence identity" with respect to the CHEPO
polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a CHEPO sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent 2 0 sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes 2 5 herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc.
and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., 3 0 South San Francisco, California or may be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX U4.OD.
All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises 3 5 a certain 9'° amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
antibody.
In another embodiment, the invention provides a vector comprising a nucleotide sequence encoding CHEPO or its variants. The vector may comprise any of the isolated nucleic acid molecules hereinabove identified.
A host cell comprising such a vector is also provided. By way of example, the host cells may be CHO cells, E.
coli, or yeast. A process for producing CHEPO polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of CHEPO and recovering CHEPO from the cell culture.
In another embodiment, the invention provides isolated CHEPO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence CHEPO
polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues from about 1 or about 28 to about 193 of Figure 3 (SED ID NOS:2 and 5).
In another aspect, the invention concerns an isolated CHEPO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81 % amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence 2 0 identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89%
amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96%
amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 5).
3 0 In a further aspect, the invention concerns an isolated CHEPO polypeptide comprising an amino acid sequence scoring at least about 80% positives, alternatively at least about 81 %
positives, alternatively at least about 82% positives, alternatively at least about 83% positives, alternatively at least about 84%
positives, alternatively at least about 859'0 positives, alternatively at least about 869'o positives, alternatively at least about 87% positives, alternatively at least about 88°io positives, alternatively at least about 89% positives, alternatively at least about 90% positives, alternatively at least 3 5 about 919'o positives, alternatively at least about 92°Yo positives, alternatively at least about 93% positives, alternatively at least about 94% positives, alternatively at least about 95% positives, alternatively at least about 96% positives, alternatively at least about 979'° positives, alternatively at least about 98% positives and alternatively at least about 99%
positives when compared with the amino acid sequence of residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID NOS:2 and 51.
In a specific aspect, the invention provides an isolated CHEPO polypeptide without the N-terminal signal sequence andlor the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the CHEPO polypeptide and recovering the CHEPO
polypeptide from the cell culture.
In yet another aspect, the invention concerns an isolated CHEPO polypeptide, comprising the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 ISEO ID NOS:2 and 51, or a fragment thereof which is biologically active or sufficient to provide a binding site for an anti-CHEPO antibody, wherein the identification of CHEPO polypeptide fragments that possess biological activity or provide a binding site for an anti-CHEPO antibody may be accomplished in a routine manner using techniques which are well known in the art. Preferably, the CHEPO fragment retains a qualitative biological activity of a native CHEPO polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a CHEPO
polypeptide having the sequence of amino acid residues from about 1 or about 28 to about 193, inclusive, of Figure 3 (SEO ID
NOS:2 and 5), or (b) the complement of the DNA molecule of (al, and if the test DNA molecule has at least about an 80%
nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, 2 0 alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 859'° nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 879'° nucleic acid sequence identity, alternatively at least about 88°Y° nucleic acid sequence identity, alternatively at least about 899'° nucleic acid sequence identity, alternatively at least about 90%
nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 2 5 92% nucleic acid sequence identity, alternatively at least about 93%
nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95%
nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) or (bl, (ii) culturing a host cell comprising the test DNA
molecule under conditions suitable for expression of 3 0 the polypeptide, and (iii) recovering the polypeptide from the cell culture.
In another embodiment, the invention provides chimeric molecules comprising a CHEPO polypeptide fused to a heterologous polypeptide or amino acid sequence, wherein the CHEPO polypeptide may comprise any CHEPO polypeptide, variant or fragment thereof as hereinbefore described. An example of such a chimeric molecule comprises a CHEPO
polypeptide fused to an epitope tag sequence or a Fc region of an immunoglobulin.
In another embodiment, the invention provides an antibody as defined below which specifically binds to a CHEPO
polypeptide as hereinbefore described. Optionally, the antibody is a monoclonal antibody, an antibody fragment or a single chain antibody.
In yet another embodiment, the invention concerns agonists and antagonists of a native CHEPO polypeptide as defined below. In a particular embodiment, the agonist or antagonist is an anti-CHEPO antibody or a small molecule.
In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a CHEPO
polypeptide which comprise contacting the CHEPO polypeptide with a candidate molecule and monitoring a biological activity mediated by said CHEPO polypeptide. Preferably, the CHEPO polypeptide is a native CHEPO polypeptide.
In a still further embodiment, the invention concerns a composition of matter comprising a CHEPO polypeptide, or an agonist or antagonist of a CHEPO polypeptide as herein described, or an anti-CHEPO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.
Another embodiment of the present invention is directed to the use of a CHEPO
polypeptide, or an agonist or antagonist thereof as herein described, or an anti-CHEPO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the CHEPO polypeptide, an agonist or antagonist thereof or an anti-CHEPO
antibody.
Yet another embodiment of the present invention is directed to CHEPO
polypeptides having altered glycosylation patterns in one or more regions of the polypeptide as compared to the native sequence CHEPO polypeptide, preferably in the region surrounding andlor including amino acid position 84 in the CHEPO
amino acids sequence shown in Figure 3 (SEO
ID NOS:2 and 51. In various embodiments, CHEPO variant polypeptides are prepared using well known techniques so as 2 0 to create an N- or 0-linked glycosylation site at or near amino acid position 84 in the CHEPO polypeptide sequence. For example, CHEPO polypeptides contemplated by the present invention include those where la) amino acids 81-84 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Met-Glu-Ual-Arg; SEO ID N0:6) are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X ISEO ID
N0:81, where X is any amino acid except for Pro; (b) amino acids 82-85 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Glu-Val-Arg-Gln; SEO ID N0:9) are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID
N0:7) or AsmX-Thr-X (SEO ID N0:8), where X is any amino acid except for Pro; (c) amino acids 83-86 of the CHEPO
amino acid sequence shown in Figure 3 (SEO
ID NOS:2 and 5) (i.e., Ual-Arg-Gln-Gln; SEO ID N0:101 are replaced by the amino acid sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X ISEO ID N0:81, where X is any amino acid except for Pro; or (d) amino acids 84-87 of the CHEPO amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5) (i.e., Arg-Gln-Gln-Ala;
SEO ID N0:11 ) are replaced by the amino acid 3 0 sequence Asn-X-Ser-X (SEO ID N0:7) or Asn-X-Thr-X (SEO ID N0:8), where X
is any amino acid except for Pro, thereby creating an N-glycosylation site at those positions. Nucleic acids encoding these variant polypeptides are also contemplated herein as are vectors and host cells comprising those nucleic acids.
BRIEF DESCRIPTION OF THE DRAWINGS
3 5 Figures 1 A-C show a nucleotide sequence (SEO ID N0:1 ) of an isolated genomic DNA molecule containing a nucleotide sequence (nucleotides 134-146, 667-812, 1071-1157, 1760-1939 and 2074-2226, exclusive of others) encoding native sequence CHEPO. Also presented in the genomic sequence are the locations of the start codon, exons and introns as well as the amino acid sequence (SEO ID N0:2) encoded by the coding sequence of SEO ID N0:1.
Figure 2 shows the cDNA sequence of the CHEPO molecule (SEtl ID N0:3) and the amino acid sequence encoded thereby (SEQ ID N0:21.
Figure 3 shows a comparison of the human erythropoietin amino acid sequence (human) (SEQ ID N0:4) and that of the chimp erythropoietin (chepo) described herein, wherein the amino acid designated X at amino acid position 142 of the CHEPO sequence is either glutamine (SEl1 ID N0:2) or lysine ISEO ID N0:5).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. Definitions The terms "CHEPO polypeptide", "CHEPO protein" and "CHEPO" when used herein encompass native sequence CHEPO and CHEPO polypeptide variants (which are further defined hereinl. The CHEPO polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant and/or synthetic methods.
A "native sequence CHEPO" comprises a polypeptide having the same amino acid sequence as a CHEPO derived from nature. Such native sequence CHEPO can be isolated from nature or can be produced by recombinant andlor synthetic means. The term "native sequence CHEPO" specifically encompasses naturally-occurring truncated or secreted forms (eg., an extracellular domain sequenceh naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the CHEPO. In one embodiment of the invention, the native sequence CHEPO is a mature or 2 0 full-length native sequence CHEPO comprising amino acids 1 to 193 of Figure 3 (SEQ ID NOS:2 and 51. Also, while the CHEPO polypeptides disclosed in Figure 3 (SEO ID NOS:2 and 5) is shown to begin with the methionine residue designated herein as amino acid position 1, it is conceivable and possible that another methionine residue located either upstream or downstream from amino acid position 1 in Figure 3 (SEQ ID NOS:2 and 5) may be employed as the starting amino acid residue for the CHEPO polypeptide.
"CHEPO variant polypeptide" means an active CHEPO polypeptide as defined below having at least about 80%
amino acid sequence identity with the amino acid sequence of (a) residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEQ ID NOS:2 and 51, (b) X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SEO ID NOS:2 and 51 or (c) another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 51.
Such CHEPO variant polypeptides include, 3 0 for instance, CHEPO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- andlor C-terminus, as well as within one or more internal domains, of the sequence of Figure 3 (SEO ID NOS:2 and 51. Ordinarily, a CHEPO variant polypeptide will have at least about 809'o amino acid sequence identity, alternatively at least about 81 amino acid sequence identity, alternatively at least about 82~o amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least 3 5 about 859'o amino acid sequence identity, alternatively at least about 86%
amino acid sequence identity, alternatively at least about 879'o amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 899'° amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 ~° amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 949'° amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 989'°
amino acid sequence identity and alternatively at least about 99% amino acid sequence identity with (a) residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 51, (b) X to 193 of the CHEPO polypeptide shown in Figure 3 (SED ID NOS:2 and 51, wherein X is any amino acid residue from 23 to 32 of Figure 3 (SEO ID NOS:2 and 5) or (c) another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5).
CHEPO variant polypeptides do not encompass the native CHEPO polypeptide sequence. Ordinarily, CHEPO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.
"Percent (%) amino acid sequence identity" with respect to the CHEPO
polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a CHEPO sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent 2 0 sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes 2 5 herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc.
and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., 3 0 South San Francisco, California or may be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX U4.OD.
All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises 3 5 a certain 9'° amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction XIY
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations, Tables 2 and 3 below demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated Comparison Protein to the amino acid sequence designated PRO .
Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program.
However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res.
25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http:llwww.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 1515, multi-pass e-value =
0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain %
amino acid sequence identity to, with, or 2 0 against a given amino acid sequence B) is calculated as follows:
100 times the fraction XIY
where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-2 5 BLAST2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the °Yo amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
"CHEPO variant polynucleotide" or CHEPO variant nucleic acid sequence means a nucleic acid molecule which encodes an active CHEPO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity 3 0 with either f a) a nucleic acid sequence which encodes residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SED ID NOS:2 and 51, (b) a nucleic acid sequence which encodes residues X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SED ID NOS:2 and 5) or (c) a nucleic acid sequence which encodes another.specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5). Ordinarily, a CHEPO variant polynucleotide will have at least about 80% nucleic 3 5 acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82%
nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 849'° nucleic acid sequence identity, alternatively at least about 85%
nucleic acid sequence identity, alternatively at least about 869'° nucleic acid sequence identity, alternatively at least about 879'° nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'° nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97%
nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 51, (b) a nucleic acid sequence which encodes residues_X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SED ID NOS:2 and 5) or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5).
CHEPO polynucleotide variants do not encompass the native CHEPO nucleotide sequence.
Ordinarily, CHEPO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 2 0 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.
"Percent (%) nucleic acid sequence identity" with respect to the CHEPO
polypeptide-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a CHEPO polypeptide-encoding nucleic acid sequence, after aligning the sequences and introducing gaps, if 2 5 necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % nucleic acid sequence 3 0 identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No.
TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may 3 5 be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX
operating system, preferably digital UNIX V4.OD. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
For purposes herein, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain 9'° nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction WIZ
where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program s alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5 below demonstrate how to calculate the %
nucleic acid sequence identity of the nucleic acid sequence designated Comparison DNA to the nucleic acid sequence designated PRO-DNA .
Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program.
However, % nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res.
25:3389-3402 (19971). The NCBI-BLAST2 sequence comparison program may be downloaded from 2 0 http:llwww.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand m all, expected occurrences = 10, minimum low complexity length = 1515, multi-pass e-value =
0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for sequence comparisons, the %
nucleic acid sequence identity 2 5 of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain ~°
nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction WIZ
where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program s alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.
3 5 In other embodiments, CHEPO variant polynucleotides are nucleic acid molecules that encode an active CHEPO
polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding the full-length CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5). CHEPO variant polypeptides may be those that are encoded by a CHEPO variant polynucleotide.
The term "positives", in the context of the amino acid sequence identity comparisons performed as described above, includes amino acid residues in the sequences compared that are not only identical, but also those that have similar properties. Amino acid residues that score a positive value to an amino acid residue of interest are those that are either identical to the amino acid residue of interest or are a preferred substitution (as defined in Table 6 below) of the amino acid residue of interest.
For purposes herein, the % value of positives of a given amino acid sequence A
to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain positives to, with, or against a given amino acid sequence B1 is calculated as follows:
100 times the fraction XIY
where X is the number of amino acid residues scoring a positive value as defined above by the sequence alignment program ALIGN-2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the °Y°
positives of A to B will not equal the % positives of B to A.
"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated andlor recovered from a component of its natural environment. Preferably, the isolated polypeptide 2 0 is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing 2 5 conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the CHEPO natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
An "isolated" nucleic acid molecule encoding a CHEPO polypeptide is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural 3 0 source of the CHEPO-encoding nucleic acid. Preferably, the isolated nucleic is free of association with all components with which it is naturally associated. An isolated CHEPO-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the CHEPO-encoding nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule encoding a CHEPO polypeptide includes CHEPO-encoding nucleic acid molecules contained in cells that ordinarily express CHEPO where, for example, the 3 5 nucleic acid molecule is in a chromosomal location different from that of natural cells.
The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretary leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretary leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-CHEPO
monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-CHEPO antibody compositions with polyepitopic specificity, single chain anti-CHEPO antibodies, and fragments of anti-CHEPO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally 2 0 is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend 2 5 to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biolo4y, Wiley Interscience Publishers,11995).
"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (11 employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride10.0015 M sodium 3 0 citrate10.1 ~ sodium dodecyl sulfate at 50 C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (vlv) formamide with 0.1 % bovine serum albumin10.1 % Fico1110.1 % polyvinylpyrrolidone150mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH
6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt s solution, sonicated salmon sperm DNA (50 glmll, 0.1 % SDS, and 10%
dextran sulfate at 42 C, with washes 3 5 at 42 C in 0.2 x SSC (sodium chloridelsodium citrate) and 50% formamide at 55 C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A
L.aboratorv Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37 C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCI,15 mM trisodium citratel, 50 mM sodium phosphate (pH 7.61, 5 x Denhardt s solution, 10% dextran sulfate, and 20 mglml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a CHEPO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes.
Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains.
Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"1, and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence 2 0 comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2/, IgE, IgD or IgM.
"Active" or "activity" for the purposes herein refers to formls) of CHEPO
which retain a biological andlor an immunological activity of native or naturally-occurring CHEPO, wherein biological activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring CHEPO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring CHEPO and an immunological activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring CHEPO. Preferred biological activities includes, for example, the ability to regulate red blood cell production, to bind to receptors on the surface of committed progenitor cells of the bone marrow andlor other 3 0 hematopoietic tissues andlor to induce proliferation andlor terminal maturation of erythroid cells.
The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native CHEPO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native CHEPO
polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies 3 5 or antibody fragments, fragments or amino acid sequence variants of native CHEPO polypeptides, peptides, small organic molecules, etc. Methods for identifying agonists or antagonists of a CHEPO
polypeptide may comprise contacting a CHEPO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the CHEPO polypeptide.
"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessens the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
"Chronic" administration refers to administration of the agents) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect lactivity) for an extended period of time. Intermittent administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.
"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc.
Preferably, the mammal is human.
Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine;
2 0 monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; andlor nonionic surfactants such as TWEEN , polyethylene glycol (PEG), and PLURONICS .
"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab'IZ, and Fv fragments; diabodies; linear 2 5 antibodies IZapata et al., Protein Ena. 8110): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily.
Pepsin treatment yields an Flab'Iz fragment that has two antigen-combining sites and is still capable of cross-linking 3 0 antigen.
"Fv" is the minimum antibody fragment which contains a complete antigemrecognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-V~ dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable 3 5 domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residues! of the constant domains bear a free thiol group. F(ab'IZ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGI, IgG2, IgG3, IgG4, IgA, and IgA2.
"Single-chain Fv" or "sFv" antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacolony of Monoclonal Antibodies vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH - VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains 2 0 are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93111161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 ( 1993).
An "isolated" antibody is one which has been identified and separated andlor recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with 2 5 diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1 ) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99%
by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue ar, preferably, silver stain.
3 0 Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope 3 5 labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glassh polysaccharides (e.g., agaroseh polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography columnl. This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
A "liposome" is a small vesicle composed of various types of lipids, phospholipids andlor surfactant which is useful for delivery of a drug (such as a CHEPO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
A small molecule is defined herein to have a molecular weight below about 500 Daltons.
Table 1 I*
*
* C-C increased from 12 to 15 * Z is average of EO
* B is average of ND
* match with stop is M; stop-stop = 0; J (joker) match = 0 .I
#define _M -8 I* value of a match with a stop *I
int -day[26][261 = {
I* A B C D E F G H I J
T U V W X Y Z *I
I* A { 2, 0,-2, 0, 0.-4, M. 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, *I 1.-1,-1, 0,-1,-2,-1, 0}, I* B { 0, 3,-4, 3, 2,-5, M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, *I 0, 1,-2, 0, 0,-3,-2, 1}, 2_ I* {-2,-4,15,-5,-5,-4,-3,-3,-2,M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5}, C *I 0,-5,-6,-5,-4, I* D { 0, 3,-5, 4, 3,-6, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, *I 1, 1,-2, 0, 0,-4,-3, 2}, I* E { 0, 2,-5, 3, 4,-5, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, *I 0, 1,-2, 0, 0,-3,-2, 3}, 1 _ I* F {-4,-5,-4,-6,-5, 9,-5,-2,-M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5}, *I 1, 0,-5, 2, 0,-4, I* G { 1, 0,-3, 1, 0,-5, _M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, *I 5,-2,-3, 0,-2,-4,-3, 0}, 0, I* {-1, 1,-3, 1, 1,-2,-2,-M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, H *I 6,-2, 0, 0,-2,-2, 2}.
2, I* I {-1,-2,-2,-2,-2, 1,-3,-2,M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2}, *I 5, 0,-2, 2, 2,-2 _ I*J*I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I* K {-1, 0,-5, 0, 0,-5,-2,M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, *I 0,-2, 0, 5,-3, 0, 0}, I* L {-2,-3,-6,-4,-3, 2,-4,-2,M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2}, */ 2, 0,-3, 6, 4,-3 _ 2 5 I* I {-1,-Z,-5.-3,-2, M,-2,-1. 0.-2,-1. 0, 2,-4, 0,-2,-1 M * 0,-3,-2, 2, 0, 0, }, 4, 6,-2 _ I* N { 0, 2,-4, 2, 1,-4, M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, * I 0, 2,-2, 0, 1,-3,-2, 1 }, I* 0 { M _M _M -M _M _M M _M -M -M _M, 0 -M -M -M _M -M
*I -M _M -M - -M -M _M -M -M _M}, I* P { 1,-1,-3,-1,-1,-5,-1,_M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, *I 0,-2, 0,-1,-3,-2,-1, 0}, I* 0 { 0, 1,-5, 2, 2,-5,-1,_M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, *I 3,-2, 0, 1,-2,-1, 3}, 1, 3 0 I* {-2, 0,-4,-1,-1,-4,-3,M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, R *I 2,-2, 0, 3,-3, 0, 0}, 0 _ I* S { 1, 0, 0, 0, 0,-3, M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, "I 1,-1,-1, 0, 0,-3,-2, 0}, 1 _ I* T { 1, 0,-2, 0, 0,-3, _M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, *I 0,-1, 0, 0, 0,-1,-1, 0}, 0, I*U*I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I* ~ { 0~-2.-2.-2--2~-1--1--2--M--1~-2.-2--1- 0- 0 4--6. 0--2.-2}, *I 4. 0.-2. 2~ 2.-2 3 5 I* I {-6,-5,-8,-7,-7, _M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6}, W * 0,-7,-3,-5, 0,-3,-2,-4,-4, I*X"I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I' Y'I {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2, M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4}, I" Z "I { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1 _M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
};
Table t Icont ) I*
*I
#include < stdio.h >
#include < ctype.h >
#define MAXJMP 16 I* max jumps in a diag *I
#define MAXGAP24 I* continue to penalize gaps don'tlarger than this *I
#define JMPS 1024 I* max jmps in an path *I
#defineMX 4 I* save if there's at least MX-1 bases since last jmp *I
#define DMAT 3 I* value of matching bases *I
#define DMIS 0 I* penalty for mismatched bases *I
#define DINSO 8 I* penalty for a gap *I
#defineDINS1 1 I* penalty per base *I
#define PINSO 8 I* penalty for a gap *I
#define PINS1 4 I* penalty per residue *I
struct jmp 2 0 short n[MAXJMP]; I* size of jmp (neg for dely] *I
unsigned short x[MAXJMP]; I* base no. of jmp in seq x *I
}; I* limits seq to 2" 16 -1 *I
struct diag ~
int score; I* score at last jmp *I
long offset; I* offset of prev block *I
short ijmp; I* current jmp index *I
struct jmp jp; I* list of jmps *I
};
struct path {
int spc; I* number of leading spaces *I
short n[JMPS]; I* size of jmp (gap) *I
int x(JMPS]; I* loc of jmp (last elem before gapl *I
3 5 };
char *ofile; I* output file name *I
char *namex[2]; I* seq names: getseqs() *I
char *prog; I* prog name for err msgs *I
char *seqx[2]; I* seqs: getseqsl) *I
int dmax; I* best diag: nwp *I
int dmax(); I* final diag *I
int dna; I* set if dna: maim) *I
int endgaps; I" set if penalizing end gaps *I
int gapx, gapy; I* total gaps in seqs *I
int IenO, lenl; I* seq lens *I
int ngapx, ngapy;I* total size of gaps *I
int smax; I* max score: nwl) *I
int *xbm; I* bitmap for matching *I
long offset; I* current offset in jmp file *I
struct *dx; I* holds diagonals diag *I
struct path pp(2]; I* holds path for seqs *I
char *calloc(1, *mallocll, *index0, *strcpy();
char *getseq0, *g calloc0;
Table 1 Icont ) Ix Needleman-Wunsch alignment program x x usage: progs filel filet x where filel and filet are two dna or two protein sequences.
x The sequences can be in upper- or lower-case an may contain ambiguity x Any lines beginning with ';', ' > ' or ' <' are ignored x Max file length is 65535 (limited by unsigned short x in the jmp struct) x A sequence with 113 or more of its elements ACGTU is assumed to be DNA
" Output is in the file "align.out"
x x The program may create a tmp file in Itmp to hold info about traceback.
" Original version developed under BSD 4.3 on a vax 8650 xl #include "nw.h"
#include "day.h"
static dbval(26] a {
1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0 2 0 ~;
static pbval[26]
1, 2 ~ (1 < < ('D'-'A')1 ~ (1 < < ('N'-'A'11, 4, 8, 16, 32, 64, 128, 256, OxFFFFFFF, 1 « 10, 1 « 11, 1 « 12, 1 « 13, 1 « 14, 1«15,1«16,1«17,1«18,1«19,1«20,1«21,1«22, 1 < < 23, 1 < < 24, 1 < < 25 ~ (1 < < ('E'-'A'1) ~ (1 < < ('O'-'A'1) };
mainlac, av] main 3 0 int ac;
char xav[];
prog - av[0];
if (ac ! = 3) {
3 5 fprintf(stderr,"usage: %s filel file2ln", prog];
fprintflstderr,"where filel and filet are two dna or two protein sequences.ln");
fprintf(stderr,"The sequences can be in upper- or lower-casein");
fprintf(stderr,"Any lines beginning with ';' or ' <' are ignoredln"1;
fprintflstderr,"Output is in the file I"align.outl"In"1;
exit111;
namex[0] - av(1];
namex[1] - av[2];
seqx(0] - getseq(namex[0], &Ien0l;
seqx[1] = getseqlnamex[1], &1en11;
xbm = (final? dbval : _pbval;
endgaps = 0; I* 1 to penalize endgaps *I
ofile = "align.out"; I* output file *I
nw0; I* fill in the matrix, get the possible jmps *I
readjmps(1; I* get the actual jmps *I
print0; I* print stats, alignment *I
cleanup(0); I* unlink any tmp files *I
Table 1 (coot 1 I* do the alignment, return best score: main() * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983 * pro: PAM 250 values * When scares are equal, we prefer mismatches to any gap, prefer * a new gap to extending an ongoing gap, and prefer a gap in seqx * to a gap in seq y.
*I
nw0 nw char *px, *py; I* seqs and ptrs *I
int *ndely, I* keep track *dely; of dely *I
int ndelx, delx;I* keep track of deli *I
int *tmp; I* for swapping row0, rowl *I
int mis; I* score for each type *I
int ins0, inst;I* insertion penalties *I
register id; I* diagonal index *I
register ij; I* jmp index *I
register *col0, *coll;I* score for curr, last row *I
2 0 register xx, yy; I* index into seqs *I
dx = (struct diag *)g callocl"to get diags", IenO+lenl + 1, sizeoflstruct diag)1;
ndely = (int *)g calloc("to get ndely", lenl +1, sizeoflint));
dely = lint *)g callocl"to get dely", lenl+1, sizeof(int)1;
col0 = (int *Ig callocl"to get col0", lenl +1, sizeof(int));
toll = (int *)g calloc("to get coil", lenl +1, sizeof(intll;
ins0 = Idna1? DINSO : PINSO;
insl = Idna)? DINS1 : PINS1;
smax = -10000;
if (endgaps) {
for (col0[0] = dely[0] _ -ins0, yy - 1; yy < = lenl; yy++) f col0[yy1 = dely[yy] = col0[yy-1] - insl;
3 5 ndely[yy] - yy;
col0(0] - 0; I" Waterman Bull Math Biol 84 "I
else for (yy = 1; yy < = lenl; yy++) dely[yy] - -ins0;
I" fill in match matrix "I
for (px = seqx[0], xx = 1; xx < - IenO; px++, xx++) {
I" initialize first entry in col "I
if (endgaps) {
if (xx - - 1) coll[0] = delx = -/ins0+instl;
else coll(0] = deli = col0[0] - insl;
ndelx = xx;
else {
2 0 col l (0] = 0;
delx - -ins0;
ndelx = 0;
Table 1 Icont 1 ...nw for (py = seqx[1], yy = 1; yy < = lenl; py++, yy++) {
mis = col0[yy-1];
if (dna) mis + _ (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
else mis += day[*px-'A'][*py-'A'l;
I* update penalty for del in x seq;
* favor new del over ongong del * ignore MAXGAP if weighting endgaps *I
if (endgaps ~ ~ ndely[yy] < MAXGAP) {
if (col0[yy] - ins0 > = dely(yy]) {
dely[yy] = col0[yy] - (ins0+insl );
ndely[yy] = 1;
} else {
dely[yy] -= insl;
2 0 ndely[yy]+ +;
} else {
if (col0[yy] - (ins0+insl) > = dely[yy]) {
dely[yy] = col0(yy] - (ins0+insl );
ndely[yy] = 1;
} else ndely[yy]+ +;
3 0 I* update penalty for del in y seq;
* favor new del over ongong del *I
if (endgaps ~ ~ ndelx < MAXGAP) {
if (coll[yy-1] - ins0 > = delx) {
delx = coil[yy-1]-(ins0+insl);
ndelx = 1;
} else ~
delx -- insl;
ndelx++;
}
} else {
if (colt[yy-1] - (ins0+insl) > = delx) {
delx = coil[yy-1]-(ins0+ins1l;
ndelx = 1;
} else ndelx++;
}
I" pick the maximum score; we're favoring " mis over any del and delx over dely "I
Table 1 Icont 1 ...nw id = xx - yy + lenl - 1;
if (mis > = delx && mis > = dely[yy]) call[yy] = mis;
else if (delx > = dely[yy]) {
coil[yy] = delx;
ij = dx[id].ijmp;
if (dx(id].jp.n[0] && (!dna ~ ~ (ndelx > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINS011 {
dx[id].ijmp++;
if (++ij > = MAXJMP) {
writejmps(idl;
ij = dx[id].ijmp = 0;
dx[id].offset = offset;
offset += sizeoflstruct jmp) + sizeofloffsetl;
dx[id].jp.n[ij] = ndelx;
2 0 dx[id].jp.x[ij] = xx;
dx[id].score = delx;
else {
coil[YV] = dely[YY];
2 5 ij = dx(id].ijmp;
if (dx[id].jp.n[0] && (!dna ~ ~ (ndely[yy] > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO)) {
dx[id].ijmp+ +;
if (++ij > = MAXJMP) {
3 0 writejmps(idl;
ij = dx(id].ijmp - 0;
dx[id].offset = offset;
offset + = sizeoflstruct jmp) + sizeofloffset);
dx[id].jp.n[ij] _ -ndely[yy];
dx[id].jp.x[ij] - xx;
dx(id].score - dely[yy];
if Ixx = = IenO && yy < len 1 ) {
I" last cal "I
if (endgaps) coil[yy]-= ins0+insl"Ilen1-yy);
if (coil(yy] > smax) {
smax = cal t [yy];
dmax = id;
if (endgaps && xx < Ien0) toll[yy-1]-= ins0+insl"pen0-xx);
if (toll[yy-1] > smax) {
smax = toll[yy-1];
dmax = id;
tmp = col0; col0 = call; coil = tmp;
(void) freellchar ")ndelyl;
(void) freellchar ")delyl;
2 5 (void) freellchar "Ico101;
paid) freellchar ")co111; }
Table 1 Icont 1 I*
*
* print() -- only routine visible outside this module * static:
* getmatl) -- trace back best path, count matches: print() * pr align/) -- print alignment of described in array p[]: print/) * dumpblockl) -- dump a block of lines with numbers, stars: pr_align() * numsl) -- put out a number line: dumpblockp * putlinel) -- put out a line (name, [num], seq, [num]I: dumpblock() * stars/) - -put a line of stars: dumpblockQ
* stripnamel] -- strip any path and prefix from a seqname *I
#include "nw.h"
#define SPC 3 #define P LINE 256 I* maximum output line *I
2 0 #define P SPC 3 I* space between name or num and seq *I
extern day[26][26];
int oleo; I* set output line length *I
FILE *fx; I" output file *I
print/) print f int Ix, ly, firstgap, lastgap; I* overlap *I
3 0 if ((fx = fopenlofile, "w"1) - - 0) {
fprintflstderr,"%s: can't write %sln", prog, ofilel;
cleanup(11;
fprintflfx, " < first sequence: %s length - %dlln", namex[0], Ien0l;
3 5 fprintflfx, " < second sequence: %s (length = %dlln", namex[1 ], lenl ];
oleo - 60;
Ix = IenO;
ly = lenl;
firstgap - lastgap = 0;
if (dmax < lenl - 1) { I* leading gap in x *I
pp[0].spc = firstgap = lenl - dmax - 1;
ly -- pp[0].spc;
else if fdmax > lenl - 1) { I* leading gap in y *I
pp[1].spc = firstgap = dmax - (lenl - 11;
Ix -= pp[1]-spc;
if (dmax0 < IenO - 1 ) { I* trailing gap in x *I
lastgap = IenO - dmax0 -1;
Ix -= lastgap;
else if (dmax0 > IenO - 1) { I* trailing gap in y *I
lastgap = dmax0 - (IenO - 1 );
ly -- lastgap;
2 0 getmat(Ix, ly, firstgap, lastgapl;
pr alignll;
Table 1 Icont ) I"
" trace back the best path, count matches "I
static getmatllx, ly, firstgap, Iastgap) getmat int Ix, ly; I" "core" (minus endgaps) "I
int firstgap, lastgap; I" leading trailing overlap "I
int nm, i0, i1, siz0, sizl;
char outx[321;
double pct;
register n0, n1;
register char "p0, "p1;
" get total matches, score "I
i0=i1 =siz0=sitl =0;
p0 s seqx[0] + PP[1].spc;
p1 = seqx[1] + pp[0].spc;
n0 - pp[1].spc + 1;
n1 = pp(0].spc + 1;
nm=0;
while ( "p0 && "p1 ) ~
if (siz0) {
p1++;
nl++;
siz0--;
else if (sizl) ~
p0++;
n0++;
siz 1--;
else ~
if (xbm["p0-'A']&xbm['p1-'A']) nm++;
ifln0++ _=pp[0].x[i0]) siz0 = pp[0].n[i0++];
iflnl++ _=pp[1].x[il]) sizl = pp[1].n[i1++];
p0++;
pl ++;
I" pct homology:
" if penalizing endgaps, base is the shorter seq " else, knock off overhangs and take shorter core 1 5 "~
if (endgaps) Ix = (IenO < Ienl1? IenO : lenl;
else Ix = (Ix < ly)? Ix : ly;
2 0 pct = 100."(double)nm1(double)Ix;
fprintf(fx, "In");
fprintf(fx, " < %d match%s in an overlap of %d: %.2f percent similarityln", nm, (nm = = 11? "" : "es", Ix, pct);
Table 1 Icont 1 fprintf(fx, " < gaps in first sequence: %d", gapx); ...getmat if (gapx) {
(void) sprintf(outx, " (%d %s%s)", ngapx, (dna)? "base":"residue", (ngapx = = 1 )? "":"s");
fprintflfx,"%s", outx);
fprintflfx, ", gaps in second sequence: %d", gapy);
if (gapy) (void) sprintf(outx, " (%d %s%s)", ngapy, (dual? "base":"residue", (ngapy = = 1 )? "":"s"];
fprintf(fx,"%s", outx);
if (dna) fprintflfx, "In < score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per baselln", smax, DMAT, DMIS, DINSO, DINS1);
else 2 0 fprintf(fx, "In < score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)In", smax, PINSO, PINS1);
if (endgaps) fprintf(fx, 2 5 " < endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%sln", firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s", lastgap, (final? "base" : "residue", hastgap -- 1)? "" : "s");
else fprintf(fx, " < endgaps not penalizedln"1;
static nm; I" matches in core --for checking "I
static Imax; I' lengths of stripped file names "I
static ij[2]; I' jmp index for a path 'I
3 5 static nc(2]; I' number at start of current line "I
static ni[2]; I* current elem number -- for gapping "I
static siz[2];
static char *ps[2]; I* ptr to current element *I
static char *po[2]; I* ptr to next output char slat *I
static char out[2][P LINE]; I" output line *I
static char star[P LINE]; I* set by stars() *I
I*
* print alignment of described in struct path pp[]
*I
static pr align/) pr align int nn; I* char count *I
int more;
register i;
for (i = 0, Imax = 0; i < 2; i++) {
nn - stripname(namex[i]~;
if (nn > Imax) 2 0 Imax - nn;
nc[i] = 1;
ni[i] - 1;
siz[i] = ij[i] = 0;
2 5 ps[i] = seqx[i];
po[i] = out[i]; }
Table t Icont 1 for Inn = nm = 0, more = 1; more; l f ...pr align for (i = more = 0; i < 2; i++) f I*
* do we have more of this sequence?
*I
if 1!*ps[i]) continue;
mare++;
if (pp[i].spc) { I* leading space *I
*po[i]++ _ , pp[i].spc--;
else if (siz[i1) { I* in a gap *I
*po[i)++ _ , ~;
siz[i]--;
else ~ I* we're putting a seq element *I
*Po[il _ *Ps[il;
if (islower(*ps[i])) *ps[i] = toupperl*ps[i]/;
po[i]++;
Ps[i1+ +;
I*
3 0 * are we at next gap for this seq?
*I
if (ni[i] _ = PP[il.x[ij[i]1) f I*
* we need to merge all gaps 3 5 * at this location *I
siz[il - PPfil.n[ij[il++1;
while (ni[il -- pp[il.x[ij[ill) siz[il +- PP[il.n[ij[il++1;
ni[i]+ +;
if (++nn -- oleo ~ ~ !more && nn) f dumpblockll;
for (i = 0; i < 2; i++) po[il - out[i];
nn-0;
I"
dump a block of lines, including numbers, stars: pr align() "I
2 0 static dumpblock() dumpblock register i;
for (i - 0; i < 2; i++) ~po[il__ _ '10';
WO 00/68376 PCT/iJS00/12370 Table 1 (coot ) ...dumpblock (void) putc('In', fx);
for (i = 0; i < 2; i++) {
if 1*out[i) && 1*out[i] !_ ~ ~ ~ ~ *(Po[ill !- ")) {
if (i - - 0) numsli);
if (i -- 0 && "out[1]) stars0;
putline(i);
if fi =- 0 && *out[1]) fprintflfx, star);
if (i -= 1) nums(i);
2 0 I*
* put out a number line: dumpblock() static nums(ix) nums 2 5 int ix; I* index in out[] holding seq line *I
char nline[P LINE];
register i, j;
register char *pn, *px, *py;
for (pn = nline, i = 0; i < Imax+P SPC; i++, pn++) *pn = . .;
for (i = nc[ix], py = out[ix]; *py; py++, pn++) f if (*py = _ " ~ ~ *PY =- '-') *pn-";
else if (i% 10 - - 0 ~ ~ 6 - - 1 && nc[ix] ! - 11) {
j - li < 0)? -i : i;
for (px - pn; j; j I= 10, px--) '"pX ' j%10 + '0';
if (i < 0) "Px - , else "Pn ° , i++;
.Pn = ,~0..
nc[ix] = i; /
for (pn = nline;'"pn; pn++) (void) putcl"pn, fxl;
(void) putcl'In', fxl;
2 0 I"
" put out a line (name, [num], seq, [num]l: dumpblockl) "I
static putlinelix) putline 2 5 int ix;
Table 1 (coot ) ...putline int i;
register char *px;
for (px = namex[ix], i = 0; *px && *px ! _ '~'; px++, i++) (void) putcl*px, fxl;
for (; i < Imax+P SPC; i++) (void) putcl' ', fxl;
* these count from 1:
* ni[] is current element (from 1) * ncp is number at start of current line *I
for (px = out[ix]; *px; px++) (void) putt(*px&Ox7F, fx);
(void) putcl'In', fx);
I*
* put a line of stars (seqs always in out[0], out[1]): dumpblockp *I
2 5 static stars() stars f int i;
register char *p0, *p1, cx, *px;
if 1! *out[O1 ~ ~ 1"out[0) a ~ ' && *(Po[O1) - _ ' ') ~ ~
!*out[11 ~ ~ 1*out[1] a = ' ' && *Ipo[1]) a a ' '1) return;
px - star;
3 5 for (i ~ Imax+P SPC; i; i--) *px++ , , ~;
for (p0 = out[0], p1 = out[1]; "p0 && "p1; p0++, p1 ++) ~
if (isalpha("p0) && isalphal"p1)) {
if (xbm["p0-'A']&xbm["p1-'A']) ~
cx = '"';
nm++;
else if (!dna && day["p0-'A']["p1-'A'] > 0) cx=";
else cx = ' ';
else 1 5 cx = , "px++ ~ cx;
"Px++ ° ~~n';
"Px ° 't0';
Table 1 (coot I
I*
* strip path or prefix from pn, return len: pr align() *I
static stripnamelpn) stripname char *pn; I* file name (may be path) *I
register char *px, *py;
PY ' ~;
for (px = pn; *px; px++) if (*px =_ 'I') PY°Px+1;
if (py) (void) strcpy(pn, py);
return(strlen(pn));
Table 1 (coot ) I*
* cleanup() -- cleanup any tmp file * getseq(1-- read in seq, set dna, len, maxlen * g calloc() -- callocp with error checkin * readjmpsU -- get the good jmps, from tmp file if necessary * writejmps() -- write a filled array of jmps to a tmp file: nw() *I
#include "nw.h"
#include < sysl file.h >
char *jname = "ItmplhomgXXXXXX"; I* tmp file for jmps *I
FILE *tj;
int cleanup0; I* cleanup tmp file *I
long Iseekll;
I*
* remove any tmp file if we blow 2 0 *I
cleanup(i) cleanup int i;
if (fj) 2 5 (void) unlink(jnamel;
exit(il;
I*
3 0 * read, return ptr to seq, set dna, len, maxlen * skip lines starting with ';', ' < ', or ' > ' * seq in upper or lower case *I
char *
3 5 getseqlfile, len) getseq char *file; I* file name *I
int *len; I* seq ten *I
f char line[1024], *pseq;
register char *px, *py;
int natgc, tlen;
FILE *fp;
if ((fp = fopenlfile,"r"11 == 0) {
fprintf(stderr,"%s: can't read %sln", prog, filet;
exit(11;
tlen = natgc = 0;
while (fgets(line, 1024, fpl) {
if ("line = - ,' ~ ~ "line = _ ' <' ~ ~ "line = - ' > ') continue;
for (px = line; *px ! _ 'In'; px++) if (isupperl*px) ~ ~ islowerl*px)) tlen++;
2 0 if (Ipseq = mallocl(unsignedlltlen+6))) _ = 01 {
fprintf(stderr,"%s: mallocl) failed to get %d bytes for %sln", prog, tlen+(i, filet;
exit111;
pseq[0] = pseq[1] = pseq[2] = pseq[3) _ '10';
Table 1 (coot 1 ...getseq PY - Pseq + 4;
*len - tlen;
rewind(fpl;
while (fgetslline, 1024, fpl) f if (*line -- ';' ~ ~ *line -- ' <' ~ ~ *line - _ ' >') continue;
for (px - line; *px !_ 'In'; px++) if (isupper(*px)) *PY++ - *Px;
else if (islowerl*px)) *py++ = toupperl*px);
if (index)"ATGCU",*(py-1))) natgc+ +;
*pY++ a ~~0~.
*PY -'10'; I
(void) fclose(fpl;
dna - natgc > (tlenl3l;
return(pseq+41;
char *
g calloclmsg, nx, sz) g calloc char *msg; I* program, calling routine *I
int nx, sz; I* number and size of elements *I
char *px, *callocll;
if ((px = callocl(unsigned)nx, (unsignedlszl) _ - 0) {
if (*msg) {
3 5 fprintf(stderr, "%s: g callocU failed %s fn-%d, sz-%d)In", prog, msg, nx, szl;
exit(11;
returnlpx);
I"' " get final jmps from dx[] or tmp file, set pp[], reset dmax: maim) "I
readjmpsl) readjmps int fd = -1;
int siz, i0, i1;
register i, j, xx;
if (fj) {
(void) fcloselfjl;
if ((fd = open(jname, 0 RDONLY, 0)) < 0) {
fprintf(stderr, "%s: can't open() %sln", prog, jname);
cleanup(1);
for (i = i0 = i1 = 0, dmax0 = dmax, xx = IenO; ; i++) ~
while (1) {
for (j = dx[dmax].ijmp; j > = 0 && dx[dmax].jp.x[j] > = xx; j--) , Table 1 (coot 1 ...readjmps if (j < 0 && dx[dmax].offset && fj) {
(void) Iseek(fd, dx[dmax].offset, 0);
(void) read(fd, (char *)&dx[dmax].jp, sizeoflstruct jmp));
(void) readlfd, (char *)&dx(dmax].offset, sizeof(dx[dmax].offset));
dx[dmax].ijmp = MAXJMP-1;
else break;
if (i > = JMPS) {
fprintflstderr, "%s: too many gaps in alignmentln", progl;
cleanupll );
if (j >=0){
siz = dx(dmax].jp.n[j];
xx = dx[dmax].jp.x[j];
dmax += siz;
if (siz < 0) { I* gap in second seq *I
pp(1].n[i1] _ -siz;
XX + = SIZ;
I*id=xx-yy+lenl-1 *I
pp[1].x[i1] = xx - dmax + lenl - 1;
9aPY+ +.
ngapy -= siz;
I* ignore MAXGAP when doing endgaps *I
siz = (-siz < MAXGAP ~ ~ endgaps)? -siz : MAXGAP;
il++;
else if (siz > 0) { I* gap in first seq *I
pp(0].n(i0] = siz;
pp[0].x[i0] = xx;
gapx++;
ngapx + - siz;
I* ignore MAXGAP when doing endgaps 'I
siz - (siz < MAXGAP ~ ~ endgapsl? siz : MAXGAP;
i0++;
else break;
I' reverse the order of jmps 'I
for (j = 0, i0--; j < i0; j++, i0--) {
i ° PP[01.n[jl; PP[01.n[!1 - PP[01.n[i0]; PP[01.n[i0] = i;
i - PPf0l.x[jl; PP[01.x[ll - PP[01.x[i01; PPfOI.x[i0] = i;
for (j - 0, i1--; j < i1; j++, i1--1 {
i - PP[11.n[jl; PP[ll.n[jl ° PP[ll.n[i11; PP[11.n[i1] = i;
i - PP[11.x[jl; PP[11.x[jl ° PP[11.x[i11; PP[11.x[i1] - i;
2 0 if (fd > = 0) (void) closelfd);
if (fjl ~
(void) unlinkljnamel;
fj-0;
2 5 offset = 0;
Table 1 (coot 1 " write a filled jmp struct offset of the prev one (if anyl: nw() "I
writejmps(ix) writejmps int ix;
{
char "mktemp(];
if (!fj) {
if (mktempljname) < 0) {
fprintflstderr, "%s: can't mktemp() %sln", prog, jnamel;
cleanupll );
if ((fj = fopen(jname, "w")) ~ = 0) {
fprintflstderr, "%s: can't write %sln", prog, jnamel;
exit111;
(void) fwritel(char ")&dx[ix].jp, sizeof(struct jmpl, 1, fj);
(void) fwritel(char ~1&dx[ix].offset, sizeofldx[ix].offsetl, 1, fj);
Table 2 PRO XXXXXXXXXXXXXXX (Length ~ 15 amino acids) Comparison Protein XXXXXYYYYYYY (Length = 12 amino acidsl amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) _ 5 divided by 15 = 33.3%
Table 3 PRO XXXXXXXXXX (Length = 10 amino acids) Comparison Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids) amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN~2) divided by (the total number of amino acid residues of the PRO polypeptide) _ 5 divided by 10 = 50%
Table 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides) Comparison DNA NNNNNNLLLLLLLLLL (Length = 16 nucleotides) nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) 6 divided by 14 = 42.9%
Table 5 PRO-DNA NNNNNNNNNNNN (Length - 12 nucleotides) Comparison DNA NNNNLLLIIU (Length = 9 nucleotides) nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) _ 4 divided by 12 = 33.3%
II. Comuositions and Methods of the Invention A. Full-len4th CHEPO Polyoeptide The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as CHEPO. In particular, DNA encoding a CHEPO
polypeptide has been identified and isolated, as disclosed in further detail in the Examples below.
B. CHEPO Variants In addition to the full-length native sequence CHEPO polypeptides described herein, it is contemplated that CHEPO variants can be prepared. CHEPO variants can be prepared by introducing appropriate nucleotide changes into the CHEPO DNA, andlar by synthesis of the desired CHEPO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the CHEPO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
Variations in the native full-length sequence CHEPO or in various domains of the CHEPO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more colons encoding the CHEPO that results in a change in the amino acid sequence of the CHEPO as compared with the native sequence CHEPO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the CHEPO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the CHEPO with that 2 0 of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural andlor chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence 2 5 and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
CHEPO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the CHEPO polypeptide.
CHEPO fragments may be prepared by any of a number of conventional techniques.
Desired peptide fragments 3 0 may be chemically synthesized. An alternative approach involves generating CHEPO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR~. Oligonucleotides that define the desired termini of the DNA
fragment are employed at the 5' and 3' primers 3 5 in the PCR. Preferably, CHEPO polypeptide fragments share at least one biological andlor immunological activity with the native CHEPO polypeptides shown in Figure 3 (SEO ID NOS:2 and 51.
In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.
Table 6 OriginalExemplary Preferred Residue Substitutions Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln; asn lys Asn (N) gln; his; lys; arg gln Asp (D) glu glu Cys (C) ser ser Gln (Q) asn asn Glu (E) asp asp Gly (G) pro; ala ala His /H) asn; gln; lys; arg arg Ile (I) leu; val; met; ala;
phe;
norleucine leu 2 Leu IL) norleucine; ile; val;
met; ala; phe ile Lys (K) arg; gln; asn arg Met (M) leu; phe; ile leu Phe (F) leu; val; ile; ala; leu tyr 2 Pro (P) ala ala Ser(S) thr thr Thr (T) ser ser Trp (W) tyr; phe tyr Tyr (Y) trp; phe; thr; ser phe 3 Val (V) ile; leu; met; phe;
ala; norleucine leu Substantial modifications in function or immunological identity of the CHEPO
polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone 3 5 in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res.. 13:4331 11986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the CHEPO variant DNA.
Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include 2 0 alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (19891]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of 2 5 variant, an isoteric amino acid can be used.
C. Modifications of CHEPO
Covalent modifications of CHEPO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a CHEPO
polypeptide with an organic derivatizing agent that 3 0 is capable of reacting with selected side chains or the N- or C- terminal residues of the CHEPO. Derivatization with bifunctional agents is useful, for instance, for crosslinking CHEPO to a water-insoluble support matrix ar surface for use in the method for purifying anti-CHEPO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bisldiazoacetyll-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobislsuccinimidylpropionate), bifunctional 3 5 maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[Ip-azidophenyl)dithio]propioimidate.
Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of praline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins:
Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983~], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the CHEPO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence CHEPO (either by removing the underlying glycasylation site or by deleting the glycosylation by chemical andlor enzymatic meansl, andlor adding one or more glycosylation sites that are not present in the native sequence CHEPO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
Addition of glycosylation sites to the CHEPO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence CHEPO (for 0-linked glycosylation sited. The CHEPO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA
encoding the CHEPO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties on the CHEPO
polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87105330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev.
Biochem., pp. 259-306 (19811.
Removal of carbohydrate moieties present on the CHEPO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Ghemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biouhvs., 259:52 (1987) and by Edge et al., Anal.
Biochem., 118:131 (19811. Enzymatic cleavage of 2 5 carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzvmol., 138:350 (19871.
Another type of covalent modification of CHEPO comprises linking the CHEPO
polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEGI, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417;
4,791,192 or 4,179,337.
3 0 The CHEPO of the present invention may also be modified in a way to form a chimeric molecule comprising CHEPO fused to another, heterologous polypeptide or amino acid sequence.
In one embodiment, such a chimeric molecule comprises a fusion of the CHEPO
with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl- terminus of the CHEPO. The presence of such epitope-tagged forms of the CHEPO can be detected using an 3 5 antibody against the tag polypeptide. Also, provision of the epitope tag enables the CHEPO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art.
Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biolo4y, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineerinp, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide (Martin et al., Science, 255:192-194 (1992)]; an -tubulin epitope peptide [Skinner et al., J. Biol. Chem.. 266:15163-15166 (19911]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].
In an alternative embodiment, the chimeric molecule may comprise a fusion of the CHEPO with an immunoglobulin or a particular region of an immunoglobulin. Far a bivalent form of the chimeric molecule (also referred to as an immunoadhesin 1, such a fusion could be to the Fc region of an IgG molecule.
The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a CHEPO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.
D. Preparation of CHEPO
The description below relates primarily to production of CHEPO by culturing cells transformed or transfected with a vector containing CHEPO nucleic acid. It is, of course, contemplated that alternative methods, which are well known 2 0 in the art, may be employed to prepare CHEPO. For instance, the CHEPO
sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques (see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H.
Freeman Co., San Francisco, CA (19691; Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the CHEPO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length CHEPO.
Isolation of ONA Encoding CHEPO
DNA encoding CHEPO may be obtained from a cDNA library prepared from tissue believed to possess the CHEPO
3 0 mRNA and to express it at a detectable level. Accordingly, human CHEPO DNA
can be conveniently obtained from a cDNA
library prepared from human tissue, such as described in the Examples. The CHEPO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).
libraries can be screened with probes (such as antibodies to the CHEPO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library 3 5 with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloninn: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 19891. An alternative means to isolate the gene encoding CHEPO is to use PCR methodology [Sambrook et al., supra;
Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 19951].
The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened.
Methods of labeling are well known in the art, and include the use of radiolabels like'ZP-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., su ra.
Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity Iat either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.
Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA
that may not have been reverse-transcribed into cDNA.
2. Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or cloning vectors described herein for CHEPO
2 0 production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnolouy: a Practical Approach, M. Butler, ed. pRL Press, 1991 ) and Sambrook et al., supra.
Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaClz, CaP04, liposome-mediated and electroporation.
Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., su ra, or electroporation is generally used for prokaryotes. Infection with Agrnbacterium tumefaciens is used far transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 3 0 (1983) and WO 89105859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virolo4y, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J.
Bact., 130:946 (1977) and Hsiao et al., Proc.
Natl. Acad. Sci. (USAI, 76:3829119791. However, other methods for introducing DNA into cells, such as by nuclear 3 5 microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymolooy, 185:527-537 (1990) and Mansour et al., Nature. 336:348-352 (19881.
Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli. Various E. cvli strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E, coli strain W3110 (ATCC 27,325) and K5 772 (ATCC
53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, eg., E. cvli, Entervbacter, Erwinia, Klebsiella, Proteus, Salmonella, eg., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. lichenifvrmis (e.g., B.
lichenifvrmis 41 P disclosed in DD 266,710 published 12 April 19891, Pseudomvnas such as P, aeruginosa, and Streptomyces. These examples are illustrative rather than limiting.
Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA
product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1 A2, which has the complete genotype tonA ; E. cvli W3110 strain 9E4, which has the complete genotype tonA ptr3; E. cvli W3110 strain 27C7 (ATCC 55,2441, which has the complete genotype tvnA
ptr3 phoA E15 (argf lac1169 degP vmpT kad; E. cvli W3110 strain 37D6, which has the complete genotype tonA ptr3 phoA E15 (argf lac1169 degP vmpT rbs7 ilvG kanr; E. coli W3110 strain 4084, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. cvli strain having mutant periplasmic protease disclosed in U.S.
Patent No. 4,946,783 issued 7 August 1990. Alternatively, in vitro methods of cloning, e.g., PCR or other nucleic acid 2 0 polymerase reactions, are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for CHEPO-encoding vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism. Others include Schizosaccharvmyces pvmbe (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); Kluyvervmyces hosts (U.S. Patent No. 4,943,529; Fleer et al., BioITechnology. 9: 968-975 (1991 )) such as, eg., K. lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J.
Bacteriol., 737 [1983]I, K. fragilis (ATCC
12,424 K. bulgaricus (ATCC 16,0451, K. wickeramii (ATCC 24,1781, K. waltii (ATCC 56,5001, K, drosophilarum (ATCC
36,906; Uan den Berg etal., BioITechnolo4y, 8: 135 (1990)), K. thermvtvlerans, and K. marxianus,~ yarrvwia (EP 402,226);
Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol.. 28: 265-278 [1988]); Candida,~ Trichvderma reesia (EP
244,234); Neurvspora crassa (Case et al., Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]h Schwanniomyces such as 3 0 Schwanniomyces occidentalis (EP 394,538 published 31 October 19901; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91100357 published 10 January 1991 ), and Aspergillus hosts such as A- nidulans (Ballance et al., Biochem. Bioohys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J., 4: 475-479 [1985]).
Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected 3 5 from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methvlotrouhs, 269 (1982).
Suitable host cells for the expression of glycosylated CHEPO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS
cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 16511; human embryonic kidney line 1293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 (19771); Chinese hamster ovary cellsl-DHFR
(CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA. 77:4216 (1980)1; mouse sertoli cells (TM4, Mother, Biol. Reorod., 23:243-251 (1980)1; human lung cells (W138, ATCC CCL 75); human liver cells IHep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51 ). The selection of the appropriate host cell is deemed to be within the skill in the art.
3. Selection and Use of a Reolicable Vector The nucleic acid (e.g., cDNA or genomic DNA) encoding CHEPO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease sitels) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation 2 0 techniques which are known to the skilled artisan.
The CHEPO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the CHEPO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal 2 5 sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, eg., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces -factor leaders, the latter described in U.S.
Patent No. 5,010,1821, or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90113646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used 3 0 to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for mast Gram-negative bacteria, the 2 plasmid origin is suitable for yeast, 3 5 and various viral origins (SV40, polyoma, adenovirus, VSV or BPVI are useful for cloning vectors in mammalian cells.
Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, eg., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the CHEPO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (19801. A suitable selection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 (Stinchcomb et al., Nature. 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (19801]. The trill gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].
Expression and cloning vectors usually contain a promoter operably linked to the CHEPO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (19781; Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trill promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA. 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding CHEPO.
Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate 2 0 kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (19801] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Ren., 7:149 (19681; Holland, Biochemistry, 17:4900 (19781], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
CHEPO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from 3 0 the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 19891, adenovirus (such as Adenovirus 21, bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (S1140), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
Transcription of a DNA encoding the CHEPO by higher eukaryotes may be increased by inserting an enhancer 3 5 sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SU40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the CHEPO coding sequence, but is preferably located at a site 5' from the promoter.
Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding CHEPO.
Still other methods, vectors, and host cells suitable for adaptation to the synthesis of CHEPO in recombinant vertebrate cell culture are described in Gething et al., Nature. 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.
4. Detectinu Gene AmplificationlExnression Gene amplification andlor expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA
(Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (19801], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including 2 0 DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene 2 5 product. Antibodies useful for immunohistochemical staining andlor assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence CHEPO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to CHEPO DNA and encoding a specific antibody epitope.
3 0 5. Purification of Polvoeutide Forms of CHEPO may be recovered from culture medium or from host cell lysates.
If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of CHEPO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.
3 5 It may be desired to purify CHEPO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE;
ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the CHEPO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzvmologv, 182 (19901; Scopes, Protein Purification: Princiules and Practice, Springer-Uerlag, New York (19821. The purification steps) selected will depend, for example, on the nature of the production process used and the particular CHEPO produced.
E. Uses for CHEPO
Nucleotide sequences (or their complement) encoding CHEPO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA
and DNA. CHEPO nucleic acid will also be useful for the preparation of CHEPO
polypeptides by the recombinant techniques described herein.
The full-length native sequence CHEPO cDNA (SED ID N0:31, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the fulhlength CHEPO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of CHEPO or CHEPO from other species) which have a desired sequence identity to the CHEPO sequence disclosed in Figure 2 (SEO ID N0:31. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the nucleotide sequence of SED
ID N0:3 wherein those regions may be determined without undue experimentation or from genomic sequences including 2 0 promoters, enhancer elements and introns of native sequence CHEPO. By way of example, a screening method will comprise isolating the coding region of the CHEPO gene using the known DNA
sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as 32P or'SS, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidinlbiotin coupling systems. Labeled probes having a sequence complementary to that of the CHEPO gene of the present invention can be used to screen libraries of 2 5 human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.
Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.
Other useful fragments of the CHEPO nucleic acids include antisense or sense oligonucleotides comprising a 3 0 singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target CHEPO mRNA (sense) or CHEPO
DNA Iantisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of CHEPO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (CancerRes. 48:2659, 1988) and van der Krol et 3 5 al. (BioTechniques 6:958, 19881.
Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to block expression of CHEPO proteins.
Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91106629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.
Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90110048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-IL-lysinel.
Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.
Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaP04-mediated DNA
transfection, electraporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either in vivo or ex viva. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLU, N2 (a retrovirus derived from M-MuLU), or the double copy vectors designated DCTSA, DCTSB and 2 0 DCT5C (see WO 90113641 ).
Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO
91104753. Suitable ligand binding molecules include, but are not limited ta, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the 2 5 ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.
Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90110448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.
3 0 The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related CHEPO coding sequences.
Nucleotide sequences encoding a CHEPO can also be used to construct hybridization probes for mapping the gene which encodes that CHEPO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as 3 5 in situ hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.
When the coding sequences for CHEPO encode a protein which binds to another protein (example, where the CHEPO is a receptorl, the CHEPO can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptorhigand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor CHEPO can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native CHEPO or a receptor for CHEPO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.
Nucleic acids which encode CHEPO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A
transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops.
In one embodiment, cDNA encoding CHEPD
can be used to clone genomic DNA encoding CHEPO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA
encoding CHEPO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for CHEPO transgene 2 0 incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding CHEPO
introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding CHEPO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals 2 5 bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.
Alternatively, non-human homologues of CHEPO can be used to construct a CHEPO
"knock out" animal which has a defective or altered gene encoding CHEPO as a result of homologous recombination between the endogenous gene encoding CHEPO and altered genomic DNA encoding CHEPO introduced into an embryonic stem cell of the animal. For example, cDNA encoding CHEPO can be used to clone genomic DNA encoding CHEPO
in accordance with established 3 0 techniques. A portion of the genomic DNA encoding CHEPO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration.
Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are 3 5 selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 19871, pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA.
Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the CHEPO polypeptide.
Nucleic acid encoding the CHEPO polypeptides may also be used in gene therapy.
In gene therapy applications, genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA.
Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in vivo. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik et al., Proc. Natl. Acad. Sci. USA 83, 4143-4146 [1986]I. The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.
There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host.
Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, 2 0 electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnolo4y 11, 205-210 [1993]I. In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are 2 5 employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting andlor to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life.
The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (19901.
For review of gene marking and gene 3 0 therapy protocols see Anderson et al., Science 256, 808-813 (19921.
The CHEPO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes.
The nucleic acid molecules encoding the CHEPO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since 3 5 relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each CHEPO
nucleic acid molecule of the present invention can be used as a chromosome marker.
The CHEPO polypeptides and nucleic acid molecules of the present invention may also be used for tissue typing, wherein the CHEPO polypeptides of the present invention may be differentially expressed in one tissue as compared to another. CHEPO nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.
The CHEPO polypeptides described herein may also be employed as therapeutic agents. The CHEPO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the CHEPO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle.
Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (198011, in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins;
hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides 1 S and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; andlor nonionic surfactants such as TWEEN'"", PLURONICSr""
or PEG.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
2 0 Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.
2 5 Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug 3 0 Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 4296.
When in vivo administration of a CHEPO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 nglkg to up to 100 mglkg of mammal body weight or more per day, preferably about 1 glkglday to 10 mglkglday, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos.
4,657,760; 5,206,344; or 5,225,212. It is 3 5 anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue. for example, may necessitate delivery in a manner different from that to another organ or tissue.
Where sustained-release administration of a CHEPO potypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the CHEPO polypeptide, microencapsulation of the CHEPO polypeptide is contemplated.
Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN-1, interleukin-2, and MN
rgp120. Johnson et al., Nat. Med.. 2: 795-799 (19961; Yasuda. Biomed. Ther., 27: 1221-1223 (19931; Hora et al., BioITechnoloay. 8: 755-758 (19901; Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adiuvant Auproach, Powell and Newman, eds, (Plenum Press: New York,19951, pp. 439-462; WO 97103692, WO 96140072, WO
96107399; and U.S Pat. No. 5,654,010.
The sustained-release formulations of these proteins were developed using poly-lactic-coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactidelglycolide polymer," in: M. Chasin and R. Langer (Eds.l, Biode4radable Polymers as Drug Delivery S sv tams (Marcel Dekker: New York, 1990), pp. 1-41.
This invention encompasses methods of screening compounds to identify those that mimic the CHEPO
polypeptide (agonistsl or prevent the effect of the CHEPO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the CHEPO polypeptides encoded by the genes 2 0 identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.
The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art. All assays for 2 5 antagonists are common in that they call for contacting the drug candidate with a CHEPO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.
In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the CHEPO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent 3 0 attachment generally is accomplished by coating the solid surface with a solution of the CHEPO polypeptide and drying.
Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the CHEPO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes 3 5 anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label. complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.
If the candidate compound interacts with but does not bind to a particular CHEPO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (Londonh 340: 245-246 (1989); Chien etal., Proc. Natl. Acad. Sci. USA. 88: 9578-9582 (19911) as disclosed by Chevray and Nathans, Proc. Natl.
Acad. Sci. USA, 89: 5789-5793 (19911. Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain.
The expression of a GAL1-/acZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for -galactosidase. A complete kit (MATCHMAKERT"') for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.
2 0 Compounds that interfere with the interaction of a gene encoding a CHEPO
polypeptide identified herein and other intro- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intro- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve 2 5 as positive control. The binding (complex formation) between the test compound and the intro- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reactionls) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.
To assay for antagonists, the CHEPO polypeptide may be added to a cell along with the compound to be screened 3 0 for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the CHEPO
polypeptide indicates that the compound is an antagonist to the CHEPO
polypeptide. Alternatively, antagonists may be detected by combining the CHEPO polypeptide and a potential antagonist with membrane-bound CHEPO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The CHEPO polypeptide can be labeled, such as by radioactivity, such that the number of CHEPO
polypeptide molecules bound to the receptor can 3 5 be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan etal., Current Protocols in Immun., 1(21: Chapter 5 (19911. Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the CHEPO palypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the CHEPO polypeptide. Transfected cells that are grown on glass slides are exposed to labeled CHEPO polypeptide. The CHEPO
polypeptide can be labeled by a variety of means including iodination or inclusion'of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.
As an alternative approach for receptor identification, labeled CHEPO
polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule.
Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.
In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled CHEPO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.
More specific examples of potential antagonists include an oligonucleotide that binds to the tusions of immunoglobulin with CHEPO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions 2 0 of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the CHEPO
polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the CHEPO
polypeptide.
Another potential CHEPO polypeptide antagonist is an antisense RNA or DNA
construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing 2 5 to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA
or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature CHEPO polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et 3 0 a/., Nucl. Acids Res., 6: 3073 (19791; Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (199111, thereby preventing transcription and the production of the CHEPO polypeptide.
The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the CHEPO polypeptide (antisense -Okano, Neurochem., 56: 560 (19911; Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Baton, FL, 19881. The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA
3 5 may be expressed in vivo to inhibit production of the CHEPO polypeptide.
When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and + 10 positions of the target gene nucleotide sequence, are preferred.
Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the CHEPO polypeptide, thereby blocking the normal biological activity of the CHEPO
polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Bioloay, 4: 469-471 (19941, and PCT publication No. WO 97133551 (published September 18, 19971.
Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, eg., PCT publication Na. WO
97133551, supra.
These small molecules can be identified by any one or more of the screening assays discussed hereinabove andlor by any other screening techniques well known for those skilled in the art.
F. Anti-CHEPO Antibodies The present invention further provides anti-CHEPO antibodies. Exemplary antibodies include polyclonal, 2 0 monoclonal, humanized, bispecific, and heteroconjugate antibodies.
Polvclonal Antibodies The anti-CHEPO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of 2 5 an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent andlor adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the CHEPO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be 3 0 employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolatel. The immunization protocol may be selected by one skilled in the art without undue experimentation.
2. Monoclonal Antibodies The anti-CHEPO antibodies may, alternatively, be monoclonal antibodies.
Monoclonal antibodies may be prepared 3 5 using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (19751. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
Alternatively, the lymphocytes may be immunized in vitro.
The immunizing agent will typically include the CHEPO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ["PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRTI, the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol..
133:3001 (19841; Brodeur et al., Monoclonal Antibody Production TechniQUes and Annlications Marcel Dekker, Inc., New York, (1987) pp. 51-63].
2 0 The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against CHEPO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme linked immunoabsorbent assay (ELISAI. Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., .
107:220 (1980).
After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [coding, suura]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
3 0 The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S.
Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced 3 5 using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CH0) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking.
Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
/n vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.
3. Human and Humanized Antibodies The anti-CHEPO antibodies of the invention may further comprise humanized antibodies or human antibodies.
2 0 Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', Flab'IZ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
2 5 In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
3 0 The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region [Fc], typically that of a human immunoglobulin [Jones et al., Nature. 321:522-525 (1986);
Riechmann et al., Nature. 332:323-329 (19881; and Presto, Curr. Oa. Struct. Biol., 2:593-596 (19921].
Methods for humanizing non-human antibodies are well known in the art.
Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid 3 5 residues are often referred to as "import" residues, which are typically taken from an "import" variable domain.
Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature. 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Uerhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboam and Winter, J. Mal. Biol., 227:381 (19911; Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therauv, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 14711):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807;
5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., BiolTechnolony 0 779-78311992); Lonberg et al., Nature 368 856-859 (19941;
Morrison, Nature 368, 812-13 (1994);
Fishwild et al., Nature Biotechnolouy 4 845-51 (1996); Neuberger, Nature Biotechnoloay 4 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).
2 0 4. Bisoecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the CHEPO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.
Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of 2 5 bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chainhight-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains. these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93108829, 3 0 published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991 ).
Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding 3 5 the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymolo4y 121:210 (19861.
According to another approach described in WO 96127011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophanl. Compensatory cavities of identical or similar size to the large side chains) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab )z bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature.
For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan et ah, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate Flab )Z fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab -TNB derivatives is then reconverted to the Fab -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
2 0 Fab fragments may be directly recovered from E. coii and chemically coupled to form bispecific antibodies.
Shalaby et al., J. Exn. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody Flab Iz molecule. Each Fab fragment was separately secreted from E. cvii and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human 2 5 breast tumor targets.
Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (19921. The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form 3 0 monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The diabody technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (V~) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and V~
domains of one fragment are forced to 3 5 pair with the complementary V~ and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et a/., J. Immunol. 147:60 (19911.
Exemplary bispecific antibodies may bind to two different epitopes on a given CHEPO polypeptide herein.
Alternatively, an anti-CHEPO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc Rl, such as Fc RI
(CD641, Fc RII (C032) and Fc RIII (CD161 so as to focus cellular defense mechanisms to the cell expressing the particular CHEPO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular CHEPO polypeptide. These antibodies possess a CHEPO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the CHEPO
polypeptide and further binds tissue factor (TF).
5. Heteroconiu4ate Antibodies Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV
infection [WO 91100360; WO 921200373;
EP 03089]. It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide 2 0 exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
6. Effector Function EnQineerinQ
It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, 2 5 e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residues) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
The homodimeric antibody thus generated may have improved internalization capability andlor increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCCI. See Caron et al., J. Exu Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-3 0 linkers as described in Wolff et al. Cancer Research. 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson etal., Anti-Cancer Drun Design, 3: 219-230 (1989).
Immunoconiu4ates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e,g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above.
Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosal, ricin A
chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaanaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include z'ZBi, "'I,'3'In, °°Y, and'B6Re.
Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediaminel, bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediaminel, diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Uitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent tar conjugation of radionucleotide to the antibody. See W094111026.
2 0 In another embodiment, the antibody may be conjugated to a "receptor"
(such streptavidin) far utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic agent le.g., a radionucleotidel.
2 5 8. Immunoliposomes The antibodies disclosed herein may also be formulated as immunoliposomes.
Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA. 82: 3688 (1985);
Hwang etal., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos.
4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
3 0 Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through fitters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem.. 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within 3 5 the liposome. See Gabizon et al., J. National Cancer Inst.. 81 (191: 1484 (19891.
9. Pharmaceutical Compositions of Antibodies Antibodies specifically binding a CHEPO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.
If the CHEPO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells.
Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically andlor produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl.
Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary far the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques 2 0 or by interfacial polymerization, for example, hydroxymethylcellulose ar gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, supra.
The formulations to be used for in viva administration must be sterile. This is readily accomplished by filtration 2 5 through sterile filtration membranes.
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylatel, or poly(vinylalcohol)), polylactides (U.S.
Pat. No. 3,773,919), copolymers of L-glutamic 3 0 acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT ~" (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetateh and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 C, 3 5 resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
G. Uses for anti-CHEPO Antibodies The anti-CHEPO antibodies of the invention have various utilities. For example, anti-CHEPO antibodies may be used in diagnostic assays for CHEPO, eg., detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunaprecipitation assays conducted in either heterogeneous or homogeneous phases (Zola, Monoclonal Antibodies:
A Manual of Techniaues, CRC Press, Inc. (1987) pp.147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as 'H,'4C,'zp, 355, or'z51, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (19621;
David et al., Biochemistry, 13:1014 (1974/; Pain et al., J. Immunol. Meth., 40:219 (19811; and Nygren, J. Histochem. and Cytochem., 30:407 (1982).
Anti-CHEPO antibodies also are useful for the affinity purification of CHEPO
from recombinant cell culture or natural sources. In this process, the antibodies against CHEPO are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample 2 0 containing the CHEPO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the CHEPO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the CHEPO
from the antibody.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
2 5 All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
EXAMPLES
Commercially available reagents referred to in the examples were used according to manufacturer's instructions 3 0 unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.
Isolation of Nucleic Acid Encodinu CHEPO
Genomic DNA was isolated from two chimpanzee cell lines (ATCC CRL1609 and CRL1857) using a Diagen kit (cat#10262) as recommended by the manufacturer's instructions. The chimp Epo gene was then obtained on 3 separate fragments by PCR using 1 g of genomic DNA as template and the following primer pairs:
EPO.F: 5'-ACCGCGCCCCCTGGACAG-3' (SED ID N0:12) EPO.INT1.R: 5'-CATCCACTTCTCCGGCCAAACTTCA-3' (SED ID N0:13) EPO.INT1F:5'-TTTGGCCGGAGAAGTGGATGC-3' (SEDIDN0:14) EPO.INT4R: 5'-TCACTCACTCACTCATTCATTCATTCATTCA-3' (SEO ID N0:15) EPO.INT4F: 5'-GTTGAATGAATGATTGAATGAATGAGTGA-3' (SED ID N0:16) EPO.R: 5'-GCACTGGAGTGTCCATGGGACAG-3' (SED ID N0:17) Each PCR reaction contained 5 I of 10x PCR Buffer (Perkin Elmerl, 1 I dNTP
(20mM1, 1 g genomic DNA, 1 I of each primer, 1 I of Taq polymerase (Clontech) and HZO to bring the total volume to 50 I. The reaction was first denatured for 4 min. at 94 C then amplified for 40 cycles of 1 min. at 94 C, 1 min. at 65 C or 66 C then extended for 1 min. at 72 C.
A last extension step of 5 min. at 72 C was performed. The reaction was then analyzed on agarose gel. PCR product of 500bp, 1200bp and 750bp were observed for each PCR product, respectively. The PCR reactions were then purified using 2 0 a Wizard kit (Promega cat # A7170) then directly sequenced. DNA sequencing of the PCR products was done using an Applied Biosystems 377 DNA Sequencer (PEIApplied Biosystems, Foster City, CA).
The chemistry used was DYE
Terminator Cycle Sequencing with dRhodamine and BIG DYE terminators (PEIApplied Biosystems, Foster City, CAI.
Sequence assembly and editing done with Sequencher software (Gene Codes, Ann Arbor, MI).
The 5 coding exons were identified by homology with the human erythropoietin sequence and assembled into a 2 5 predicted full length cDNA. The coding region of CHEPO cDNA is 579 nucleotides long (Figure 1 ) and encodes a predicted protein of 193 amino acids (Figure 3). There are 3 putative signal cleavage sites predicted after amino acid residue 22, 24 and 27. In accordance with the N-terminus of human Epo, the latest one is likely to correspond to the cleavage site for chimp Epo. The hydrophobic 27 amino acid signal peptide is followed by a 166 amino acid long mature protein containing 3 potential N-glycosylation sites. A single nucleotide polymorphism is present in the predicted sequence obtained from 3 0 CRL1609 and changes the protein sequence at amino acid position 142 from a D to a K. Alignment of the chimp Epo protein with the human sequence indicates a single change at amino acid position 84 (Figure 3).
Use of CHEPO cDNA as a hybridization urobe 35 The following method describes use of a nucleotide sequence encoding CHEPO
as a hybridization probe.
DNA comprising the coding sequence of full-length or mature CHEPO (as shown in Figure 2, SEO ID N0:3) is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of CHEP01 in human tissue cDNA libraries or human tissue genomic libraries.
Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled CHEPO-derived probe to the filters is performed in a solution of 50%
formamide, 5x SSC, 0.1 % SDS, 0.1 % sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1 x SSC and 0.19'o SDS at 42°C.
DNAs having a desired sequence identity with the DNA encoding full-length native sequence CHEPO can then be identified using standard techniques known in the art.
Expression of CHEPO in E. coli This example illustrates preparation of an unglycosylated form of CHEPO by recombinant expression in E. coli.
The DNA sequence encoding CHEPO (SEO ID N0:3) is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector.
A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector 2 0 will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage sitel, the CHEPO coding region, lambda transcriptional terminator, and an argU gene.
The ligation mixture is then used to transform a selected E. cvli strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB
plates and antibiotic resistant colonies are then 2 5 selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.
Selected clones can be grown overnight in liquid culture medium such as LB
broth supplemented with antibiotics.
The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.
After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet 3 0 obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized CHEPO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.
CHEPO may be expressed in E. coli in a poly-His tagged form, using the following procedure. The DNA encoding CHEPO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and 3 5 reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase.
The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an E. coli host based on strain 52 (W3110 fuhA(tonA) Ion galE rpoHtsIhtpRts) clpP(laclql. Transformants are first grown in LB containing 50 mglml carbenicillin at 30 C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH4)ZS04, 0.71 g sodium citrate 2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 ml water, as well as 110 mM
MPOS, pH 7.3, 0.55% Iwlv) glucose and 7 mM MgS04) and grown for approximately 20-30 hours at 30 C with shaking.
Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells.
Cell pellets are frozen until purification and refolding.
E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (wlv) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1 M
and 0.02 M, respectively, and the solution is stirred overnight at 4 C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.41 and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM
imidazole (Calbiochem, Utrol gradeL pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4 C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.
The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCI, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM
EDTA. Refolding volumes are chosen 2 0 so that the final protein concentration is between 50 to 100 microgramslml. The refolding solution is stirred gently at 4 C
for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 31. Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R11H reversed phase column using a mobile buffer of 0.1 % TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots 2 5 of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin 3 0 from the samples.
Fractions containing the desired folded CHEPO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.
Expression of CHEPO in mammalian cells This example illustrates preparation of a potentially glycosylated form of CHEPO by recombinant expression in mammalian cells.
The vector, pRK5 (see EP 307,247, published March 15, 1989], is employed as the expression vector.
Optionally, the CHEPO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the CHEPO DNA
using ligation methods such as described in Sambrook et al., suura. The resulting vector is called pRKS-CHEPO.
In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components andlor antibiotics. About 10 g pRKS-CHEPO DNA is mixed with about 1 g DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543 (19821] and dissolved in 500 I of 1 mM Tris-HCI, 0.1 mM EDTA, 0.227 M CaClz. To this mixture is added, dropwise, 500 I of 50 mM HEPES (pH 7.35], 280 mM NaCI, 1.5 mM NaPO,, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20~'o glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.
Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 Cilml'SS-cysteine and 200 Cilml 35S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may 2 0 be dried and exposed to film for a selected period of time to reveal the presence of CHEPO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.
In an alternative technique, CHEPO may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (19811. 293 cells are grown to maximal density in a spinner flask and 700 g pRKS-CHEPO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 glml bovine insulin and 0.1 glml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed CHEPO can then 3 0 be concentrated and purified by any selected method, such as dialysis andlor column chromatography.
In another embodiment, CHEPO can be expressed in CHO cells. The pRKS-CHEPO can be transfected into CHO
cells using known reagents such as CaP04 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alonel or medium containing a radiolabel such as 35S-methionine. After determining the presence of CHEPO polypeptide, the culture medium may be replaced with serum free medium. Preferably, 3 5 the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed CHEPO can then be concentrated and purified by any selected method.
Epitope-tagged CHEPO may also be expressed in host CHO cells. The CHEPO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged CHEPO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones.
Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged CHEPO can then be concentrated and purified by any selected method, such as by Niz'-chelate affinity chromatography.
CHEPO may also be expressed in CHO andlor COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.
Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG
construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains andlor is a poly-His tagged form.
Following PCR amplification, the respective DNAs are subcloned in a CHO
expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology Unit 3.16, John Wiley and Sons (1997).
CHO expression vectors are constructed to have compatible restriction sites 5 and 3 of the DNA of interest to allow the convenient shuttling of cDNA s. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res.
24:9 (1774-1779 (1996), and uses the SV40 early promoterlenhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR1. DHFR expression permits selection for stable maintenance of the plasmid following 2 0 transfection.
Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect (Quiagen), Dosper or Fugene (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately 3 x 10'' cells are frozen in an ampule for further growth and production as described below.
2 5 The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mls of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 m filtered PS20 with 5% 0.2 m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL
spinner containing 90 mL of selective media.
After 1-2 days. the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated 3 0 at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 ml spinners are seeded with 3 x 105 ceIIsImL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2 x 106 ceIIsImL. On day 0, the cell number pH ie determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted 3 5 to 33°C, and 30 mL of 500 gIL glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH
is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 709'0, the cell culture is harvested by centrifugation and filtering through a 0.22 m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.
For the poly-His tagged constructs, the proteins are purified using a Ni-NTA
column (Qiagenl. Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCI
and 5 mM imidazole at a flow rate of 4-5 mllmin. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCI and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
Immunoadhesin IFc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above far the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.
Expression of CHEPO in Yeast 2 0 The following method describes recombinant expression of CHEPO in yeast.
First, yeast expression vectors are constructed for intracellular production or secretion of CHEPO from the ADH21GAPDH promoter. DNA encoding CHEPO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of CHEPO. For secretion, DNA encoding CHEPO can be cloned into the selected plasmid, together with DNA encoding the ADH21GAPDH promoter, a native CHEPO signal peptide or other 2 5 mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signalheader sequence, and linker sequences (if needed) for expression of CHEPO.
Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10~ trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.
3 0 Recombinant CHEPO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing CHEPO may further be purified using selected column chromatography resins.
3 5 Expression of CHEPO in Baculovirus-Infected Insect Cells The following method describes recombinant expression of CHEPO in Baculovirus-infected insect cells.
The sequence coding for CHEPO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags hike Fc regions of IgGI. A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding CHEPO or the desired portion of the coding sequence of CHEPO
such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.
Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoIdT"' virus DNA
(Pharmingen) into Spodoptera frugiperda ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications.
Viral infection and protein expression are performed as described by 0'Reilley et al., Baculovirus expression vectors: A
Laboratory Manual, Oxford: Oxford University Press (19941.
Expressed poly-his tagged CHEPO can then be purified, for example, by Nip'-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (19931. Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl2; 0.1 mM EDTA; 10% glycerol; 0.1 % NP-40; 0.4 M KCI), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCI, 10~ glycerol, pH 7.8) and filtered through a 0.45 m filter. A Niz'-NTA agarose column (commercially available from Qiagen) is prepared 2 0 with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline AZeo with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer 150 mM phosphate;
300 mM NaCI, 109'o glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching AZeo baseline again, the column is developed with a 0 to 500 mM Imidazoie gradient in the secondary wash buffer. One mL fractions are collected 2 5 and analyzed by SDS-PAGE and silver staining or Western blot with Nip'-NTA-conjugated to alkaline phosphatase (Qiagen).
Fractions containing the eluted His,o-tagged CHEPO are pooled and dialyzed against loading buffer.
Alternatively, purification of the IgG tagged (or Fc tagged) CHEPO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.
Preparation of Antibodies that Bind CHEPO
This example illustrates preparation of monoclonal antibodies which can specifically bind CHEPO.
Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, su ra. Immunogens that may be employed include purified CHEPO, fusion proteins containing CHEPO, and cells 3 5 expressing recombinant CHEPO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.
Mice, such as Balblc, are immunized with the CHEPO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-CHEPO antibodies.
After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of CHEPO. Three to four days later, the mice are sacrificed and the spleen cells are harvested.
The spleen cells are then fused (using 359'o polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.l, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.
The hybridoma cells will be screened in an ELISA for reactivity against CHEPO.
Determination of "positive"
hybridoma cells secreting the desired monoclonal antibodies against CHEPO is within the skill in the art.
The positive hybridoma cells can be injected intraperitoneally into syngeneic Balblc mice to produce ascites containing the anti-CHEPO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography.
Alternatively, affinity chromatography based upon binding 2 0 of antibody to protein A or protein G can be employed.
Purification of CHEPO Polynentides Usina Specific Antibodies Native or recombinant CHEPO polypeptides may be purified by a variety of standard techniques in the art of 2 5 protein purification. For example, pro-CHEPO polypeptide, mature CHEPO
polypeptide, or pre-CHEPO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the CHEPO
polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-CHEPO
polypeptide antibody to an activated chromatographic resin.
Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by 3 0 purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A.
Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE'""
(Pharmacia LKB Biotechnologyl. The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.
3 5 Such an immunoaffinity column is utilized in the purification of CHEPO
polypeptide by preparing a fraction from cells containing CHEPO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble CHEPO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.
A soluble CHEPO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CHEPO
polypeptide (eg., high ionic strength buffers in the presence of detergentl. Then, the column is eluted under conditions that disrupt antibodyICHEPO polypeptide binding (e.g., a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ionl, and CHEPO polypeptide is collected.
Drug Screening This invention is particularly useful for screening compounds by using CHEPO
polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The CHEPO
polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the CHEPO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between CHEPO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the CHEPO polypeptide and its target cell or target receptors caused 2 0 by the agent being tested.
Thus, the present invention provides methods of screening for drugs or any other agents which can affect a CHEPO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an CHEPO
polypeptide or fragment thereof and assaying (1) for the presence of a complex between the agent and the CHEPO
polypeptide or fragment, or (ii) for the presence of a complex between the CHEPO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the CHEPO polypeptide or fragment is typically labeled. After suitable incubation, free CHEPO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to CHEPO polypeptide or to interfere with the CHEPO polypeptidelcell complex.
Another technique for drug screening provides high throughput screening for compounds having suitable binding 3 0 affinity to a polypeptide and is described in detail in WO 84103564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a CHEPO polypeptide, the peptide test compounds are reacted with CHEPO polypeptide and washed.
Bound CHEPO polypeptide is detected by methods well known in the art. Purified CHEPO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.
In addition, non-neutralizing antibodies can 3 5 be used to capture the peptide and immobilize it on the solid support.
This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding CHEPO polypeptide specifically compete with a test compound for binding to CHEPO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one ar more antigenic determinants with CHEPO polypeptide.
Rational Dru4 Design The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (ie., a CHEPO polypeptide) or of small molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the CHEPO polypeptide or which enhance or interfere with the function of the CHEPO polypeptide in vivo (c.f., Hodgson, BioITechnoloay, 9: 19-21 (1991)1.
In one approach, the three-dimensional structure of the CHEPO polypeptide, or of an CHEPO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the CHEPO polypeptide must be ascertained to elucidate the structure and to determine active sitels) of the molecule. Less often, useful information regarding the structure of the CHEPO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous CHEPO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda et al., 2 0 J. Biochem., 113:742-746 (1993).
It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would 2 5 be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.
By virtue of the present invention, sufficient amounts of the CHEPO
polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the CHEPO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition 3 0 to x-ray crystallography.
The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention as claimed. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations, Tables 2 and 3 below demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated Comparison Protein to the amino acid sequence designated PRO .
Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program.
However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res.
25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http:llwww.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 1515, multi-pass e-value =
0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain %
amino acid sequence identity to, with, or 2 0 against a given amino acid sequence B) is calculated as follows:
100 times the fraction XIY
where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-2 5 BLAST2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the °Yo amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
"CHEPO variant polynucleotide" or CHEPO variant nucleic acid sequence means a nucleic acid molecule which encodes an active CHEPO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity 3 0 with either f a) a nucleic acid sequence which encodes residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SED ID NOS:2 and 51, (b) a nucleic acid sequence which encodes residues X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SED ID NOS:2 and 5) or (c) a nucleic acid sequence which encodes another.specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5). Ordinarily, a CHEPO variant polynucleotide will have at least about 80% nucleic 3 5 acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82%
nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 849'° nucleic acid sequence identity, alternatively at least about 85%
nucleic acid sequence identity, alternatively at least about 869'° nucleic acid sequence identity, alternatively at least about 879'° nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 959'° nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97%
nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with either (a) a nucleic acid sequence which encodes residues 1 or about 28 to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 51, (b) a nucleic acid sequence which encodes residues_X to 193 of the CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5), wherein X is any amino acid residue from 23 to 32 of Figure 3 (SED ID NOS:2 and 5) or (c) a nucleic acid sequence which encodes another specifically derived fragment of the amino acid sequence shown in Figure 3 (SEO ID NOS:2 and 5).
CHEPO polynucleotide variants do not encompass the native CHEPO nucleotide sequence.
Ordinarily, CHEPO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 2 0 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.
"Percent (%) nucleic acid sequence identity" with respect to the CHEPO
polypeptide-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a CHEPO polypeptide-encoding nucleic acid sequence, after aligning the sequences and introducing gaps, if 2 5 necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % nucleic acid sequence 3 0 identity values are obtained as described below by using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No.
TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may 3 5 be compiled from the source code provided in Table 1. The ALIGN-2 program should be compiled for use on a UNIX
operating system, preferably digital UNIX V4.OD. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
For purposes herein, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain 9'° nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction WIZ
where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program s alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5 below demonstrate how to calculate the %
nucleic acid sequence identity of the nucleic acid sequence designated Comparison DNA to the nucleic acid sequence designated PRO-DNA .
Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program.
However, % nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res.
25:3389-3402 (19971). The NCBI-BLAST2 sequence comparison program may be downloaded from 2 0 http:llwww.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand m all, expected occurrences = 10, minimum low complexity length = 1515, multi-pass e-value =
0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for sequence comparisons, the %
nucleic acid sequence identity 2 5 of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain ~°
nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction WIZ
where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program s alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.
3 5 In other embodiments, CHEPO variant polynucleotides are nucleic acid molecules that encode an active CHEPO
polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding the full-length CHEPO polypeptide shown in Figure 3 (SEO ID NOS:2 and 5). CHEPO variant polypeptides may be those that are encoded by a CHEPO variant polynucleotide.
The term "positives", in the context of the amino acid sequence identity comparisons performed as described above, includes amino acid residues in the sequences compared that are not only identical, but also those that have similar properties. Amino acid residues that score a positive value to an amino acid residue of interest are those that are either identical to the amino acid residue of interest or are a preferred substitution (as defined in Table 6 below) of the amino acid residue of interest.
For purposes herein, the % value of positives of a given amino acid sequence A
to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain positives to, with, or against a given amino acid sequence B1 is calculated as follows:
100 times the fraction XIY
where X is the number of amino acid residues scoring a positive value as defined above by the sequence alignment program ALIGN-2 in that program s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the °Y°
positives of A to B will not equal the % positives of B to A.
"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated andlor recovered from a component of its natural environment. Preferably, the isolated polypeptide 2 0 is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing 2 5 conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the CHEPO natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
An "isolated" nucleic acid molecule encoding a CHEPO polypeptide is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural 3 0 source of the CHEPO-encoding nucleic acid. Preferably, the isolated nucleic is free of association with all components with which it is naturally associated. An isolated CHEPO-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the CHEPO-encoding nucleic acid molecule as it exists in natural cells. However, an isolated nucleic acid molecule encoding a CHEPO polypeptide includes CHEPO-encoding nucleic acid molecules contained in cells that ordinarily express CHEPO where, for example, the 3 5 nucleic acid molecule is in a chromosomal location different from that of natural cells.
The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretary leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretary leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-CHEPO
monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-CHEPO antibody compositions with polyepitopic specificity, single chain anti-CHEPO antibodies, and fragments of anti-CHEPO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally 2 0 is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend 2 5 to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biolo4y, Wiley Interscience Publishers,11995).
"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (11 employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride10.0015 M sodium 3 0 citrate10.1 ~ sodium dodecyl sulfate at 50 C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (vlv) formamide with 0.1 % bovine serum albumin10.1 % Fico1110.1 % polyvinylpyrrolidone150mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH
6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt s solution, sonicated salmon sperm DNA (50 glmll, 0.1 % SDS, and 10%
dextran sulfate at 42 C, with washes 3 5 at 42 C in 0.2 x SSC (sodium chloridelsodium citrate) and 50% formamide at 55 C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A
L.aboratorv Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37 C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCI,15 mM trisodium citratel, 50 mM sodium phosphate (pH 7.61, 5 x Denhardt s solution, 10% dextran sulfate, and 20 mglml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a CHEPO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes.
Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains.
Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"1, and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence 2 0 comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2/, IgE, IgD or IgM.
"Active" or "activity" for the purposes herein refers to formls) of CHEPO
which retain a biological andlor an immunological activity of native or naturally-occurring CHEPO, wherein biological activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring CHEPO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring CHEPO and an immunological activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring CHEPO. Preferred biological activities includes, for example, the ability to regulate red blood cell production, to bind to receptors on the surface of committed progenitor cells of the bone marrow andlor other 3 0 hematopoietic tissues andlor to induce proliferation andlor terminal maturation of erythroid cells.
The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native CHEPO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native CHEPO
polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies 3 5 or antibody fragments, fragments or amino acid sequence variants of native CHEPO polypeptides, peptides, small organic molecules, etc. Methods for identifying agonists or antagonists of a CHEPO
polypeptide may comprise contacting a CHEPO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the CHEPO polypeptide.
"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessens the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
"Chronic" administration refers to administration of the agents) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect lactivity) for an extended period of time. Intermittent administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.
"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc.
Preferably, the mammal is human.
Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine;
2 0 monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; andlor nonionic surfactants such as TWEEN , polyethylene glycol (PEG), and PLURONICS .
"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab'IZ, and Fv fragments; diabodies; linear 2 5 antibodies IZapata et al., Protein Ena. 8110): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily.
Pepsin treatment yields an Flab'Iz fragment that has two antigen-combining sites and is still capable of cross-linking 3 0 antigen.
"Fv" is the minimum antibody fragment which contains a complete antigemrecognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-V~ dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable 3 5 domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residues! of the constant domains bear a free thiol group. F(ab'IZ antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGI, IgG2, IgG3, IgG4, IgA, and IgA2.
"Single-chain Fv" or "sFv" antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacolony of Monoclonal Antibodies vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH - VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains 2 0 are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93111161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 ( 1993).
An "isolated" antibody is one which has been identified and separated andlor recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with 2 5 diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1 ) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99%
by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue ar, preferably, silver stain.
3 0 Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope 3 5 labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glassh polysaccharides (e.g., agaroseh polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography columnl. This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
A "liposome" is a small vesicle composed of various types of lipids, phospholipids andlor surfactant which is useful for delivery of a drug (such as a CHEPO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
A small molecule is defined herein to have a molecular weight below about 500 Daltons.
Table 1 I*
*
* C-C increased from 12 to 15 * Z is average of EO
* B is average of ND
* match with stop is M; stop-stop = 0; J (joker) match = 0 .I
#define _M -8 I* value of a match with a stop *I
int -day[26][261 = {
I* A B C D E F G H I J
T U V W X Y Z *I
I* A { 2, 0,-2, 0, 0.-4, M. 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, *I 1.-1,-1, 0,-1,-2,-1, 0}, I* B { 0, 3,-4, 3, 2,-5, M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, *I 0, 1,-2, 0, 0,-3,-2, 1}, 2_ I* {-2,-4,15,-5,-5,-4,-3,-3,-2,M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5}, C *I 0,-5,-6,-5,-4, I* D { 0, 3,-5, 4, 3,-6, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, *I 1, 1,-2, 0, 0,-4,-3, 2}, I* E { 0, 2,-5, 3, 4,-5, M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, *I 0, 1,-2, 0, 0,-3,-2, 3}, 1 _ I* F {-4,-5,-4,-6,-5, 9,-5,-2,-M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5}, *I 1, 0,-5, 2, 0,-4, I* G { 1, 0,-3, 1, 0,-5, _M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, *I 5,-2,-3, 0,-2,-4,-3, 0}, 0, I* {-1, 1,-3, 1, 1,-2,-2,-M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, H *I 6,-2, 0, 0,-2,-2, 2}.
2, I* I {-1,-2,-2,-2,-2, 1,-3,-2,M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2}, *I 5, 0,-2, 2, 2,-2 _ I*J*I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I* K {-1, 0,-5, 0, 0,-5,-2,M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, *I 0,-2, 0, 5,-3, 0, 0}, I* L {-2,-3,-6,-4,-3, 2,-4,-2,M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2}, */ 2, 0,-3, 6, 4,-3 _ 2 5 I* I {-1,-Z,-5.-3,-2, M,-2,-1. 0.-2,-1. 0, 2,-4, 0,-2,-1 M * 0,-3,-2, 2, 0, 0, }, 4, 6,-2 _ I* N { 0, 2,-4, 2, 1,-4, M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, * I 0, 2,-2, 0, 1,-3,-2, 1 }, I* 0 { M _M _M -M _M _M M _M -M -M _M, 0 -M -M -M _M -M
*I -M _M -M - -M -M _M -M -M _M}, I* P { 1,-1,-3,-1,-1,-5,-1,_M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, *I 0,-2, 0,-1,-3,-2,-1, 0}, I* 0 { 0, 1,-5, 2, 2,-5,-1,_M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, *I 3,-2, 0, 1,-2,-1, 3}, 1, 3 0 I* {-2, 0,-4,-1,-1,-4,-3,M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, R *I 2,-2, 0, 3,-3, 0, 0}, 0 _ I* S { 1, 0, 0, 0, 0,-3, M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, "I 1,-1,-1, 0, 0,-3,-2, 0}, 1 _ I* T { 1, 0,-2, 0, 0,-3, _M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, *I 0,-1, 0, 0, 0,-1,-1, 0}, 0, I*U*I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I* ~ { 0~-2.-2.-2--2~-1--1--2--M--1~-2.-2--1- 0- 0 4--6. 0--2.-2}, *I 4. 0.-2. 2~ 2.-2 3 5 I* I {-6,-5,-8,-7,-7, _M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6}, W * 0,-7,-3,-5, 0,-3,-2,-4,-4, I*X"I {0,0,0,0,0,0,0,0,0,0,0,0,0,0-M,0,0,0,0,0,0,0,0,0,0,0}, I' Y'I {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2, M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4}, I" Z "I { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1 _M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
};
Table t Icont ) I*
*I
#include < stdio.h >
#include < ctype.h >
#define MAXJMP 16 I* max jumps in a diag *I
#define MAXGAP24 I* continue to penalize gaps don'tlarger than this *I
#define JMPS 1024 I* max jmps in an path *I
#defineMX 4 I* save if there's at least MX-1 bases since last jmp *I
#define DMAT 3 I* value of matching bases *I
#define DMIS 0 I* penalty for mismatched bases *I
#define DINSO 8 I* penalty for a gap *I
#defineDINS1 1 I* penalty per base *I
#define PINSO 8 I* penalty for a gap *I
#define PINS1 4 I* penalty per residue *I
struct jmp 2 0 short n[MAXJMP]; I* size of jmp (neg for dely] *I
unsigned short x[MAXJMP]; I* base no. of jmp in seq x *I
}; I* limits seq to 2" 16 -1 *I
struct diag ~
int score; I* score at last jmp *I
long offset; I* offset of prev block *I
short ijmp; I* current jmp index *I
struct jmp jp; I* list of jmps *I
};
struct path {
int spc; I* number of leading spaces *I
short n[JMPS]; I* size of jmp (gap) *I
int x(JMPS]; I* loc of jmp (last elem before gapl *I
3 5 };
char *ofile; I* output file name *I
char *namex[2]; I* seq names: getseqs() *I
char *prog; I* prog name for err msgs *I
char *seqx[2]; I* seqs: getseqsl) *I
int dmax; I* best diag: nwp *I
int dmax(); I* final diag *I
int dna; I* set if dna: maim) *I
int endgaps; I" set if penalizing end gaps *I
int gapx, gapy; I* total gaps in seqs *I
int IenO, lenl; I* seq lens *I
int ngapx, ngapy;I* total size of gaps *I
int smax; I* max score: nwl) *I
int *xbm; I* bitmap for matching *I
long offset; I* current offset in jmp file *I
struct *dx; I* holds diagonals diag *I
struct path pp(2]; I* holds path for seqs *I
char *calloc(1, *mallocll, *index0, *strcpy();
char *getseq0, *g calloc0;
Table 1 Icont ) Ix Needleman-Wunsch alignment program x x usage: progs filel filet x where filel and filet are two dna or two protein sequences.
x The sequences can be in upper- or lower-case an may contain ambiguity x Any lines beginning with ';', ' > ' or ' <' are ignored x Max file length is 65535 (limited by unsigned short x in the jmp struct) x A sequence with 113 or more of its elements ACGTU is assumed to be DNA
" Output is in the file "align.out"
x x The program may create a tmp file in Itmp to hold info about traceback.
" Original version developed under BSD 4.3 on a vax 8650 xl #include "nw.h"
#include "day.h"
static dbval(26] a {
1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0 2 0 ~;
static pbval[26]
1, 2 ~ (1 < < ('D'-'A')1 ~ (1 < < ('N'-'A'11, 4, 8, 16, 32, 64, 128, 256, OxFFFFFFF, 1 « 10, 1 « 11, 1 « 12, 1 « 13, 1 « 14, 1«15,1«16,1«17,1«18,1«19,1«20,1«21,1«22, 1 < < 23, 1 < < 24, 1 < < 25 ~ (1 < < ('E'-'A'1) ~ (1 < < ('O'-'A'1) };
mainlac, av] main 3 0 int ac;
char xav[];
prog - av[0];
if (ac ! = 3) {
3 5 fprintf(stderr,"usage: %s filel file2ln", prog];
fprintflstderr,"where filel and filet are two dna or two protein sequences.ln");
fprintf(stderr,"The sequences can be in upper- or lower-casein");
fprintf(stderr,"Any lines beginning with ';' or ' <' are ignoredln"1;
fprintflstderr,"Output is in the file I"align.outl"In"1;
exit111;
namex[0] - av(1];
namex[1] - av[2];
seqx(0] - getseq(namex[0], &Ien0l;
seqx[1] = getseqlnamex[1], &1en11;
xbm = (final? dbval : _pbval;
endgaps = 0; I* 1 to penalize endgaps *I
ofile = "align.out"; I* output file *I
nw0; I* fill in the matrix, get the possible jmps *I
readjmps(1; I* get the actual jmps *I
print0; I* print stats, alignment *I
cleanup(0); I* unlink any tmp files *I
Table 1 (coot 1 I* do the alignment, return best score: main() * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983 * pro: PAM 250 values * When scares are equal, we prefer mismatches to any gap, prefer * a new gap to extending an ongoing gap, and prefer a gap in seqx * to a gap in seq y.
*I
nw0 nw char *px, *py; I* seqs and ptrs *I
int *ndely, I* keep track *dely; of dely *I
int ndelx, delx;I* keep track of deli *I
int *tmp; I* for swapping row0, rowl *I
int mis; I* score for each type *I
int ins0, inst;I* insertion penalties *I
register id; I* diagonal index *I
register ij; I* jmp index *I
register *col0, *coll;I* score for curr, last row *I
2 0 register xx, yy; I* index into seqs *I
dx = (struct diag *)g callocl"to get diags", IenO+lenl + 1, sizeoflstruct diag)1;
ndely = (int *)g calloc("to get ndely", lenl +1, sizeoflint));
dely = lint *)g callocl"to get dely", lenl+1, sizeof(int)1;
col0 = (int *Ig callocl"to get col0", lenl +1, sizeof(int));
toll = (int *)g calloc("to get coil", lenl +1, sizeof(intll;
ins0 = Idna1? DINSO : PINSO;
insl = Idna)? DINS1 : PINS1;
smax = -10000;
if (endgaps) {
for (col0[0] = dely[0] _ -ins0, yy - 1; yy < = lenl; yy++) f col0[yy1 = dely[yy] = col0[yy-1] - insl;
3 5 ndely[yy] - yy;
col0(0] - 0; I" Waterman Bull Math Biol 84 "I
else for (yy = 1; yy < = lenl; yy++) dely[yy] - -ins0;
I" fill in match matrix "I
for (px = seqx[0], xx = 1; xx < - IenO; px++, xx++) {
I" initialize first entry in col "I
if (endgaps) {
if (xx - - 1) coll[0] = delx = -/ins0+instl;
else coll(0] = deli = col0[0] - insl;
ndelx = xx;
else {
2 0 col l (0] = 0;
delx - -ins0;
ndelx = 0;
Table 1 Icont 1 ...nw for (py = seqx[1], yy = 1; yy < = lenl; py++, yy++) {
mis = col0[yy-1];
if (dna) mis + _ (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
else mis += day[*px-'A'][*py-'A'l;
I* update penalty for del in x seq;
* favor new del over ongong del * ignore MAXGAP if weighting endgaps *I
if (endgaps ~ ~ ndely[yy] < MAXGAP) {
if (col0[yy] - ins0 > = dely(yy]) {
dely[yy] = col0[yy] - (ins0+insl );
ndely[yy] = 1;
} else {
dely[yy] -= insl;
2 0 ndely[yy]+ +;
} else {
if (col0[yy] - (ins0+insl) > = dely[yy]) {
dely[yy] = col0(yy] - (ins0+insl );
ndely[yy] = 1;
} else ndely[yy]+ +;
3 0 I* update penalty for del in y seq;
* favor new del over ongong del *I
if (endgaps ~ ~ ndelx < MAXGAP) {
if (coll[yy-1] - ins0 > = delx) {
delx = coil[yy-1]-(ins0+insl);
ndelx = 1;
} else ~
delx -- insl;
ndelx++;
}
} else {
if (colt[yy-1] - (ins0+insl) > = delx) {
delx = coil[yy-1]-(ins0+ins1l;
ndelx = 1;
} else ndelx++;
}
I" pick the maximum score; we're favoring " mis over any del and delx over dely "I
Table 1 Icont 1 ...nw id = xx - yy + lenl - 1;
if (mis > = delx && mis > = dely[yy]) call[yy] = mis;
else if (delx > = dely[yy]) {
coil[yy] = delx;
ij = dx[id].ijmp;
if (dx(id].jp.n[0] && (!dna ~ ~ (ndelx > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINS011 {
dx[id].ijmp++;
if (++ij > = MAXJMP) {
writejmps(idl;
ij = dx[id].ijmp = 0;
dx[id].offset = offset;
offset += sizeoflstruct jmp) + sizeofloffsetl;
dx[id].jp.n[ij] = ndelx;
2 0 dx[id].jp.x[ij] = xx;
dx[id].score = delx;
else {
coil[YV] = dely[YY];
2 5 ij = dx(id].ijmp;
if (dx[id].jp.n[0] && (!dna ~ ~ (ndely[yy] > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO)) {
dx[id].ijmp+ +;
if (++ij > = MAXJMP) {
3 0 writejmps(idl;
ij = dx(id].ijmp - 0;
dx[id].offset = offset;
offset + = sizeoflstruct jmp) + sizeofloffset);
dx[id].jp.n[ij] _ -ndely[yy];
dx[id].jp.x[ij] - xx;
dx(id].score - dely[yy];
if Ixx = = IenO && yy < len 1 ) {
I" last cal "I
if (endgaps) coil[yy]-= ins0+insl"Ilen1-yy);
if (coil(yy] > smax) {
smax = cal t [yy];
dmax = id;
if (endgaps && xx < Ien0) toll[yy-1]-= ins0+insl"pen0-xx);
if (toll[yy-1] > smax) {
smax = toll[yy-1];
dmax = id;
tmp = col0; col0 = call; coil = tmp;
(void) freellchar ")ndelyl;
(void) freellchar ")delyl;
2 5 (void) freellchar "Ico101;
paid) freellchar ")co111; }
Table 1 Icont 1 I*
*
* print() -- only routine visible outside this module * static:
* getmatl) -- trace back best path, count matches: print() * pr align/) -- print alignment of described in array p[]: print/) * dumpblockl) -- dump a block of lines with numbers, stars: pr_align() * numsl) -- put out a number line: dumpblockp * putlinel) -- put out a line (name, [num], seq, [num]I: dumpblock() * stars/) - -put a line of stars: dumpblockQ
* stripnamel] -- strip any path and prefix from a seqname *I
#include "nw.h"
#define SPC 3 #define P LINE 256 I* maximum output line *I
2 0 #define P SPC 3 I* space between name or num and seq *I
extern day[26][26];
int oleo; I* set output line length *I
FILE *fx; I" output file *I
print/) print f int Ix, ly, firstgap, lastgap; I* overlap *I
3 0 if ((fx = fopenlofile, "w"1) - - 0) {
fprintflstderr,"%s: can't write %sln", prog, ofilel;
cleanup(11;
fprintflfx, " < first sequence: %s length - %dlln", namex[0], Ien0l;
3 5 fprintflfx, " < second sequence: %s (length = %dlln", namex[1 ], lenl ];
oleo - 60;
Ix = IenO;
ly = lenl;
firstgap - lastgap = 0;
if (dmax < lenl - 1) { I* leading gap in x *I
pp[0].spc = firstgap = lenl - dmax - 1;
ly -- pp[0].spc;
else if fdmax > lenl - 1) { I* leading gap in y *I
pp[1].spc = firstgap = dmax - (lenl - 11;
Ix -= pp[1]-spc;
if (dmax0 < IenO - 1 ) { I* trailing gap in x *I
lastgap = IenO - dmax0 -1;
Ix -= lastgap;
else if (dmax0 > IenO - 1) { I* trailing gap in y *I
lastgap = dmax0 - (IenO - 1 );
ly -- lastgap;
2 0 getmat(Ix, ly, firstgap, lastgapl;
pr alignll;
Table 1 Icont ) I"
" trace back the best path, count matches "I
static getmatllx, ly, firstgap, Iastgap) getmat int Ix, ly; I" "core" (minus endgaps) "I
int firstgap, lastgap; I" leading trailing overlap "I
int nm, i0, i1, siz0, sizl;
char outx[321;
double pct;
register n0, n1;
register char "p0, "p1;
" get total matches, score "I
i0=i1 =siz0=sitl =0;
p0 s seqx[0] + PP[1].spc;
p1 = seqx[1] + pp[0].spc;
n0 - pp[1].spc + 1;
n1 = pp(0].spc + 1;
nm=0;
while ( "p0 && "p1 ) ~
if (siz0) {
p1++;
nl++;
siz0--;
else if (sizl) ~
p0++;
n0++;
siz 1--;
else ~
if (xbm["p0-'A']&xbm['p1-'A']) nm++;
ifln0++ _=pp[0].x[i0]) siz0 = pp[0].n[i0++];
iflnl++ _=pp[1].x[il]) sizl = pp[1].n[i1++];
p0++;
pl ++;
I" pct homology:
" if penalizing endgaps, base is the shorter seq " else, knock off overhangs and take shorter core 1 5 "~
if (endgaps) Ix = (IenO < Ienl1? IenO : lenl;
else Ix = (Ix < ly)? Ix : ly;
2 0 pct = 100."(double)nm1(double)Ix;
fprintf(fx, "In");
fprintf(fx, " < %d match%s in an overlap of %d: %.2f percent similarityln", nm, (nm = = 11? "" : "es", Ix, pct);
Table 1 Icont 1 fprintf(fx, " < gaps in first sequence: %d", gapx); ...getmat if (gapx) {
(void) sprintf(outx, " (%d %s%s)", ngapx, (dna)? "base":"residue", (ngapx = = 1 )? "":"s");
fprintflfx,"%s", outx);
fprintflfx, ", gaps in second sequence: %d", gapy);
if (gapy) (void) sprintf(outx, " (%d %s%s)", ngapy, (dual? "base":"residue", (ngapy = = 1 )? "":"s"];
fprintf(fx,"%s", outx);
if (dna) fprintflfx, "In < score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per baselln", smax, DMAT, DMIS, DINSO, DINS1);
else 2 0 fprintf(fx, "In < score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)In", smax, PINSO, PINS1);
if (endgaps) fprintf(fx, 2 5 " < endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%sln", firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s", lastgap, (final? "base" : "residue", hastgap -- 1)? "" : "s");
else fprintf(fx, " < endgaps not penalizedln"1;
static nm; I" matches in core --for checking "I
static Imax; I' lengths of stripped file names "I
static ij[2]; I' jmp index for a path 'I
3 5 static nc(2]; I' number at start of current line "I
static ni[2]; I* current elem number -- for gapping "I
static siz[2];
static char *ps[2]; I* ptr to current element *I
static char *po[2]; I* ptr to next output char slat *I
static char out[2][P LINE]; I" output line *I
static char star[P LINE]; I* set by stars() *I
I*
* print alignment of described in struct path pp[]
*I
static pr align/) pr align int nn; I* char count *I
int more;
register i;
for (i = 0, Imax = 0; i < 2; i++) {
nn - stripname(namex[i]~;
if (nn > Imax) 2 0 Imax - nn;
nc[i] = 1;
ni[i] - 1;
siz[i] = ij[i] = 0;
2 5 ps[i] = seqx[i];
po[i] = out[i]; }
Table t Icont 1 for Inn = nm = 0, more = 1; more; l f ...pr align for (i = more = 0; i < 2; i++) f I*
* do we have more of this sequence?
*I
if 1!*ps[i]) continue;
mare++;
if (pp[i].spc) { I* leading space *I
*po[i]++ _ , pp[i].spc--;
else if (siz[i1) { I* in a gap *I
*po[i)++ _ , ~;
siz[i]--;
else ~ I* we're putting a seq element *I
*Po[il _ *Ps[il;
if (islower(*ps[i])) *ps[i] = toupperl*ps[i]/;
po[i]++;
Ps[i1+ +;
I*
3 0 * are we at next gap for this seq?
*I
if (ni[i] _ = PP[il.x[ij[i]1) f I*
* we need to merge all gaps 3 5 * at this location *I
siz[il - PPfil.n[ij[il++1;
while (ni[il -- pp[il.x[ij[ill) siz[il +- PP[il.n[ij[il++1;
ni[i]+ +;
if (++nn -- oleo ~ ~ !more && nn) f dumpblockll;
for (i = 0; i < 2; i++) po[il - out[i];
nn-0;
I"
dump a block of lines, including numbers, stars: pr align() "I
2 0 static dumpblock() dumpblock register i;
for (i - 0; i < 2; i++) ~po[il__ _ '10';
WO 00/68376 PCT/iJS00/12370 Table 1 (coot ) ...dumpblock (void) putc('In', fx);
for (i = 0; i < 2; i++) {
if 1*out[i) && 1*out[i] !_ ~ ~ ~ ~ *(Po[ill !- ")) {
if (i - - 0) numsli);
if (i -- 0 && "out[1]) stars0;
putline(i);
if fi =- 0 && *out[1]) fprintflfx, star);
if (i -= 1) nums(i);
2 0 I*
* put out a number line: dumpblock() static nums(ix) nums 2 5 int ix; I* index in out[] holding seq line *I
char nline[P LINE];
register i, j;
register char *pn, *px, *py;
for (pn = nline, i = 0; i < Imax+P SPC; i++, pn++) *pn = . .;
for (i = nc[ix], py = out[ix]; *py; py++, pn++) f if (*py = _ " ~ ~ *PY =- '-') *pn-";
else if (i% 10 - - 0 ~ ~ 6 - - 1 && nc[ix] ! - 11) {
j - li < 0)? -i : i;
for (px - pn; j; j I= 10, px--) '"pX ' j%10 + '0';
if (i < 0) "Px - , else "Pn ° , i++;
.Pn = ,~0..
nc[ix] = i; /
for (pn = nline;'"pn; pn++) (void) putcl"pn, fxl;
(void) putcl'In', fxl;
2 0 I"
" put out a line (name, [num], seq, [num]l: dumpblockl) "I
static putlinelix) putline 2 5 int ix;
Table 1 (coot ) ...putline int i;
register char *px;
for (px = namex[ix], i = 0; *px && *px ! _ '~'; px++, i++) (void) putcl*px, fxl;
for (; i < Imax+P SPC; i++) (void) putcl' ', fxl;
* these count from 1:
* ni[] is current element (from 1) * ncp is number at start of current line *I
for (px = out[ix]; *px; px++) (void) putt(*px&Ox7F, fx);
(void) putcl'In', fx);
I*
* put a line of stars (seqs always in out[0], out[1]): dumpblockp *I
2 5 static stars() stars f int i;
register char *p0, *p1, cx, *px;
if 1! *out[O1 ~ ~ 1"out[0) a ~ ' && *(Po[O1) - _ ' ') ~ ~
!*out[11 ~ ~ 1*out[1] a = ' ' && *Ipo[1]) a a ' '1) return;
px - star;
3 5 for (i ~ Imax+P SPC; i; i--) *px++ , , ~;
for (p0 = out[0], p1 = out[1]; "p0 && "p1; p0++, p1 ++) ~
if (isalpha("p0) && isalphal"p1)) {
if (xbm["p0-'A']&xbm["p1-'A']) ~
cx = '"';
nm++;
else if (!dna && day["p0-'A']["p1-'A'] > 0) cx=";
else cx = ' ';
else 1 5 cx = , "px++ ~ cx;
"Px++ ° ~~n';
"Px ° 't0';
Table 1 (coot I
I*
* strip path or prefix from pn, return len: pr align() *I
static stripnamelpn) stripname char *pn; I* file name (may be path) *I
register char *px, *py;
PY ' ~;
for (px = pn; *px; px++) if (*px =_ 'I') PY°Px+1;
if (py) (void) strcpy(pn, py);
return(strlen(pn));
Table 1 (coot ) I*
* cleanup() -- cleanup any tmp file * getseq(1-- read in seq, set dna, len, maxlen * g calloc() -- callocp with error checkin * readjmpsU -- get the good jmps, from tmp file if necessary * writejmps() -- write a filled array of jmps to a tmp file: nw() *I
#include "nw.h"
#include < sysl file.h >
char *jname = "ItmplhomgXXXXXX"; I* tmp file for jmps *I
FILE *tj;
int cleanup0; I* cleanup tmp file *I
long Iseekll;
I*
* remove any tmp file if we blow 2 0 *I
cleanup(i) cleanup int i;
if (fj) 2 5 (void) unlink(jnamel;
exit(il;
I*
3 0 * read, return ptr to seq, set dna, len, maxlen * skip lines starting with ';', ' < ', or ' > ' * seq in upper or lower case *I
char *
3 5 getseqlfile, len) getseq char *file; I* file name *I
int *len; I* seq ten *I
f char line[1024], *pseq;
register char *px, *py;
int natgc, tlen;
FILE *fp;
if ((fp = fopenlfile,"r"11 == 0) {
fprintf(stderr,"%s: can't read %sln", prog, filet;
exit(11;
tlen = natgc = 0;
while (fgets(line, 1024, fpl) {
if ("line = - ,' ~ ~ "line = _ ' <' ~ ~ "line = - ' > ') continue;
for (px = line; *px ! _ 'In'; px++) if (isupperl*px) ~ ~ islowerl*px)) tlen++;
2 0 if (Ipseq = mallocl(unsignedlltlen+6))) _ = 01 {
fprintf(stderr,"%s: mallocl) failed to get %d bytes for %sln", prog, tlen+(i, filet;
exit111;
pseq[0] = pseq[1] = pseq[2] = pseq[3) _ '10';
Table 1 (coot 1 ...getseq PY - Pseq + 4;
*len - tlen;
rewind(fpl;
while (fgetslline, 1024, fpl) f if (*line -- ';' ~ ~ *line -- ' <' ~ ~ *line - _ ' >') continue;
for (px - line; *px !_ 'In'; px++) if (isupper(*px)) *PY++ - *Px;
else if (islowerl*px)) *py++ = toupperl*px);
if (index)"ATGCU",*(py-1))) natgc+ +;
*pY++ a ~~0~.
*PY -'10'; I
(void) fclose(fpl;
dna - natgc > (tlenl3l;
return(pseq+41;
char *
g calloclmsg, nx, sz) g calloc char *msg; I* program, calling routine *I
int nx, sz; I* number and size of elements *I
char *px, *callocll;
if ((px = callocl(unsigned)nx, (unsignedlszl) _ - 0) {
if (*msg) {
3 5 fprintf(stderr, "%s: g callocU failed %s fn-%d, sz-%d)In", prog, msg, nx, szl;
exit(11;
returnlpx);
I"' " get final jmps from dx[] or tmp file, set pp[], reset dmax: maim) "I
readjmpsl) readjmps int fd = -1;
int siz, i0, i1;
register i, j, xx;
if (fj) {
(void) fcloselfjl;
if ((fd = open(jname, 0 RDONLY, 0)) < 0) {
fprintf(stderr, "%s: can't open() %sln", prog, jname);
cleanup(1);
for (i = i0 = i1 = 0, dmax0 = dmax, xx = IenO; ; i++) ~
while (1) {
for (j = dx[dmax].ijmp; j > = 0 && dx[dmax].jp.x[j] > = xx; j--) , Table 1 (coot 1 ...readjmps if (j < 0 && dx[dmax].offset && fj) {
(void) Iseek(fd, dx[dmax].offset, 0);
(void) read(fd, (char *)&dx[dmax].jp, sizeoflstruct jmp));
(void) readlfd, (char *)&dx(dmax].offset, sizeof(dx[dmax].offset));
dx[dmax].ijmp = MAXJMP-1;
else break;
if (i > = JMPS) {
fprintflstderr, "%s: too many gaps in alignmentln", progl;
cleanupll );
if (j >=0){
siz = dx(dmax].jp.n[j];
xx = dx[dmax].jp.x[j];
dmax += siz;
if (siz < 0) { I* gap in second seq *I
pp(1].n[i1] _ -siz;
XX + = SIZ;
I*id=xx-yy+lenl-1 *I
pp[1].x[i1] = xx - dmax + lenl - 1;
9aPY+ +.
ngapy -= siz;
I* ignore MAXGAP when doing endgaps *I
siz = (-siz < MAXGAP ~ ~ endgaps)? -siz : MAXGAP;
il++;
else if (siz > 0) { I* gap in first seq *I
pp(0].n(i0] = siz;
pp[0].x[i0] = xx;
gapx++;
ngapx + - siz;
I* ignore MAXGAP when doing endgaps 'I
siz - (siz < MAXGAP ~ ~ endgapsl? siz : MAXGAP;
i0++;
else break;
I' reverse the order of jmps 'I
for (j = 0, i0--; j < i0; j++, i0--) {
i ° PP[01.n[jl; PP[01.n[!1 - PP[01.n[i0]; PP[01.n[i0] = i;
i - PPf0l.x[jl; PP[01.x[ll - PP[01.x[i01; PPfOI.x[i0] = i;
for (j - 0, i1--; j < i1; j++, i1--1 {
i - PP[11.n[jl; PP[ll.n[jl ° PP[ll.n[i11; PP[11.n[i1] = i;
i - PP[11.x[jl; PP[11.x[jl ° PP[11.x[i11; PP[11.x[i1] - i;
2 0 if (fd > = 0) (void) closelfd);
if (fjl ~
(void) unlinkljnamel;
fj-0;
2 5 offset = 0;
Table 1 (coot 1 " write a filled jmp struct offset of the prev one (if anyl: nw() "I
writejmps(ix) writejmps int ix;
{
char "mktemp(];
if (!fj) {
if (mktempljname) < 0) {
fprintflstderr, "%s: can't mktemp() %sln", prog, jnamel;
cleanupll );
if ((fj = fopen(jname, "w")) ~ = 0) {
fprintflstderr, "%s: can't write %sln", prog, jnamel;
exit111;
(void) fwritel(char ")&dx[ix].jp, sizeof(struct jmpl, 1, fj);
(void) fwritel(char ~1&dx[ix].offset, sizeofldx[ix].offsetl, 1, fj);
Table 2 PRO XXXXXXXXXXXXXXX (Length ~ 15 amino acids) Comparison Protein XXXXXYYYYYYY (Length = 12 amino acidsl amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) _ 5 divided by 15 = 33.3%
Table 3 PRO XXXXXXXXXX (Length = 10 amino acids) Comparison Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids) amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN~2) divided by (the total number of amino acid residues of the PRO polypeptide) _ 5 divided by 10 = 50%
Table 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides) Comparison DNA NNNNNNLLLLLLLLLL (Length = 16 nucleotides) nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) 6 divided by 14 = 42.9%
Table 5 PRO-DNA NNNNNNNNNNNN (Length - 12 nucleotides) Comparison DNA NNNNLLLIIU (Length = 9 nucleotides) nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) _ 4 divided by 12 = 33.3%
II. Comuositions and Methods of the Invention A. Full-len4th CHEPO Polyoeptide The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as CHEPO. In particular, DNA encoding a CHEPO
polypeptide has been identified and isolated, as disclosed in further detail in the Examples below.
B. CHEPO Variants In addition to the full-length native sequence CHEPO polypeptides described herein, it is contemplated that CHEPO variants can be prepared. CHEPO variants can be prepared by introducing appropriate nucleotide changes into the CHEPO DNA, andlar by synthesis of the desired CHEPO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the CHEPO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
Variations in the native full-length sequence CHEPO or in various domains of the CHEPO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more colons encoding the CHEPO that results in a change in the amino acid sequence of the CHEPO as compared with the native sequence CHEPO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the CHEPO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the CHEPO with that 2 0 of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural andlor chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence 2 5 and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
CHEPO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the CHEPO polypeptide.
CHEPO fragments may be prepared by any of a number of conventional techniques.
Desired peptide fragments 3 0 may be chemically synthesized. An alternative approach involves generating CHEPO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR~. Oligonucleotides that define the desired termini of the DNA
fragment are employed at the 5' and 3' primers 3 5 in the PCR. Preferably, CHEPO polypeptide fragments share at least one biological andlor immunological activity with the native CHEPO polypeptides shown in Figure 3 (SEO ID NOS:2 and 51.
In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.
Table 6 OriginalExemplary Preferred Residue Substitutions Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln; asn lys Asn (N) gln; his; lys; arg gln Asp (D) glu glu Cys (C) ser ser Gln (Q) asn asn Glu (E) asp asp Gly (G) pro; ala ala His /H) asn; gln; lys; arg arg Ile (I) leu; val; met; ala;
phe;
norleucine leu 2 Leu IL) norleucine; ile; val;
met; ala; phe ile Lys (K) arg; gln; asn arg Met (M) leu; phe; ile leu Phe (F) leu; val; ile; ala; leu tyr 2 Pro (P) ala ala Ser(S) thr thr Thr (T) ser ser Trp (W) tyr; phe tyr Tyr (Y) trp; phe; thr; ser phe 3 Val (V) ile; leu; met; phe;
ala; norleucine leu Substantial modifications in function or immunological identity of the CHEPO
polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone 3 5 in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res.. 13:4331 11986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the CHEPO variant DNA.
Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include 2 0 alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (19891]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of 2 5 variant, an isoteric amino acid can be used.
C. Modifications of CHEPO
Covalent modifications of CHEPO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a CHEPO
polypeptide with an organic derivatizing agent that 3 0 is capable of reacting with selected side chains or the N- or C- terminal residues of the CHEPO. Derivatization with bifunctional agents is useful, for instance, for crosslinking CHEPO to a water-insoluble support matrix ar surface for use in the method for purifying anti-CHEPO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bisldiazoacetyll-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobislsuccinimidylpropionate), bifunctional 3 5 maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[Ip-azidophenyl)dithio]propioimidate.
Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of praline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins:
Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983~], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the CHEPO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence CHEPO (either by removing the underlying glycasylation site or by deleting the glycosylation by chemical andlor enzymatic meansl, andlor adding one or more glycosylation sites that are not present in the native sequence CHEPO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
Addition of glycosylation sites to the CHEPO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence CHEPO (for 0-linked glycosylation sited. The CHEPO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA
encoding the CHEPO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties on the CHEPO
polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87105330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev.
Biochem., pp. 259-306 (19811.
Removal of carbohydrate moieties present on the CHEPO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Ghemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biouhvs., 259:52 (1987) and by Edge et al., Anal.
Biochem., 118:131 (19811. Enzymatic cleavage of 2 5 carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzvmol., 138:350 (19871.
Another type of covalent modification of CHEPO comprises linking the CHEPO
polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEGI, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417;
4,791,192 or 4,179,337.
3 0 The CHEPO of the present invention may also be modified in a way to form a chimeric molecule comprising CHEPO fused to another, heterologous polypeptide or amino acid sequence.
In one embodiment, such a chimeric molecule comprises a fusion of the CHEPO
with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl- terminus of the CHEPO. The presence of such epitope-tagged forms of the CHEPO can be detected using an 3 5 antibody against the tag polypeptide. Also, provision of the epitope tag enables the CHEPO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art.
Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biolo4y, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineerinp, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide (Martin et al., Science, 255:192-194 (1992)]; an -tubulin epitope peptide [Skinner et al., J. Biol. Chem.. 266:15163-15166 (19911]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].
In an alternative embodiment, the chimeric molecule may comprise a fusion of the CHEPO with an immunoglobulin or a particular region of an immunoglobulin. Far a bivalent form of the chimeric molecule (also referred to as an immunoadhesin 1, such a fusion could be to the Fc region of an IgG molecule.
The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a CHEPO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.
D. Preparation of CHEPO
The description below relates primarily to production of CHEPO by culturing cells transformed or transfected with a vector containing CHEPO nucleic acid. It is, of course, contemplated that alternative methods, which are well known 2 0 in the art, may be employed to prepare CHEPO. For instance, the CHEPO
sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques (see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H.
Freeman Co., San Francisco, CA (19691; Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the CHEPO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length CHEPO.
Isolation of ONA Encoding CHEPO
DNA encoding CHEPO may be obtained from a cDNA library prepared from tissue believed to possess the CHEPO
3 0 mRNA and to express it at a detectable level. Accordingly, human CHEPO DNA
can be conveniently obtained from a cDNA
library prepared from human tissue, such as described in the Examples. The CHEPO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).
libraries can be screened with probes (such as antibodies to the CHEPO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library 3 5 with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloninn: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 19891. An alternative means to isolate the gene encoding CHEPO is to use PCR methodology [Sambrook et al., supra;
Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 19951].
The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened.
Methods of labeling are well known in the art, and include the use of radiolabels like'ZP-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., su ra.
Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity Iat either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.
Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA
that may not have been reverse-transcribed into cDNA.
2. Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or cloning vectors described herein for CHEPO
2 0 production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnolouy: a Practical Approach, M. Butler, ed. pRL Press, 1991 ) and Sambrook et al., supra.
Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaClz, CaP04, liposome-mediated and electroporation.
Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., su ra, or electroporation is generally used for prokaryotes. Infection with Agrnbacterium tumefaciens is used far transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 3 0 (1983) and WO 89105859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virolo4y, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J.
Bact., 130:946 (1977) and Hsiao et al., Proc.
Natl. Acad. Sci. (USAI, 76:3829119791. However, other methods for introducing DNA into cells, such as by nuclear 3 5 microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymolooy, 185:527-537 (1990) and Mansour et al., Nature. 336:348-352 (19881.
Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli. Various E. cvli strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E, coli strain W3110 (ATCC 27,325) and K5 772 (ATCC
53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, eg., E. cvli, Entervbacter, Erwinia, Klebsiella, Proteus, Salmonella, eg., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. lichenifvrmis (e.g., B.
lichenifvrmis 41 P disclosed in DD 266,710 published 12 April 19891, Pseudomvnas such as P, aeruginosa, and Streptomyces. These examples are illustrative rather than limiting.
Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA
product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1 A2, which has the complete genotype tonA ; E. cvli W3110 strain 9E4, which has the complete genotype tonA ptr3; E. cvli W3110 strain 27C7 (ATCC 55,2441, which has the complete genotype tvnA
ptr3 phoA E15 (argf lac1169 degP vmpT kad; E. cvli W3110 strain 37D6, which has the complete genotype tonA ptr3 phoA E15 (argf lac1169 degP vmpT rbs7 ilvG kanr; E. coli W3110 strain 4084, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. cvli strain having mutant periplasmic protease disclosed in U.S.
Patent No. 4,946,783 issued 7 August 1990. Alternatively, in vitro methods of cloning, e.g., PCR or other nucleic acid 2 0 polymerase reactions, are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for CHEPO-encoding vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism. Others include Schizosaccharvmyces pvmbe (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); Kluyvervmyces hosts (U.S. Patent No. 4,943,529; Fleer et al., BioITechnology. 9: 968-975 (1991 )) such as, eg., K. lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J.
Bacteriol., 737 [1983]I, K. fragilis (ATCC
12,424 K. bulgaricus (ATCC 16,0451, K. wickeramii (ATCC 24,1781, K. waltii (ATCC 56,5001, K, drosophilarum (ATCC
36,906; Uan den Berg etal., BioITechnolo4y, 8: 135 (1990)), K. thermvtvlerans, and K. marxianus,~ yarrvwia (EP 402,226);
Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol.. 28: 265-278 [1988]); Candida,~ Trichvderma reesia (EP
244,234); Neurvspora crassa (Case et al., Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]h Schwanniomyces such as 3 0 Schwanniomyces occidentalis (EP 394,538 published 31 October 19901; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91100357 published 10 January 1991 ), and Aspergillus hosts such as A- nidulans (Ballance et al., Biochem. Bioohys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J., 4: 475-479 [1985]).
Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected 3 5 from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methvlotrouhs, 269 (1982).
Suitable host cells for the expression of glycosylated CHEPO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS
cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 16511; human embryonic kidney line 1293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 (19771); Chinese hamster ovary cellsl-DHFR
(CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA. 77:4216 (1980)1; mouse sertoli cells (TM4, Mother, Biol. Reorod., 23:243-251 (1980)1; human lung cells (W138, ATCC CCL 75); human liver cells IHep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51 ). The selection of the appropriate host cell is deemed to be within the skill in the art.
3. Selection and Use of a Reolicable Vector The nucleic acid (e.g., cDNA or genomic DNA) encoding CHEPO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease sitels) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation 2 0 techniques which are known to the skilled artisan.
The CHEPO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the CHEPO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal 2 5 sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, eg., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces -factor leaders, the latter described in U.S.
Patent No. 5,010,1821, or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90113646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used 3 0 to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for mast Gram-negative bacteria, the 2 plasmid origin is suitable for yeast, 3 5 and various viral origins (SV40, polyoma, adenovirus, VSV or BPVI are useful for cloning vectors in mammalian cells.
Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, eg., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the CHEPO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (19801. A suitable selection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 (Stinchcomb et al., Nature. 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (19801]. The trill gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].
Expression and cloning vectors usually contain a promoter operably linked to the CHEPO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the -lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (19781; Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trill promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA. 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding CHEPO.
Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate 2 0 kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (19801] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Ren., 7:149 (19681; Holland, Biochemistry, 17:4900 (19781], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
CHEPO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from 3 0 the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 19891, adenovirus (such as Adenovirus 21, bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (S1140), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
Transcription of a DNA encoding the CHEPO by higher eukaryotes may be increased by inserting an enhancer 3 5 sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SU40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the CHEPO coding sequence, but is preferably located at a site 5' from the promoter.
Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding CHEPO.
Still other methods, vectors, and host cells suitable for adaptation to the synthesis of CHEPO in recombinant vertebrate cell culture are described in Gething et al., Nature. 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.
4. Detectinu Gene AmplificationlExnression Gene amplification andlor expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA
(Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (19801], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including 2 0 DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene 2 5 product. Antibodies useful for immunohistochemical staining andlor assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence CHEPO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to CHEPO DNA and encoding a specific antibody epitope.
3 0 5. Purification of Polvoeutide Forms of CHEPO may be recovered from culture medium or from host cell lysates.
If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of CHEPO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.
3 5 It may be desired to purify CHEPO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE;
ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the CHEPO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzvmologv, 182 (19901; Scopes, Protein Purification: Princiules and Practice, Springer-Uerlag, New York (19821. The purification steps) selected will depend, for example, on the nature of the production process used and the particular CHEPO produced.
E. Uses for CHEPO
Nucleotide sequences (or their complement) encoding CHEPO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA
and DNA. CHEPO nucleic acid will also be useful for the preparation of CHEPO
polypeptides by the recombinant techniques described herein.
The full-length native sequence CHEPO cDNA (SED ID N0:31, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the fulhlength CHEPO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of CHEPO or CHEPO from other species) which have a desired sequence identity to the CHEPO sequence disclosed in Figure 2 (SEO ID N0:31. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the nucleotide sequence of SED
ID N0:3 wherein those regions may be determined without undue experimentation or from genomic sequences including 2 0 promoters, enhancer elements and introns of native sequence CHEPO. By way of example, a screening method will comprise isolating the coding region of the CHEPO gene using the known DNA
sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as 32P or'SS, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidinlbiotin coupling systems. Labeled probes having a sequence complementary to that of the CHEPO gene of the present invention can be used to screen libraries of 2 5 human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.
Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.
Other useful fragments of the CHEPO nucleic acids include antisense or sense oligonucleotides comprising a 3 0 singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target CHEPO mRNA (sense) or CHEPO
DNA Iantisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of CHEPO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (CancerRes. 48:2659, 1988) and van der Krol et 3 5 al. (BioTechniques 6:958, 19881.
Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to block expression of CHEPO proteins.
Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91106629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.
Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90110048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-IL-lysinel.
Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.
Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaP04-mediated DNA
transfection, electraporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either in vivo or ex viva. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLU, N2 (a retrovirus derived from M-MuLU), or the double copy vectors designated DCTSA, DCTSB and 2 0 DCT5C (see WO 90113641 ).
Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO
91104753. Suitable ligand binding molecules include, but are not limited ta, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the 2 5 ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.
Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90110448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.
3 0 The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related CHEPO coding sequences.
Nucleotide sequences encoding a CHEPO can also be used to construct hybridization probes for mapping the gene which encodes that CHEPO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as 3 5 in situ hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.
When the coding sequences for CHEPO encode a protein which binds to another protein (example, where the CHEPO is a receptorl, the CHEPO can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptorhigand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor CHEPO can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native CHEPO or a receptor for CHEPO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.
Nucleic acids which encode CHEPO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A
transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops.
In one embodiment, cDNA encoding CHEPD
can be used to clone genomic DNA encoding CHEPO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA
encoding CHEPO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for CHEPO transgene 2 0 incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding CHEPO
introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding CHEPO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals 2 5 bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.
Alternatively, non-human homologues of CHEPO can be used to construct a CHEPO
"knock out" animal which has a defective or altered gene encoding CHEPO as a result of homologous recombination between the endogenous gene encoding CHEPO and altered genomic DNA encoding CHEPO introduced into an embryonic stem cell of the animal. For example, cDNA encoding CHEPO can be used to clone genomic DNA encoding CHEPO
in accordance with established 3 0 techniques. A portion of the genomic DNA encoding CHEPO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration.
Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are 3 5 selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 19871, pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA.
Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the CHEPO polypeptide.
Nucleic acid encoding the CHEPO polypeptides may also be used in gene therapy.
In gene therapy applications, genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA.
Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in vivo. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik et al., Proc. Natl. Acad. Sci. USA 83, 4143-4146 [1986]I. The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.
There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host.
Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, 2 0 electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnolo4y 11, 205-210 [1993]I. In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are 2 5 employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting andlor to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life.
The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (19901.
For review of gene marking and gene 3 0 therapy protocols see Anderson et al., Science 256, 808-813 (19921.
The CHEPO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes.
The nucleic acid molecules encoding the CHEPO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since 3 5 relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each CHEPO
nucleic acid molecule of the present invention can be used as a chromosome marker.
The CHEPO polypeptides and nucleic acid molecules of the present invention may also be used for tissue typing, wherein the CHEPO polypeptides of the present invention may be differentially expressed in one tissue as compared to another. CHEPO nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.
The CHEPO polypeptides described herein may also be employed as therapeutic agents. The CHEPO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the CHEPO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle.
Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (198011, in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins;
hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides 1 S and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; andlor nonionic surfactants such as TWEEN'"", PLURONICSr""
or PEG.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
2 0 Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.
2 5 Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In Toxicokinetics and New Drug 3 0 Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 4296.
When in vivo administration of a CHEPO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 nglkg to up to 100 mglkg of mammal body weight or more per day, preferably about 1 glkglday to 10 mglkglday, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos.
4,657,760; 5,206,344; or 5,225,212. It is 3 5 anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue. for example, may necessitate delivery in a manner different from that to another organ or tissue.
Where sustained-release administration of a CHEPO potypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the CHEPO polypeptide, microencapsulation of the CHEPO polypeptide is contemplated.
Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN-1, interleukin-2, and MN
rgp120. Johnson et al., Nat. Med.. 2: 795-799 (19961; Yasuda. Biomed. Ther., 27: 1221-1223 (19931; Hora et al., BioITechnoloay. 8: 755-758 (19901; Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adiuvant Auproach, Powell and Newman, eds, (Plenum Press: New York,19951, pp. 439-462; WO 97103692, WO 96140072, WO
96107399; and U.S Pat. No. 5,654,010.
The sustained-release formulations of these proteins were developed using poly-lactic-coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactidelglycolide polymer," in: M. Chasin and R. Langer (Eds.l, Biode4radable Polymers as Drug Delivery S sv tams (Marcel Dekker: New York, 1990), pp. 1-41.
This invention encompasses methods of screening compounds to identify those that mimic the CHEPO
polypeptide (agonistsl or prevent the effect of the CHEPO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the CHEPO polypeptides encoded by the genes 2 0 identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.
The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art. All assays for 2 5 antagonists are common in that they call for contacting the drug candidate with a CHEPO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.
In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the CHEPO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent 3 0 attachment generally is accomplished by coating the solid surface with a solution of the CHEPO polypeptide and drying.
Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the CHEPO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes 3 5 anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label. complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.
If the candidate compound interacts with but does not bind to a particular CHEPO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (Londonh 340: 245-246 (1989); Chien etal., Proc. Natl. Acad. Sci. USA. 88: 9578-9582 (19911) as disclosed by Chevray and Nathans, Proc. Natl.
Acad. Sci. USA, 89: 5789-5793 (19911. Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain.
The expression of a GAL1-/acZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for -galactosidase. A complete kit (MATCHMAKERT"') for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.
2 0 Compounds that interfere with the interaction of a gene encoding a CHEPO
polypeptide identified herein and other intro- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intro- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve 2 5 as positive control. The binding (complex formation) between the test compound and the intro- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reactionls) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.
To assay for antagonists, the CHEPO polypeptide may be added to a cell along with the compound to be screened 3 0 for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the CHEPO
polypeptide indicates that the compound is an antagonist to the CHEPO
polypeptide. Alternatively, antagonists may be detected by combining the CHEPO polypeptide and a potential antagonist with membrane-bound CHEPO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The CHEPO polypeptide can be labeled, such as by radioactivity, such that the number of CHEPO
polypeptide molecules bound to the receptor can 3 5 be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan etal., Current Protocols in Immun., 1(21: Chapter 5 (19911. Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the CHEPO palypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the CHEPO polypeptide. Transfected cells that are grown on glass slides are exposed to labeled CHEPO polypeptide. The CHEPO
polypeptide can be labeled by a variety of means including iodination or inclusion'of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.
As an alternative approach for receptor identification, labeled CHEPO
polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule.
Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.
In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled CHEPO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.
More specific examples of potential antagonists include an oligonucleotide that binds to the tusions of immunoglobulin with CHEPO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions 2 0 of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the CHEPO
polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the CHEPO
polypeptide.
Another potential CHEPO polypeptide antagonist is an antisense RNA or DNA
construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing 2 5 to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA
or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature CHEPO polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et 3 0 a/., Nucl. Acids Res., 6: 3073 (19791; Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (199111, thereby preventing transcription and the production of the CHEPO polypeptide.
The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the CHEPO polypeptide (antisense -Okano, Neurochem., 56: 560 (19911; Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Baton, FL, 19881. The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA
3 5 may be expressed in vivo to inhibit production of the CHEPO polypeptide.
When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and + 10 positions of the target gene nucleotide sequence, are preferred.
Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the CHEPO polypeptide, thereby blocking the normal biological activity of the CHEPO
polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Bioloay, 4: 469-471 (19941, and PCT publication No. WO 97133551 (published September 18, 19971.
Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, eg., PCT publication Na. WO
97133551, supra.
These small molecules can be identified by any one or more of the screening assays discussed hereinabove andlor by any other screening techniques well known for those skilled in the art.
F. Anti-CHEPO Antibodies The present invention further provides anti-CHEPO antibodies. Exemplary antibodies include polyclonal, 2 0 monoclonal, humanized, bispecific, and heteroconjugate antibodies.
Polvclonal Antibodies The anti-CHEPO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of 2 5 an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent andlor adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the CHEPO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be 3 0 employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolatel. The immunization protocol may be selected by one skilled in the art without undue experimentation.
2. Monoclonal Antibodies The anti-CHEPO antibodies may, alternatively, be monoclonal antibodies.
Monoclonal antibodies may be prepared 3 5 using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (19751. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
Alternatively, the lymphocytes may be immunized in vitro.
The immunizing agent will typically include the CHEPO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ["PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRTI, the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol..
133:3001 (19841; Brodeur et al., Monoclonal Antibody Production TechniQUes and Annlications Marcel Dekker, Inc., New York, (1987) pp. 51-63].
2 0 The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against CHEPO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme linked immunoabsorbent assay (ELISAI. Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., .
107:220 (1980).
After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [coding, suura]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
3 0 The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S.
Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced 3 5 using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CH0) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking.
Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
/n vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.
3. Human and Humanized Antibodies The anti-CHEPO antibodies of the invention may further comprise humanized antibodies or human antibodies.
2 0 Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', Flab'IZ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
2 5 In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
3 0 The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region [Fc], typically that of a human immunoglobulin [Jones et al., Nature. 321:522-525 (1986);
Riechmann et al., Nature. 332:323-329 (19881; and Presto, Curr. Oa. Struct. Biol., 2:593-596 (19921].
Methods for humanizing non-human antibodies are well known in the art.
Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid 3 5 residues are often referred to as "import" residues, which are typically taken from an "import" variable domain.
Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature. 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Uerhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboam and Winter, J. Mal. Biol., 227:381 (19911; Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therauv, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 14711):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807;
5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., BiolTechnolony 0 779-78311992); Lonberg et al., Nature 368 856-859 (19941;
Morrison, Nature 368, 812-13 (1994);
Fishwild et al., Nature Biotechnolouy 4 845-51 (1996); Neuberger, Nature Biotechnoloay 4 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).
2 0 4. Bisoecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the CHEPO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.
Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of 2 5 bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chainhight-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains. these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93108829, 3 0 published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991 ).
Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding 3 5 the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymolo4y 121:210 (19861.
According to another approach described in WO 96127011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophanl. Compensatory cavities of identical or similar size to the large side chains) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab )z bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature.
For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan et ah, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate Flab )Z fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab -TNB derivatives is then reconverted to the Fab -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
2 0 Fab fragments may be directly recovered from E. coii and chemically coupled to form bispecific antibodies.
Shalaby et al., J. Exn. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody Flab Iz molecule. Each Fab fragment was separately secreted from E. cvii and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human 2 5 breast tumor targets.
Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (19921. The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form 3 0 monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The diabody technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (V~) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and V~
domains of one fragment are forced to 3 5 pair with the complementary V~ and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et a/., J. Immunol. 147:60 (19911.
Exemplary bispecific antibodies may bind to two different epitopes on a given CHEPO polypeptide herein.
Alternatively, an anti-CHEPO polypeptide arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc Rl, such as Fc RI
(CD641, Fc RII (C032) and Fc RIII (CD161 so as to focus cellular defense mechanisms to the cell expressing the particular CHEPO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular CHEPO polypeptide. These antibodies possess a CHEPO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the CHEPO
polypeptide and further binds tissue factor (TF).
5. Heteroconiu4ate Antibodies Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV
infection [WO 91100360; WO 921200373;
EP 03089]. It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide 2 0 exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
6. Effector Function EnQineerinQ
It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, 2 5 e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residues) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
The homodimeric antibody thus generated may have improved internalization capability andlor increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCCI. See Caron et al., J. Exu Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-3 0 linkers as described in Wolff et al. Cancer Research. 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson etal., Anti-Cancer Drun Design, 3: 219-230 (1989).
Immunoconiu4ates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e,g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above.
Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosal, ricin A
chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaanaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include z'ZBi, "'I,'3'In, °°Y, and'B6Re.
Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediaminel, bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediaminel, diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Uitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent tar conjugation of radionucleotide to the antibody. See W094111026.
2 0 In another embodiment, the antibody may be conjugated to a "receptor"
(such streptavidin) far utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic agent le.g., a radionucleotidel.
2 5 8. Immunoliposomes The antibodies disclosed herein may also be formulated as immunoliposomes.
Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA. 82: 3688 (1985);
Hwang etal., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos.
4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
3 0 Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through fitters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem.. 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within 3 5 the liposome. See Gabizon et al., J. National Cancer Inst.. 81 (191: 1484 (19891.
9. Pharmaceutical Compositions of Antibodies Antibodies specifically binding a CHEPO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.
If the CHEPO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells.
Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically andlor produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl.
Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary far the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques 2 0 or by interfacial polymerization, for example, hydroxymethylcellulose ar gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, supra.
The formulations to be used for in viva administration must be sterile. This is readily accomplished by filtration 2 5 through sterile filtration membranes.
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylatel, or poly(vinylalcohol)), polylactides (U.S.
Pat. No. 3,773,919), copolymers of L-glutamic 3 0 acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT ~" (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetateh and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 C, 3 5 resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
G. Uses for anti-CHEPO Antibodies The anti-CHEPO antibodies of the invention have various utilities. For example, anti-CHEPO antibodies may be used in diagnostic assays for CHEPO, eg., detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunaprecipitation assays conducted in either heterogeneous or homogeneous phases (Zola, Monoclonal Antibodies:
A Manual of Techniaues, CRC Press, Inc. (1987) pp.147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as 'H,'4C,'zp, 355, or'z51, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (19621;
David et al., Biochemistry, 13:1014 (1974/; Pain et al., J. Immunol. Meth., 40:219 (19811; and Nygren, J. Histochem. and Cytochem., 30:407 (1982).
Anti-CHEPO antibodies also are useful for the affinity purification of CHEPO
from recombinant cell culture or natural sources. In this process, the antibodies against CHEPO are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample 2 0 containing the CHEPO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the CHEPO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the CHEPO
from the antibody.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
2 5 All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
EXAMPLES
Commercially available reagents referred to in the examples were used according to manufacturer's instructions 3 0 unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.
Isolation of Nucleic Acid Encodinu CHEPO
Genomic DNA was isolated from two chimpanzee cell lines (ATCC CRL1609 and CRL1857) using a Diagen kit (cat#10262) as recommended by the manufacturer's instructions. The chimp Epo gene was then obtained on 3 separate fragments by PCR using 1 g of genomic DNA as template and the following primer pairs:
EPO.F: 5'-ACCGCGCCCCCTGGACAG-3' (SED ID N0:12) EPO.INT1.R: 5'-CATCCACTTCTCCGGCCAAACTTCA-3' (SED ID N0:13) EPO.INT1F:5'-TTTGGCCGGAGAAGTGGATGC-3' (SEDIDN0:14) EPO.INT4R: 5'-TCACTCACTCACTCATTCATTCATTCATTCA-3' (SEO ID N0:15) EPO.INT4F: 5'-GTTGAATGAATGATTGAATGAATGAGTGA-3' (SED ID N0:16) EPO.R: 5'-GCACTGGAGTGTCCATGGGACAG-3' (SED ID N0:17) Each PCR reaction contained 5 I of 10x PCR Buffer (Perkin Elmerl, 1 I dNTP
(20mM1, 1 g genomic DNA, 1 I of each primer, 1 I of Taq polymerase (Clontech) and HZO to bring the total volume to 50 I. The reaction was first denatured for 4 min. at 94 C then amplified for 40 cycles of 1 min. at 94 C, 1 min. at 65 C or 66 C then extended for 1 min. at 72 C.
A last extension step of 5 min. at 72 C was performed. The reaction was then analyzed on agarose gel. PCR product of 500bp, 1200bp and 750bp were observed for each PCR product, respectively. The PCR reactions were then purified using 2 0 a Wizard kit (Promega cat # A7170) then directly sequenced. DNA sequencing of the PCR products was done using an Applied Biosystems 377 DNA Sequencer (PEIApplied Biosystems, Foster City, CA).
The chemistry used was DYE
Terminator Cycle Sequencing with dRhodamine and BIG DYE terminators (PEIApplied Biosystems, Foster City, CAI.
Sequence assembly and editing done with Sequencher software (Gene Codes, Ann Arbor, MI).
The 5 coding exons were identified by homology with the human erythropoietin sequence and assembled into a 2 5 predicted full length cDNA. The coding region of CHEPO cDNA is 579 nucleotides long (Figure 1 ) and encodes a predicted protein of 193 amino acids (Figure 3). There are 3 putative signal cleavage sites predicted after amino acid residue 22, 24 and 27. In accordance with the N-terminus of human Epo, the latest one is likely to correspond to the cleavage site for chimp Epo. The hydrophobic 27 amino acid signal peptide is followed by a 166 amino acid long mature protein containing 3 potential N-glycosylation sites. A single nucleotide polymorphism is present in the predicted sequence obtained from 3 0 CRL1609 and changes the protein sequence at amino acid position 142 from a D to a K. Alignment of the chimp Epo protein with the human sequence indicates a single change at amino acid position 84 (Figure 3).
Use of CHEPO cDNA as a hybridization urobe 35 The following method describes use of a nucleotide sequence encoding CHEPO
as a hybridization probe.
DNA comprising the coding sequence of full-length or mature CHEPO (as shown in Figure 2, SEO ID N0:3) is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of CHEP01 in human tissue cDNA libraries or human tissue genomic libraries.
Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled CHEPO-derived probe to the filters is performed in a solution of 50%
formamide, 5x SSC, 0.1 % SDS, 0.1 % sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1 x SSC and 0.19'o SDS at 42°C.
DNAs having a desired sequence identity with the DNA encoding full-length native sequence CHEPO can then be identified using standard techniques known in the art.
Expression of CHEPO in E. coli This example illustrates preparation of an unglycosylated form of CHEPO by recombinant expression in E. coli.
The DNA sequence encoding CHEPO (SEO ID N0:3) is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector.
A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector 2 0 will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage sitel, the CHEPO coding region, lambda transcriptional terminator, and an argU gene.
The ligation mixture is then used to transform a selected E. cvli strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB
plates and antibiotic resistant colonies are then 2 5 selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.
Selected clones can be grown overnight in liquid culture medium such as LB
broth supplemented with antibiotics.
The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.
After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet 3 0 obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized CHEPO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.
CHEPO may be expressed in E. coli in a poly-His tagged form, using the following procedure. The DNA encoding CHEPO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and 3 5 reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase.
The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an E. coli host based on strain 52 (W3110 fuhA(tonA) Ion galE rpoHtsIhtpRts) clpP(laclql. Transformants are first grown in LB containing 50 mglml carbenicillin at 30 C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH4)ZS04, 0.71 g sodium citrate 2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 ml water, as well as 110 mM
MPOS, pH 7.3, 0.55% Iwlv) glucose and 7 mM MgS04) and grown for approximately 20-30 hours at 30 C with shaking.
Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells.
Cell pellets are frozen until purification and refolding.
E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (wlv) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1 M
and 0.02 M, respectively, and the solution is stirred overnight at 4 C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.41 and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM
imidazole (Calbiochem, Utrol gradeL pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4 C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.
The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCI, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM
EDTA. Refolding volumes are chosen 2 0 so that the final protein concentration is between 50 to 100 microgramslml. The refolding solution is stirred gently at 4 C
for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 31. Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R11H reversed phase column using a mobile buffer of 0.1 % TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots 2 5 of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin 3 0 from the samples.
Fractions containing the desired folded CHEPO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.
Expression of CHEPO in mammalian cells This example illustrates preparation of a potentially glycosylated form of CHEPO by recombinant expression in mammalian cells.
The vector, pRK5 (see EP 307,247, published March 15, 1989], is employed as the expression vector.
Optionally, the CHEPO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the CHEPO DNA
using ligation methods such as described in Sambrook et al., suura. The resulting vector is called pRKS-CHEPO.
In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components andlor antibiotics. About 10 g pRKS-CHEPO DNA is mixed with about 1 g DNA encoding the VA RNA gene [Thimmappaya et al., Cell, 31:543 (19821] and dissolved in 500 I of 1 mM Tris-HCI, 0.1 mM EDTA, 0.227 M CaClz. To this mixture is added, dropwise, 500 I of 50 mM HEPES (pH 7.35], 280 mM NaCI, 1.5 mM NaPO,, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20~'o glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.
Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 Cilml'SS-cysteine and 200 Cilml 35S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may 2 0 be dried and exposed to film for a selected period of time to reveal the presence of CHEPO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.
In an alternative technique, CHEPO may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (19811. 293 cells are grown to maximal density in a spinner flask and 700 g pRKS-CHEPO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 glml bovine insulin and 0.1 glml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed CHEPO can then 3 0 be concentrated and purified by any selected method, such as dialysis andlor column chromatography.
In another embodiment, CHEPO can be expressed in CHO cells. The pRKS-CHEPO can be transfected into CHO
cells using known reagents such as CaP04 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alonel or medium containing a radiolabel such as 35S-methionine. After determining the presence of CHEPO polypeptide, the culture medium may be replaced with serum free medium. Preferably, 3 5 the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed CHEPO can then be concentrated and purified by any selected method.
Epitope-tagged CHEPO may also be expressed in host CHO cells. The CHEPO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged CHEPO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones.
Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged CHEPO can then be concentrated and purified by any selected method, such as by Niz'-chelate affinity chromatography.
CHEPO may also be expressed in CHO andlor COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.
Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG
construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains andlor is a poly-His tagged form.
Following PCR amplification, the respective DNAs are subcloned in a CHO
expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology Unit 3.16, John Wiley and Sons (1997).
CHO expression vectors are constructed to have compatible restriction sites 5 and 3 of the DNA of interest to allow the convenient shuttling of cDNA s. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res.
24:9 (1774-1779 (1996), and uses the SV40 early promoterlenhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR1. DHFR expression permits selection for stable maintenance of the plasmid following 2 0 transfection.
Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect (Quiagen), Dosper or Fugene (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately 3 x 10'' cells are frozen in an ampule for further growth and production as described below.
2 5 The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mls of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 m filtered PS20 with 5% 0.2 m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL
spinner containing 90 mL of selective media.
After 1-2 days. the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated 3 0 at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 ml spinners are seeded with 3 x 105 ceIIsImL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at 1.2 x 106 ceIIsImL. On day 0, the cell number pH ie determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted 3 5 to 33°C, and 30 mL of 500 gIL glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH
is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 709'0, the cell culture is harvested by centrifugation and filtering through a 0.22 m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.
For the poly-His tagged constructs, the proteins are purified using a Ni-NTA
column (Qiagenl. Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCI
and 5 mM imidazole at a flow rate of 4-5 mllmin. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCI and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
Immunoadhesin IFc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above far the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.
Expression of CHEPO in Yeast 2 0 The following method describes recombinant expression of CHEPO in yeast.
First, yeast expression vectors are constructed for intracellular production or secretion of CHEPO from the ADH21GAPDH promoter. DNA encoding CHEPO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of CHEPO. For secretion, DNA encoding CHEPO can be cloned into the selected plasmid, together with DNA encoding the ADH21GAPDH promoter, a native CHEPO signal peptide or other 2 5 mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signalheader sequence, and linker sequences (if needed) for expression of CHEPO.
Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10~ trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.
3 0 Recombinant CHEPO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing CHEPO may further be purified using selected column chromatography resins.
3 5 Expression of CHEPO in Baculovirus-Infected Insect Cells The following method describes recombinant expression of CHEPO in Baculovirus-infected insect cells.
The sequence coding for CHEPO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags hike Fc regions of IgGI. A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding CHEPO or the desired portion of the coding sequence of CHEPO
such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.
Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoIdT"' virus DNA
(Pharmingen) into Spodoptera frugiperda ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications.
Viral infection and protein expression are performed as described by 0'Reilley et al., Baculovirus expression vectors: A
Laboratory Manual, Oxford: Oxford University Press (19941.
Expressed poly-his tagged CHEPO can then be purified, for example, by Nip'-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (19931. Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl2; 0.1 mM EDTA; 10% glycerol; 0.1 % NP-40; 0.4 M KCI), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCI, 10~ glycerol, pH 7.8) and filtered through a 0.45 m filter. A Niz'-NTA agarose column (commercially available from Qiagen) is prepared 2 0 with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline AZeo with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer 150 mM phosphate;
300 mM NaCI, 109'o glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching AZeo baseline again, the column is developed with a 0 to 500 mM Imidazoie gradient in the secondary wash buffer. One mL fractions are collected 2 5 and analyzed by SDS-PAGE and silver staining or Western blot with Nip'-NTA-conjugated to alkaline phosphatase (Qiagen).
Fractions containing the eluted His,o-tagged CHEPO are pooled and dialyzed against loading buffer.
Alternatively, purification of the IgG tagged (or Fc tagged) CHEPO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.
Preparation of Antibodies that Bind CHEPO
This example illustrates preparation of monoclonal antibodies which can specifically bind CHEPO.
Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, su ra. Immunogens that may be employed include purified CHEPO, fusion proteins containing CHEPO, and cells 3 5 expressing recombinant CHEPO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.
Mice, such as Balblc, are immunized with the CHEPO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-CHEPO antibodies.
After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of CHEPO. Three to four days later, the mice are sacrificed and the spleen cells are harvested.
The spleen cells are then fused (using 359'o polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.l, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.
The hybridoma cells will be screened in an ELISA for reactivity against CHEPO.
Determination of "positive"
hybridoma cells secreting the desired monoclonal antibodies against CHEPO is within the skill in the art.
The positive hybridoma cells can be injected intraperitoneally into syngeneic Balblc mice to produce ascites containing the anti-CHEPO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography.
Alternatively, affinity chromatography based upon binding 2 0 of antibody to protein A or protein G can be employed.
Purification of CHEPO Polynentides Usina Specific Antibodies Native or recombinant CHEPO polypeptides may be purified by a variety of standard techniques in the art of 2 5 protein purification. For example, pro-CHEPO polypeptide, mature CHEPO
polypeptide, or pre-CHEPO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the CHEPO
polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-CHEPO
polypeptide antibody to an activated chromatographic resin.
Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by 3 0 purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A.
Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE'""
(Pharmacia LKB Biotechnologyl. The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.
3 5 Such an immunoaffinity column is utilized in the purification of CHEPO
polypeptide by preparing a fraction from cells containing CHEPO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble CHEPO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.
A soluble CHEPO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of CHEPO
polypeptide (eg., high ionic strength buffers in the presence of detergentl. Then, the column is eluted under conditions that disrupt antibodyICHEPO polypeptide binding (e.g., a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ionl, and CHEPO polypeptide is collected.
Drug Screening This invention is particularly useful for screening compounds by using CHEPO
polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The CHEPO
polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the CHEPO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between CHEPO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the CHEPO polypeptide and its target cell or target receptors caused 2 0 by the agent being tested.
Thus, the present invention provides methods of screening for drugs or any other agents which can affect a CHEPO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an CHEPO
polypeptide or fragment thereof and assaying (1) for the presence of a complex between the agent and the CHEPO
polypeptide or fragment, or (ii) for the presence of a complex between the CHEPO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the CHEPO polypeptide or fragment is typically labeled. After suitable incubation, free CHEPO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to CHEPO polypeptide or to interfere with the CHEPO polypeptidelcell complex.
Another technique for drug screening provides high throughput screening for compounds having suitable binding 3 0 affinity to a polypeptide and is described in detail in WO 84103564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a CHEPO polypeptide, the peptide test compounds are reacted with CHEPO polypeptide and washed.
Bound CHEPO polypeptide is detected by methods well known in the art. Purified CHEPO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.
In addition, non-neutralizing antibodies can 3 5 be used to capture the peptide and immobilize it on the solid support.
This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding CHEPO polypeptide specifically compete with a test compound for binding to CHEPO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one ar more antigenic determinants with CHEPO polypeptide.
Rational Dru4 Design The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (ie., a CHEPO polypeptide) or of small molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the CHEPO polypeptide or which enhance or interfere with the function of the CHEPO polypeptide in vivo (c.f., Hodgson, BioITechnoloay, 9: 19-21 (1991)1.
In one approach, the three-dimensional structure of the CHEPO polypeptide, or of an CHEPO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the CHEPO polypeptide must be ascertained to elucidate the structure and to determine active sitels) of the molecule. Less often, useful information regarding the structure of the CHEPO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous CHEPO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda et al., 2 0 J. Biochem., 113:742-746 (1993).
It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would 2 5 be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.
By virtue of the present invention, sufficient amounts of the CHEPO
polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the CHEPO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition 3 0 to x-ray crystallography.
The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention as claimed. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.
Claims
2. An isolated nucleic acid molecule comprising nucleotides 1 or about 82 to about 579 of Figure 2 (SEQ
ID NO:31.
3. An isolated nucleic acid molecule comprising the nucleotide sequence of Figure 2 (SEQ ID NO:31.
4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the sequence of amino and residues from about 1 ar about 28 to about 193 of Figure 2 (SEQ ID NO:2).
9. A vector comprising the nucleic acid molecule of any one of Claims 2, 3, 4, 39 or 42.
10. The vector of Claim 9, wherein said nucleic acid molecule is operably linked to control sequences recognized by a host cell transformed which the vector.
11. A host cell comprising the vector of Claim 9.
i2. The host cell of Claim 11, wherein said cell is a CHO cell.
13. The host cell of Claim 11, wherein said cell is an E coil.
14. The host cell of Claim 11, wherein said cell is a yeast cell.
15. A process far producing a polypeptide comprising culturing the host cell of Claim 11 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.
17. An isolated polypeptide comprising amino acid residues 1 or about 28 to about 193 of Figure 2 (SEQ
ID NO:2).
22. A chimeric molecule comprising the polypeptide of any one of Claims 17, 40 or 41 fused to a heterologous amino acid sequence.
23. The chimeric molecule of Claim 22, wherein said heterologous amino acid sequence is an epitope tag sequence.
24. The chimeric molecule of Claim 22, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
25. An antibody which specifically hinds to the polypeptide of any one of Claims 17, 40 or 41.
26. The antibody of Claim 24, wherein said antibody is a monoclonal antibody.
27. The antibody of Claim 24, wherein said antibody is a humanized antibody.
34. A polypeptide comprising an amino acid sequence selected from the group consisting of:
(1) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRNXSXQQAVEVWQGLALLSEAVLRGDA
LLV
NSSQPWEPLQLHVDKAVSGLRSITTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SED ID NO:18);
(2) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRNXSXQQAVEVWDGLALLSEAVLRGDA
LLV
NSSDPWEPLDLHUDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:19);
(3) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWKRNXTXODAVEVWOGLALLSEAVLRGQA
LLV
NSSDPWEPLDLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEO ID NO:20);
(4) APPRLICOSRVLERYLLEAKEAENITTGCAEHCSLNENITVPTKVNFYAWKRNXTXDQAVEVWOGLALLSEAVLRGDAL
LV
NSSQPWEPLDLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRYYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:21);
(5) APPRLICDSRULERYLLEAKEAENITTGCAEHCSLNENITVPDTINNFYAWKRMNXSXQAVEVWDGLALLSEAVLRGOA
LL
VNSSDPWEPLDLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:22);
(6) APPRLICDSRULFRYLLEAKEAEN(TTGCAEHCSLNENITVPDTKVNFYAWKRMNXSXOAVEVWOGLALLSEAVLRGQA
LL
VNSSaPWEPLQLHVDKAVSGIRSLTTLLRALGAKKEAISPPDAASAAPLRT1TADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGOR (SEQ ID NO: 23);
(7) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMNXTXDAVEVWQGLALLSEAVLRGQA
LL
VNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SED 10 NO:25);
(8) APPRLICDSRVLFRYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMENXSXAVEVWOGLALISEAVLRGQA
LL
VNSSQPWEPLaLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:26);
(9) APPRLICDSRULERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWKRMENXSXAVEVWDGLALLSEAVLRGDA
LL
VNSSQPWEPLQLHVOKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:27);
(10) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKNFYAWKRMENXTXAVEVWOGIAILSEAVLRGDAL
L
VNSSOPWEPLQLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGOR (SEO ID NO:28);
(11) QPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITUPDTKVNFYAWKRMENXTXAVEVWGLALLSEAVLRGQALL
VNSSOPWEPLOLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITAOTFRKLFRUYSNFLRGKLKLYTGEA
CR
TGQR (SED ID NO:29);
(12) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKRMEVNXSXVEVWDGCALLSEAVLRGDAL
LV
NSSDPWEPLQLHUDKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTITAOTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEO ID ND:30);
(13) APPRLICOSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKRMEVNXSXVEVWAGLALLSEAVLRGOAL
LV
NSSQPWEPLOLHVDKAVSGLRSLTTLLHALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFIRGKLKLYTGEAC
RT
GDR (SEQ ID NO:31); and (14) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKUNFYAWKRMEVNXTXVEVWOGLALLSEAVLRGQAL
LV
NSSQPWEPLOLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:33), wherein X is any amino acid except for proline.
35. The polypeptide according to Claim 34, which comprises an amino acid sequence selected from the group consisting of:
(1) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPOTKVNFYAWK
RNX
SXQQAVEVWOGLALLSEAVLRGQALLUNSSQPWEPLOLHVOKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:34);
(2) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKUNFYAWKR
NX
SXOOAVEVWQGLALLSEAVLRGOALLVNSSOPWEPLQLHVOKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SED ID N:35):
(3) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKR
NX
TXQQAVEVWOGLALLSEAVLRGQALLVNSSOPWEPLOLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:36):
(4) MGVHEGPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RNX
TXQQAEVWOGLALLSEAVLRGALLUNSSQPWEPLDLHVDKAVSGLRSLLLRALGAKKEAISPPDAASAAPLRTITAD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID NO:371;
(5) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWK
RMN
XSXOAVEVWQGLALLSEAVLRGOALLVNSSQPWEPLOLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTIT
AD
TFRKLFRUYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:38);
(6) RMN
XSXOAVEVWnGLALLSEAVLRGQALLVNSSOPWEPLQLHVDKAVSGLRSLTTLLRALGAKKEAISPPOAASAAPLRTIT
AO
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID N0:39);
(7) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RMN
XTXQAVEVW~GLALLSEAVLRGDALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGA~KEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:40);
(8) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RMN
XTXQAVEVWDGLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPIRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID NO:41);
(9) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
NXSXAVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGA~KEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:42);
(10) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTINNFYAWK
RME
NXSXAVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHUDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:43);
(11) MGHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKR
ME
NXTXAVEVW~GLALLSEAVLRG~ALLVNSSOPWEPL~LHV~KAVSGLRSLTTLLRALGAQKEAISPP~AASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:44);
(12) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRULERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RME
NXTXAVEVWQGLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:45);
(13) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RME
VNXSXVEVW~GLALLSEAVLRGUALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTTT
AD
TFRKIFRVYSNFLRGKIKLYTGEACRTG~R (SEQ ID NO:46);
(14) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
VNXSXVEVW~GLALLSEAVLRG~ALLVNSS~PWEPLOLHVDKAVSGLRSITTLLRALGAKKEAISPPDAASAAPLRTIT
A~
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:47);
(15) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPOTKVNFYAWK
RME
VNXTXVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHV~KAVSGLRSLTTLLRALGA~KEAISPPOAASAAPLRTIT
AD
TFRKLFRVYSNFIRGKLKIYTGEACRTG~R (SEQ ID NO:48); and (16) MGVHECPAWLWLLLSLESLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
VNXTXVEVW~GLALLSEAVLRG~ALLVNSSDPWEPL~LHV~KAVSGLRSLTTLLRALGAKKEAISPP~AASAAPLRTIT
A~
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:49), wherein X is any amino acid except for protine.
36. A chimeric molecule comprising a polypeptide of Claim 34 or 35 fused to a heteralogous amino acid sequence.
37. The chimeric molecule of Claim 36, wherein said heterologaus amino acid sequence is an apitope tag sequence.
38. The chimeric molecule of Claim 36, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
39. An isolated nucleic acid molecule consisting of the nucleotide sequence of Figure 2 (SEQ ID NO:3).
40. An isolated polypeptide consisting of amino add residues 1 or about 28 to about 193 of Figure 2 (SEQ
ID NO:2).
41. An isolated polypeptide encoded by nucleotides 1 or about 82 to about 579 of Figure 2 (SEQ ID NO:3).
42. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes the chimeric molecule of any one of Claim 22, 23, 24, 36, 37 or 38.
ID NO:31.
3. An isolated nucleic acid molecule comprising the nucleotide sequence of Figure 2 (SEQ ID NO:31.
4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the sequence of amino and residues from about 1 ar about 28 to about 193 of Figure 2 (SEQ ID NO:2).
9. A vector comprising the nucleic acid molecule of any one of Claims 2, 3, 4, 39 or 42.
10. The vector of Claim 9, wherein said nucleic acid molecule is operably linked to control sequences recognized by a host cell transformed which the vector.
11. A host cell comprising the vector of Claim 9.
i2. The host cell of Claim 11, wherein said cell is a CHO cell.
13. The host cell of Claim 11, wherein said cell is an E coil.
14. The host cell of Claim 11, wherein said cell is a yeast cell.
15. A process far producing a polypeptide comprising culturing the host cell of Claim 11 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.
17. An isolated polypeptide comprising amino acid residues 1 or about 28 to about 193 of Figure 2 (SEQ
ID NO:2).
22. A chimeric molecule comprising the polypeptide of any one of Claims 17, 40 or 41 fused to a heterologous amino acid sequence.
23. The chimeric molecule of Claim 22, wherein said heterologous amino acid sequence is an epitope tag sequence.
24. The chimeric molecule of Claim 22, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
25. An antibody which specifically hinds to the polypeptide of any one of Claims 17, 40 or 41.
26. The antibody of Claim 24, wherein said antibody is a monoclonal antibody.
27. The antibody of Claim 24, wherein said antibody is a humanized antibody.
34. A polypeptide comprising an amino acid sequence selected from the group consisting of:
(1) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRNXSXQQAVEVWQGLALLSEAVLRGDA
LLV
NSSQPWEPLQLHVDKAVSGLRSITTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SED ID NO:18);
(2) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRNXSXQQAVEVWDGLALLSEAVLRGDA
LLV
NSSDPWEPLDLHUDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:19);
(3) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWKRNXTXODAVEVWOGLALLSEAVLRGQA
LLV
NSSDPWEPLDLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEO ID NO:20);
(4) APPRLICOSRVLERYLLEAKEAENITTGCAEHCSLNENITVPTKVNFYAWKRNXTXDQAVEVWOGLALLSEAVLRGDAL
LV
NSSQPWEPLDLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRYYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:21);
(5) APPRLICDSRULERYLLEAKEAENITTGCAEHCSLNENITVPDTINNFYAWKRMNXSXQAVEVWDGLALLSEAVLRGOA
LL
VNSSDPWEPLDLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:22);
(6) APPRLICDSRULFRYLLEAKEAEN(TTGCAEHCSLNENITVPDTKVNFYAWKRMNXSXOAVEVWOGLALLSEAVLRGQA
LL
VNSSaPWEPLQLHVDKAVSGIRSLTTLLRALGAKKEAISPPDAASAAPLRT1TADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGOR (SEQ ID NO: 23);
(7) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMNXTXDAVEVWQGLALLSEAVLRGQA
LL
VNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SED 10 NO:25);
(8) APPRLICDSRVLFRYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMENXSXAVEVWOGLALISEAVLRGQA
LL
VNSSQPWEPLaLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:26);
(9) APPRLICDSRULERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWKRMENXSXAVEVWDGLALLSEAVLRGDA
LL
VNSSQPWEPLQLHVOKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGDR (SEQ ID NO:27);
(10) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKNFYAWKRMENXTXAVEVWOGIAILSEAVLRGDAL
L
VNSSOPWEPLQLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEA
CR
TGOR (SEO ID NO:28);
(11) QPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITUPDTKVNFYAWKRMENXTXAVEVWGLALLSEAVLRGQALL
VNSSOPWEPLOLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITAOTFRKLFRUYSNFLRGKLKLYTGEA
CR
TGQR (SED ID NO:29);
(12) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKRMEVNXSXVEVWDGCALLSEAVLRGDAL
LV
NSSDPWEPLQLHUDKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTITAOTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEO ID ND:30);
(13) APPRLICOSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKRMEVNXSXVEVWAGLALLSEAVLRGOAL
LV
NSSQPWEPLOLHVDKAVSGLRSLTTLLHALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFIRGKLKLYTGEAC
RT
GDR (SEQ ID NO:31); and (14) APPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKUNFYAWKRMEVNXTXVEVWOGLALLSEAVLRGQAL
LV
NSSQPWEPLOLHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEAC
RT
GDR (SEQ ID NO:33), wherein X is any amino acid except for proline.
35. The polypeptide according to Claim 34, which comprises an amino acid sequence selected from the group consisting of:
(1) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPOTKVNFYAWK
RNX
SXQQAVEVWOGLALLSEAVLRGQALLUNSSQPWEPLOLHVOKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:34);
(2) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKUNFYAWKR
NX
SXOOAVEVWQGLALLSEAVLRGOALLVNSSOPWEPLQLHVOKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SED ID N:35):
(3) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSWENITVPDTKVNFYAWKR
NX
TXQQAVEVWOGLALLSEAVLRGQALLVNSSOPWEPLOLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:36):
(4) MGVHEGPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RNX
TXQQAEVWOGLALLSEAVLRGALLUNSSQPWEPLDLHVDKAVSGLRSLLLRALGAKKEAISPPDAASAAPLRTITAD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID NO:371;
(5) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITUPDTKVNFYAWK
RMN
XSXOAVEVWQGLALLSEAVLRGOALLVNSSQPWEPLOLHVDKAVSGLRSLTTLLRALGAOKEAISPPDAASAAPLRTIT
AD
TFRKLFRUYSNFLRGKLKLYTGEACRTGDR (SEO ID NO:38);
(6) RMN
XSXOAVEVWnGLALLSEAVLRGQALLVNSSOPWEPLQLHVDKAVSGLRSLTTLLRALGAKKEAISPPOAASAAPLRTIT
AO
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID N0:39);
(7) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RMN
XTXQAVEVW~GLALLSEAVLRGDALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGA~KEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:40);
(8) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RMN
XTXQAVEVWDGLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPIRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTGDR (SEQ ID NO:41);
(9) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
NXSXAVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGA~KEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:42);
(10) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTINNFYAWK
RME
NXSXAVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHUDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:43);
(11) MGHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKR
ME
NXTXAVEVW~GLALLSEAVLRG~ALLVNSSOPWEPL~LHV~KAVSGLRSLTTLLRALGAQKEAISPP~AASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:44);
(12) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRULERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RME
NXTXAVEVWQGLALLSEAVLRG~ALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGAKKEAISPPDAASAAPLRTIT
AD
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:45);
(13) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVP~TKVNFYAWK
RME
VNXSXVEVW~GLALLSEAVLRGUALLVNSS~PWEPL~LHVDKAVSGLRSLTTLLRALGADKEAISPPDAASAAPLRTTT
AD
TFRKIFRVYSNFLRGKIKLYTGEACRTG~R (SEQ ID NO:46);
(14) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
VNXSXVEVW~GLALLSEAVLRG~ALLVNSS~PWEPLOLHVDKAVSGLRSITTLLRALGAKKEAISPPDAASAAPLRTIT
A~
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:47);
(15) MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPOTKVNFYAWK
RME
VNXTXVEVW~GLALLSEAVLRG~ALLVNSS~PWEPL~LHV~KAVSGLRSLTTLLRALGA~KEAISPPOAASAAPLRTIT
AD
TFRKLFRVYSNFIRGKLKIYTGEACRTG~R (SEQ ID NO:48); and (16) MGVHECPAWLWLLLSLESLPLGLPVLGAPPRLIC~SRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWK
RME
VNXTXVEVW~GLALLSEAVLRG~ALLVNSSDPWEPL~LHV~KAVSGLRSLTTLLRALGAKKEAISPP~AASAAPLRTIT
A~
TFRKLFRVYSNFLRGKLKLYTGEACRTG~R (SEQ ID NO:49), wherein X is any amino acid except for protine.
36. A chimeric molecule comprising a polypeptide of Claim 34 or 35 fused to a heteralogous amino acid sequence.
37. The chimeric molecule of Claim 36, wherein said heterologaus amino acid sequence is an apitope tag sequence.
38. The chimeric molecule of Claim 36, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
39. An isolated nucleic acid molecule consisting of the nucleotide sequence of Figure 2 (SEQ ID NO:3).
40. An isolated polypeptide consisting of amino add residues 1 or about 28 to about 193 of Figure 2 (SEQ
ID NO:2).
41. An isolated polypeptide encoded by nucleotides 1 or about 82 to about 579 of Figure 2 (SEQ ID NO:3).
42. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes the chimeric molecule of any one of Claim 22, 23, 24, 36, 37 or 38.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30730799A | 1999-05-07 | 1999-05-07 | |
US09/307,307 | 1999-05-07 | ||
PCT/US2000/012370 WO2000068376A1 (en) | 1999-05-07 | 2000-05-05 | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
USUNKNOWN | 2002-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2369605A1 true CA2369605A1 (en) | 2000-11-16 |
Family
ID=23189154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002369605A Abandoned CA2369605A1 (en) | 1999-05-07 | 2000-05-05 | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2369605A1 (en) |
ZA (1) | ZA200107911B (en) |
-
2000
- 2000-05-05 CA CA002369605A patent/CA2369605A1/en not_active Abandoned
-
2001
- 2001-09-26 ZA ZA200107911A patent/ZA200107911B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200107911B (en) | 2003-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6551799B2 (en) | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders | |
US8178082B2 (en) | Methods for up-regulating PAP1 in animals suffering from pancreatic disorders | |
EP1196570A2 (en) | Human polypeptides and methods for the use thereof | |
US20020155543A1 (en) | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders | |
US20020042367A1 (en) | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders | |
US6831060B2 (en) | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same | |
CA2384089A1 (en) | Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity | |
US20070174922A1 (en) | Nucleic acid encoding novel type-1 cytokine receptor glm-r | |
US6555343B1 (en) | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same | |
WO2002016611A2 (en) | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders | |
US6740520B2 (en) | Cytokine receptor and nucleic acids encoding the same | |
US7642242B2 (en) | PRO34128 polypeptides | |
AU766507B2 (en) | Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same | |
AU2003213166B2 (en) | Novel polypeptides having sequence similarity to GDNFR and nucleic acids encoding the same | |
CA2419541C (en) | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders | |
AU783117B2 (en) | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity | |
US20100285016A1 (en) | PRO34128 nucleic acids | |
ZA200102380B (en) | Methods and compositions for inhibiting neoplastic cell growth. | |
US20030044897A1 (en) | Novel secreted polypeptide and methods of treatment of bone disorders | |
AU2003204815B2 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
CA2369605A1 (en) | Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same | |
CA2441700A1 (en) | Polypeptides and nucleic acids for bolekine | |
AU2002306526A1 (en) | Chimpanzee erythropoietin (chepo) - immunoadhesins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |